INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31001, 29110, 'Venlafaxine', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31002, 29111, 'Venlafaxine', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31003, 29212, 'Venlafaxine', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31004, 29213, 'Venlafaxine', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31005, 29214, 'Venlafaxine', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31006, 30447, 'Venlafaxine', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31007, 31559, 'Venlafaxine', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31008, 32779, 'Venlafaxine', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31009, 4005, 'Venlafaxine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31010, 4006, 'Venlafaxine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31011, 4010, 'Venlafaxine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31012, 6386, 'Venlafaxine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31013, 12174, 'Venlafaxine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31014, 17234, 'Venlafaxine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31015, 17235, 'Venlafaxine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31016, 17236, 'Venlafaxine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31017, 18100, 'Venlafaxine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31018, 18106, 'Venlafaxine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31019, 19873, 'Venlafaxine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31020, 19874, 'Venlafaxine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31021, 19875, 'Venlafaxine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31022, 20709, 'Venlafaxine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31023, 20711, 'Venlafaxine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31024, 20712, 'Venlafaxine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31025, 21072, 'Venlafaxine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31026, 29096, 'Venlafaxine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31027, 29097, 'Venlafaxine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31028, 29098, 'Venlafaxine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31029, 29099, 'Venlafaxine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31030, 29103, 'Venlafaxine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31031, 29110, 'Venlafaxine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31032, 29111, 'Venlafaxine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31033, 29212, 'Venlafaxine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31034, 29213, 'Venlafaxine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31035, 29214, 'Venlafaxine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31036, 30447, 'Venlafaxine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31037, 31559, 'Venlafaxine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31038, 32779, 'Venlafaxine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31039, 4005, 'Venlafaxine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31040, 4006, 'Venlafaxine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31041, 4010, 'Venlafaxine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31042, 6386, 'Venlafaxine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31043, 12174, 'Venlafaxine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31044, 17234, 'Venlafaxine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31045, 17235, 'Venlafaxine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31046, 17236, 'Venlafaxine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31047, 18100, 'Venlafaxine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31048, 18106, 'Venlafaxine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31049, 19873, 'Venlafaxine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31050, 19874, 'Venlafaxine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31051, 19875, 'Venlafaxine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31052, 20709, 'Venlafaxine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31053, 20711, 'Venlafaxine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31054, 20712, 'Venlafaxine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31055, 21072, 'Venlafaxine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31056, 29096, 'Venlafaxine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31057, 29097, 'Venlafaxine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31058, 29098, 'Venlafaxine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31059, 29099, 'Venlafaxine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31060, 29103, 'Venlafaxine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31061, 29110, 'Venlafaxine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31062, 29111, 'Venlafaxine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31063, 29212, 'Venlafaxine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31064, 29213, 'Venlafaxine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31065, 29214, 'Venlafaxine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31066, 30447, 'Venlafaxine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31067, 31559, 'Venlafaxine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31068, 32779, 'Venlafaxine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31069, 4005, 'Venlafaxine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31070, 4006, 'Venlafaxine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31071, 4010, 'Venlafaxine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31072, 6386, 'Venlafaxine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31073, 12174, 'Venlafaxine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31074, 17234, 'Venlafaxine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31075, 17235, 'Venlafaxine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31076, 17236, 'Venlafaxine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31077, 18100, 'Venlafaxine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31078, 18106, 'Venlafaxine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31079, 19873, 'Venlafaxine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31080, 19874, 'Venlafaxine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31081, 19875, 'Venlafaxine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31082, 20709, 'Venlafaxine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31083, 20711, 'Venlafaxine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31084, 20712, 'Venlafaxine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31085, 21072, 'Venlafaxine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31086, 29096, 'Venlafaxine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31087, 29097, 'Venlafaxine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31088, 29098, 'Venlafaxine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31089, 29099, 'Venlafaxine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31090, 29103, 'Venlafaxine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31091, 29110, 'Venlafaxine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31092, 29111, 'Venlafaxine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31093, 29212, 'Venlafaxine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31094, 29213, 'Venlafaxine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31095, 29214, 'Venlafaxine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31096, 30447, 'Venlafaxine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31097, 31559, 'Venlafaxine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31098, 32779, 'Venlafaxine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31099, 4005, 'Venlafaxine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31100, 4006, 'Venlafaxine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31101, 4010, 'Venlafaxine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31102, 6386, 'Venlafaxine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31103, 12174, 'Venlafaxine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31104, 17234, 'Venlafaxine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31105, 17235, 'Venlafaxine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31106, 17236, 'Venlafaxine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31107, 18100, 'Venlafaxine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31108, 18106, 'Venlafaxine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31109, 19873, 'Venlafaxine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31110, 19874, 'Venlafaxine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31111, 19875, 'Venlafaxine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31112, 20709, 'Venlafaxine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31113, 20711, 'Venlafaxine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31114, 20712, 'Venlafaxine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31115, 21072, 'Venlafaxine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31116, 29096, 'Venlafaxine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31117, 29097, 'Venlafaxine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31118, 29098, 'Venlafaxine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31119, 29099, 'Venlafaxine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31120, 29103, 'Venlafaxine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31121, 29110, 'Venlafaxine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31122, 29111, 'Venlafaxine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31123, 29212, 'Venlafaxine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31124, 29213, 'Venlafaxine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31125, 29214, 'Venlafaxine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31126, 30447, 'Venlafaxine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31127, 31559, 'Venlafaxine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31128, 32779, 'Venlafaxine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31129, 4005, 'Venlafaxine', 'Weight Loss', 'The use of venlafaxine may occasionally cause significant, dose-dependent weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  The loss of at least 5% of body weight occurred in 6% to 7% of treated patients in premarketing studies, compared to 1% to 2% for placebo.  Anorexia may occur in approximately 10% of patients.  Weight change should be monitored during therapy if venlafaxine is used in malnourished or underweight patients.', '1', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E "A comparison of venlafaxine, trazodone, and placebo in major depression." J Clin Psychopharmacol 14 (1994):  99-106', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31130, 4006, 'Venlafaxine', 'Weight Loss', 'The use of venlafaxine may occasionally cause significant, dose-dependent weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  The loss of at least 5% of body weight occurred in 6% to 7% of treated patients in premarketing studies, compared to 1% to 2% for placebo.  Anorexia may occur in approximately 10% of patients.  Weight change should be monitored during therapy if venlafaxine is used in malnourished or underweight patients.', '1', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E "A comparison of venlafaxine, trazodone, and placebo in major depression." J Clin Psychopharmacol 14 (1994):  99-106', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31131, 4010, 'Venlafaxine', 'Weight Loss', 'The use of venlafaxine may occasionally cause significant, dose-dependent weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  The loss of at least 5% of body weight occurred in 6% to 7% of treated patients in premarketing studies, compared to 1% to 2% for placebo.  Anorexia may occur in approximately 10% of patients.  Weight change should be monitored during therapy if venlafaxine is used in malnourished or underweight patients.', '1', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E "A comparison of venlafaxine, trazodone, and placebo in major depression." J Clin Psychopharmacol 14 (1994):  99-106', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31132, 6386, 'Venlafaxine', 'Weight Loss', 'The use of venlafaxine may occasionally cause significant, dose-dependent weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  The loss of at least 5% of body weight occurred in 6% to 7% of treated patients in premarketing studies, compared to 1% to 2% for placebo.  Anorexia may occur in approximately 10% of patients.  Weight change should be monitored during therapy if venlafaxine is used in malnourished or underweight patients.', '1', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E "A comparison of venlafaxine, trazodone, and placebo in major depression." J Clin Psychopharmacol 14 (1994):  99-106', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31133, 12174, 'Venlafaxine', 'Weight Loss', 'The use of venlafaxine may occasionally cause significant, dose-dependent weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  The loss of at least 5% of body weight occurred in 6% to 7% of treated patients in premarketing studies, compared to 1% to 2% for placebo.  Anorexia may occur in approximately 10% of patients.  Weight change should be monitored during therapy if venlafaxine is used in malnourished or underweight patients.', '1', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E "A comparison of venlafaxine, trazodone, and placebo in major depression." J Clin Psychopharmacol 14 (1994):  99-106', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31134, 17234, 'Venlafaxine', 'Weight Loss', 'The use of venlafaxine may occasionally cause significant, dose-dependent weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  The loss of at least 5% of body weight occurred in 6% to 7% of treated patients in premarketing studies, compared to 1% to 2% for placebo.  Anorexia may occur in approximately 10% of patients.  Weight change should be monitored during therapy if venlafaxine is used in malnourished or underweight patients.', '1', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E "A comparison of venlafaxine, trazodone, and placebo in major depression." J Clin Psychopharmacol 14 (1994):  99-106', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31135, 17235, 'Venlafaxine', 'Weight Loss', 'The use of venlafaxine may occasionally cause significant, dose-dependent weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  The loss of at least 5% of body weight occurred in 6% to 7% of treated patients in premarketing studies, compared to 1% to 2% for placebo.  Anorexia may occur in approximately 10% of patients.  Weight change should be monitored during therapy if venlafaxine is used in malnourished or underweight patients.', '1', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E "A comparison of venlafaxine, trazodone, and placebo in major depression." J Clin Psychopharmacol 14 (1994):  99-106', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31136, 17236, 'Venlafaxine', 'Weight Loss', 'The use of venlafaxine may occasionally cause significant, dose-dependent weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  The loss of at least 5% of body weight occurred in 6% to 7% of treated patients in premarketing studies, compared to 1% to 2% for placebo.  Anorexia may occur in approximately 10% of patients.  Weight change should be monitored during therapy if venlafaxine is used in malnourished or underweight patients.', '1', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E "A comparison of venlafaxine, trazodone, and placebo in major depression." J Clin Psychopharmacol 14 (1994):  99-106', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31137, 18100, 'Venlafaxine', 'Weight Loss', 'The use of venlafaxine may occasionally cause significant, dose-dependent weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  The loss of at least 5% of body weight occurred in 6% to 7% of treated patients in premarketing studies, compared to 1% to 2% for placebo.  Anorexia may occur in approximately 10% of patients.  Weight change should be monitored during therapy if venlafaxine is used in malnourished or underweight patients.', '1', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E "A comparison of venlafaxine, trazodone, and placebo in major depression." J Clin Psychopharmacol 14 (1994):  99-106', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31138, 18106, 'Venlafaxine', 'Weight Loss', 'The use of venlafaxine may occasionally cause significant, dose-dependent weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  The loss of at least 5% of body weight occurred in 6% to 7% of treated patients in premarketing studies, compared to 1% to 2% for placebo.  Anorexia may occur in approximately 10% of patients.  Weight change should be monitored during therapy if venlafaxine is used in malnourished or underweight patients.', '1', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E "A comparison of venlafaxine, trazodone, and placebo in major depression." J Clin Psychopharmacol 14 (1994):  99-106', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31139, 19873, 'Venlafaxine', 'Weight Loss', 'The use of venlafaxine may occasionally cause significant, dose-dependent weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  The loss of at least 5% of body weight occurred in 6% to 7% of treated patients in premarketing studies, compared to 1% to 2% for placebo.  Anorexia may occur in approximately 10% of patients.  Weight change should be monitored during therapy if venlafaxine is used in malnourished or underweight patients.', '1', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E "A comparison of venlafaxine, trazodone, and placebo in major depression." J Clin Psychopharmacol 14 (1994):  99-106', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31140, 19874, 'Venlafaxine', 'Weight Loss', 'The use of venlafaxine may occasionally cause significant, dose-dependent weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  The loss of at least 5% of body weight occurred in 6% to 7% of treated patients in premarketing studies, compared to 1% to 2% for placebo.  Anorexia may occur in approximately 10% of patients.  Weight change should be monitored during therapy if venlafaxine is used in malnourished or underweight patients.', '1', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E "A comparison of venlafaxine, trazodone, and placebo in major depression." J Clin Psychopharmacol 14 (1994):  99-106', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31141, 19875, 'Venlafaxine', 'Weight Loss', 'The use of venlafaxine may occasionally cause significant, dose-dependent weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  The loss of at least 5% of body weight occurred in 6% to 7% of treated patients in premarketing studies, compared to 1% to 2% for placebo.  Anorexia may occur in approximately 10% of patients.  Weight change should be monitored during therapy if venlafaxine is used in malnourished or underweight patients.', '1', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E "A comparison of venlafaxine, trazodone, and placebo in major depression." J Clin Psychopharmacol 14 (1994):  99-106', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31142, 20709, 'Venlafaxine', 'Weight Loss', 'The use of venlafaxine may occasionally cause significant, dose-dependent weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  The loss of at least 5% of body weight occurred in 6% to 7% of treated patients in premarketing studies, compared to 1% to 2% for placebo.  Anorexia may occur in approximately 10% of patients.  Weight change should be monitored during therapy if venlafaxine is used in malnourished or underweight patients.', '1', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E "A comparison of venlafaxine, trazodone, and placebo in major depression." J Clin Psychopharmacol 14 (1994):  99-106', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31143, 20711, 'Venlafaxine', 'Weight Loss', 'The use of venlafaxine may occasionally cause significant, dose-dependent weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  The loss of at least 5% of body weight occurred in 6% to 7% of treated patients in premarketing studies, compared to 1% to 2% for placebo.  Anorexia may occur in approximately 10% of patients.  Weight change should be monitored during therapy if venlafaxine is used in malnourished or underweight patients.', '1', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E "A comparison of venlafaxine, trazodone, and placebo in major depression." J Clin Psychopharmacol 14 (1994):  99-106', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31144, 20712, 'Venlafaxine', 'Weight Loss', 'The use of venlafaxine may occasionally cause significant, dose-dependent weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  The loss of at least 5% of body weight occurred in 6% to 7% of treated patients in premarketing studies, compared to 1% to 2% for placebo.  Anorexia may occur in approximately 10% of patients.  Weight change should be monitored during therapy if venlafaxine is used in malnourished or underweight patients.', '1', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E "A comparison of venlafaxine, trazodone, and placebo in major depression." J Clin Psychopharmacol 14 (1994):  99-106', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31145, 21072, 'Venlafaxine', 'Weight Loss', 'The use of venlafaxine may occasionally cause significant, dose-dependent weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  The loss of at least 5% of body weight occurred in 6% to 7% of treated patients in premarketing studies, compared to 1% to 2% for placebo.  Anorexia may occur in approximately 10% of patients.  Weight change should be monitored during therapy if venlafaxine is used in malnourished or underweight patients.', '1', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E "A comparison of venlafaxine, trazodone, and placebo in major depression." J Clin Psychopharmacol 14 (1994):  99-106', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31146, 29096, 'Venlafaxine', 'Weight Loss', 'The use of venlafaxine may occasionally cause significant, dose-dependent weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  The loss of at least 5% of body weight occurred in 6% to 7% of treated patients in premarketing studies, compared to 1% to 2% for placebo.  Anorexia may occur in approximately 10% of patients.  Weight change should be monitored during therapy if venlafaxine is used in malnourished or underweight patients.', '1', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E "A comparison of venlafaxine, trazodone, and placebo in major depression." J Clin Psychopharmacol 14 (1994):  99-106', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31147, 29097, 'Venlafaxine', 'Weight Loss', 'The use of venlafaxine may occasionally cause significant, dose-dependent weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  The loss of at least 5% of body weight occurred in 6% to 7% of treated patients in premarketing studies, compared to 1% to 2% for placebo.  Anorexia may occur in approximately 10% of patients.  Weight change should be monitored during therapy if venlafaxine is used in malnourished or underweight patients.', '1', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E "A comparison of venlafaxine, trazodone, and placebo in major depression." J Clin Psychopharmacol 14 (1994):  99-106', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31148, 29098, 'Venlafaxine', 'Weight Loss', 'The use of venlafaxine may occasionally cause significant, dose-dependent weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  The loss of at least 5% of body weight occurred in 6% to 7% of treated patients in premarketing studies, compared to 1% to 2% for placebo.  Anorexia may occur in approximately 10% of patients.  Weight change should be monitored during therapy if venlafaxine is used in malnourished or underweight patients.', '1', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E "A comparison of venlafaxine, trazodone, and placebo in major depression." J Clin Psychopharmacol 14 (1994):  99-106', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31149, 29099, 'Venlafaxine', 'Weight Loss', 'The use of venlafaxine may occasionally cause significant, dose-dependent weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  The loss of at least 5% of body weight occurred in 6% to 7% of treated patients in premarketing studies, compared to 1% to 2% for placebo.  Anorexia may occur in approximately 10% of patients.  Weight change should be monitored during therapy if venlafaxine is used in malnourished or underweight patients.', '1', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E "A comparison of venlafaxine, trazodone, and placebo in major depression." J Clin Psychopharmacol 14 (1994):  99-106', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31150, 29103, 'Venlafaxine', 'Weight Loss', 'The use of venlafaxine may occasionally cause significant, dose-dependent weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  The loss of at least 5% of body weight occurred in 6% to 7% of treated patients in premarketing studies, compared to 1% to 2% for placebo.  Anorexia may occur in approximately 10% of patients.  Weight change should be monitored during therapy if venlafaxine is used in malnourished or underweight patients.', '1', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E "A comparison of venlafaxine, trazodone, and placebo in major depression." J Clin Psychopharmacol 14 (1994):  99-106', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31151, 29110, 'Venlafaxine', 'Weight Loss', 'The use of venlafaxine may occasionally cause significant, dose-dependent weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  The loss of at least 5% of body weight occurred in 6% to 7% of treated patients in premarketing studies, compared to 1% to 2% for placebo.  Anorexia may occur in approximately 10% of patients.  Weight change should be monitored during therapy if venlafaxine is used in malnourished or underweight patients.', '1', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E "A comparison of venlafaxine, trazodone, and placebo in major depression." J Clin Psychopharmacol 14 (1994):  99-106', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31152, 29111, 'Venlafaxine', 'Weight Loss', 'The use of venlafaxine may occasionally cause significant, dose-dependent weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  The loss of at least 5% of body weight occurred in 6% to 7% of treated patients in premarketing studies, compared to 1% to 2% for placebo.  Anorexia may occur in approximately 10% of patients.  Weight change should be monitored during therapy if venlafaxine is used in malnourished or underweight patients.', '1', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E "A comparison of venlafaxine, trazodone, and placebo in major depression." J Clin Psychopharmacol 14 (1994):  99-106', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31153, 29212, 'Venlafaxine', 'Weight Loss', 'The use of venlafaxine may occasionally cause significant, dose-dependent weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  The loss of at least 5% of body weight occurred in 6% to 7% of treated patients in premarketing studies, compared to 1% to 2% for placebo.  Anorexia may occur in approximately 10% of patients.  Weight change should be monitored during therapy if venlafaxine is used in malnourished or underweight patients.', '1', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E "A comparison of venlafaxine, trazodone, and placebo in major depression." J Clin Psychopharmacol 14 (1994):  99-106', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31154, 29213, 'Venlafaxine', 'Weight Loss', 'The use of venlafaxine may occasionally cause significant, dose-dependent weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  The loss of at least 5% of body weight occurred in 6% to 7% of treated patients in premarketing studies, compared to 1% to 2% for placebo.  Anorexia may occur in approximately 10% of patients.  Weight change should be monitored during therapy if venlafaxine is used in malnourished or underweight patients.', '1', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E "A comparison of venlafaxine, trazodone, and placebo in major depression." J Clin Psychopharmacol 14 (1994):  99-106', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31155, 29214, 'Venlafaxine', 'Weight Loss', 'The use of venlafaxine may occasionally cause significant, dose-dependent weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  The loss of at least 5% of body weight occurred in 6% to 7% of treated patients in premarketing studies, compared to 1% to 2% for placebo.  Anorexia may occur in approximately 10% of patients.  Weight change should be monitored during therapy if venlafaxine is used in malnourished or underweight patients.', '1', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E "A comparison of venlafaxine, trazodone, and placebo in major depression." J Clin Psychopharmacol 14 (1994):  99-106', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31156, 30447, 'Venlafaxine', 'Weight Loss', 'The use of venlafaxine may occasionally cause significant, dose-dependent weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  The loss of at least 5% of body weight occurred in 6% to 7% of treated patients in premarketing studies, compared to 1% to 2% for placebo.  Anorexia may occur in approximately 10% of patients.  Weight change should be monitored during therapy if venlafaxine is used in malnourished or underweight patients.', '1', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E "A comparison of venlafaxine, trazodone, and placebo in major depression." J Clin Psychopharmacol 14 (1994):  99-106', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31157, 31559, 'Venlafaxine', 'Weight Loss', 'The use of venlafaxine may occasionally cause significant, dose-dependent weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  The loss of at least 5% of body weight occurred in 6% to 7% of treated patients in premarketing studies, compared to 1% to 2% for placebo.  Anorexia may occur in approximately 10% of patients.  Weight change should be monitored during therapy if venlafaxine is used in malnourished or underweight patients.', '1', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E "A comparison of venlafaxine, trazodone, and placebo in major depression." J Clin Psychopharmacol 14 (1994):  99-106', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31158, 32779, 'Venlafaxine', 'Weight Loss', 'The use of venlafaxine may occasionally cause significant, dose-dependent weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  The loss of at least 5% of body weight occurred in 6% to 7% of treated patients in premarketing studies, compared to 1% to 2% for placebo.  Anorexia may occur in approximately 10% of patients.  Weight change should be monitored during therapy if venlafaxine is used in malnourished or underweight patients.', '1', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E "A comparison of venlafaxine, trazodone, and placebo in major depression." J Clin Psychopharmacol 14 (1994):  99-106', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31159, 28911, 'Valganciclovir', 'Neutropenia', 'Severe leukopenia, neutropenia, anemia, thrombocytopenia, pancytopenia, bone marrow aplasia, and aplastic anemia have been reported in patients treated with valganciclovir.  The use of this agent should be avoided if the absolute neutrophil count is less than 500 cells/L, the platelet count is less than 25,000//L, or the hemoglobin is less than 8 g/dL.  Complete blood counts with differential and platelet counts should be performed frequently, especially in patients that developed leukopenia after using a nucleoside analog, or in whom neutrophil counts are less than 1000 cells/L at the beginning of treatment.  Therapy with this agent should be administered with caution in patients with bone marrow depression.  Increased monitoring is recommended.', '3', '"Product Information. Valcyte (valganciclovir)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31160, 28911, 'Valganciclovir', 'Kidney Diseases', 'Acute renal failure has been documented in elderly patients (with or without reduced renal function), patients who receive concomitant nephrotoxic drugs, or inadequately hydrated patients.  Adequate hydration, dose reduction and close monitoring of renal function are recommended when using valganciclovir in these patients.  The tablet form of valganciclovir should not be used in adult patients on hemodialysis (CrCl less than 10 mL/min).', '3', '"Product Information. Valcyte (valganciclovir)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31161, 28911, 'Valganciclovir', 'Hepatic Insufficiency', 'Monitoring is recommended when using valganciclovir in patients with hepatic impairment as the safety and efficacy of this agent has not been studied in these patients.', '2', '"Product Information. Valcyte (valganciclovir)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31162, 29091, 'Venetoclax', 'Hepatic Insufficiency', 'In vitro studies demonstrated that venetoclax is predominantly metabolized in the liver by CYP450 3A4/5.  Based on pharmacokinetic analysis with subjects with mild and moderate hepatic impairment, the venetoclax exposures were similar to those with normal hepatic function; therefore, no dose adjustment is recommended in patients with mild or moderate hepatic impairment.  Based on the drug metabolism, an increase in adverse events might result in patients with moderate to severe hepatic impairment.  It is recommended to monitor patients with moderate to severe hepatic impairment carefully for signs of toxicity during the initiation and the weekly dose ramp-up phase.  Caution is advised when using this agent in patients with severe hepatic impairment as it pharmacokinetics has not been studied.', '2', '"Product Information. Venclexta (venetoclax)." AbbVie US LLC  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31163, 31915, 'Venetoclax', 'Hepatic Insufficiency', 'In vitro studies demonstrated that venetoclax is predominantly metabolized in the liver by CYP450 3A4/5.  Based on pharmacokinetic analysis with subjects with mild and moderate hepatic impairment, the venetoclax exposures were similar to those with normal hepatic function; therefore, no dose adjustment is recommended in patients with mild or moderate hepatic impairment.  Based on the drug metabolism, an increase in adverse events might result in patients with moderate to severe hepatic impairment.  It is recommended to monitor patients with moderate to severe hepatic impairment carefully for signs of toxicity during the initiation and the weekly dose ramp-up phase.  Caution is advised when using this agent in patients with severe hepatic impairment as it pharmacokinetics has not been studied.', '2', '"Product Information. Venclexta (venetoclax)." AbbVie US LLC  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31164, 29091, 'Venetoclax', 'Neutropenia', 'Venetoclax can cause neutropenia.  It is recommended to monitor for fever and signs suggestive of an infection.  Monitor complete blood count during the course of therapy and reduce dose or interrupt treatment for severe neutropenia.  Therapy with this agent should be administered cautiously in patients with preexisting bone marrow depression or blood dyscrasias.', '2', '"Product Information. Venclexta (venetoclax)." AbbVie US LLC  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31165, 31915, 'Venetoclax', 'Neutropenia', 'Venetoclax can cause neutropenia.  It is recommended to monitor for fever and signs suggestive of an infection.  Monitor complete blood count during the course of therapy and reduce dose or interrupt treatment for severe neutropenia.  Therapy with this agent should be administered cautiously in patients with preexisting bone marrow depression or blood dyscrasias.', '2', '"Product Information. Venclexta (venetoclax)." AbbVie US LLC  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31166, 29091, 'Venetoclax', 'Tumor Lysis Syndrome', 'Based on pharmacokinetic analysis with subjects with mild and moderate renal impairment, the venetoclax exposures were similar to those with normal renal function; therefore, no dose adjustment is recommended in these patients.  The pharmacokinetics of venetoclax has not been studied in subjects with severe renal impairment.  Patients with reduced renal function are at increased risk of tumor lysis syndrome (TLS) and these patients may require more intensive monitoring and care to reduce the risk of TLS at the start of treatment.  Patients should be assessed for risk factor that may contribute to an increase risk for TLS and complete blood chemistries should be monitored regularly.  Dose interruption is recommended if needed based on clinical findings.', '2', '"Product Information. Venclexta (venetoclax)." AbbVie US LLC  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31167, 31915, 'Venetoclax', 'Tumor Lysis Syndrome', 'Based on pharmacokinetic analysis with subjects with mild and moderate renal impairment, the venetoclax exposures were similar to those with normal renal function; therefore, no dose adjustment is recommended in these patients.  The pharmacokinetics of venetoclax has not been studied in subjects with severe renal impairment.  Patients with reduced renal function are at increased risk of tumor lysis syndrome (TLS) and these patients may require more intensive monitoring and care to reduce the risk of TLS at the start of treatment.  Patients should be assessed for risk factor that may contribute to an increase risk for TLS and complete blood chemistries should be monitored regularly.  Dose interruption is recommended if needed based on clinical findings.', '2', '"Product Information. Venclexta (venetoclax)." AbbVie US LLC  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31168, 0, 'Vibrio cholerae CVD 103-HgR strain live antigen (live)', 'IMMUNE SUPPRESSION', 'The expected antibody responses may not be obtained when live attenuated vaccines and/or toxoids are administered to immunosuppressed persons, including those receiving immunosuppressive therapy.  Caution and close monitoring is advised.', '2', '"Product Information. Menactra (meningococcal conjugate vaccine)." sanofi pasteur  (2005):|"Product Information. ActHIB (haemophilus b conjugate (PRP-T) vaccine)." sanofi pasteur  (2022):|"Product Information. Bexsero (meningococcal group B vaccine)." Novartis Vaccines & Diagnostics Inc  (2022):|"Product Information. Trumenba (meningococcal group B vaccine)." Pfizer U.S. Pharmaceuticals Group  (2022):|"Product Information. Hiberix (haemophilus b conjugate (PRP-T) vaccine)." GlaxoSmithKline  (2022):|"Product Information. Vaxchora (cholera vaccine, live)." PaxVax  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31169, 12071, 'Vancomycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31170, 12072, 'Vancomycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31171, 12074, 'Vancomycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31172, 18077, 'Vancomycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31173, 18078, 'Vancomycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31174, 21315, 'Vancomycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31175, 28959, 'Vancomycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31176, 28961, 'Vancomycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31177, 28964, 'Vancomycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31178, 28966, 'Vancomycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31179, 28967, 'Vancomycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31180, 29204, 'Vancomycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31181, 31576, 'Vancomycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31182, 32122, 'Vancomycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31183, 32293, 'Vancomycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31184, 33827, 'Vancomycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31185, 33828, 'Vancomycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31186, 12071, 'Vancomycin', 'Ototoxicity', 'Intravenous use of vancomycin may cause damage to the auditory branch of the eighth cranial nerve.  Permanent hearing loss has been reported.  Tinnitus sometimes precedes the onset of deafness, which may progress despite withdrawal of the drug.  Therapy with vancomycin, particularly if prolonged (> 10 days), should be administered cautiously in patients with preexisting auditory impairment or tinnitus, since it may delay the recognition or confound the diagnosis of a drug-induced ototoxic effect.  To minimize the risk of toxicity, the usual dosage should not be exceeded, use with other ototoxic agents should be avoided, and serum drug concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Ototoxicity has generally been associated with serum vancomycin levels of 80 to 100 mcg/mL, although toxic reactions have also been reported at levels as low as 25 mcg/mL.  Serial audiograms should be obtained in patients old enough to be tested, and the dosage reduced or therapy withdrawn promptly if signs and symptoms of toxicity develop.Oral vancomycin is generally not associated with systemic toxicity due to poor absorption from the gastrointestinal tract.  However, clinically significant serum concentrations have been reported in some patients following multiple oral doses of vancomycin for active Clostridium difficile pseudomembranous colitis.  Therefore, when vancomycin is administered orally, clinicians may want to heed the usual warnings and precautions associated with intravenous use of the drug.', '3', 'Traber PG, Levine DP "Vancomycin ototoxicity in a patient with normal renal function." Ann Intern Med 95 (1981):  458-60|Sorrell TC, Collignon PJ "A prospective study of adverse reactions associated with vancomycin therapy." J Antimicrob Chemother 16 (1985):  235-41|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31187, 12072, 'Vancomycin', 'Ototoxicity', 'Intravenous use of vancomycin may cause damage to the auditory branch of the eighth cranial nerve.  Permanent hearing loss has been reported.  Tinnitus sometimes precedes the onset of deafness, which may progress despite withdrawal of the drug.  Therapy with vancomycin, particularly if prolonged (> 10 days), should be administered cautiously in patients with preexisting auditory impairment or tinnitus, since it may delay the recognition or confound the diagnosis of a drug-induced ototoxic effect.  To minimize the risk of toxicity, the usual dosage should not be exceeded, use with other ototoxic agents should be avoided, and serum drug concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Ototoxicity has generally been associated with serum vancomycin levels of 80 to 100 mcg/mL, although toxic reactions have also been reported at levels as low as 25 mcg/mL.  Serial audiograms should be obtained in patients old enough to be tested, and the dosage reduced or therapy withdrawn promptly if signs and symptoms of toxicity develop.Oral vancomycin is generally not associated with systemic toxicity due to poor absorption from the gastrointestinal tract.  However, clinically significant serum concentrations have been reported in some patients following multiple oral doses of vancomycin for active Clostridium difficile pseudomembranous colitis.  Therefore, when vancomycin is administered orally, clinicians may want to heed the usual warnings and precautions associated with intravenous use of the drug.', '3', 'Traber PG, Levine DP "Vancomycin ototoxicity in a patient with normal renal function." Ann Intern Med 95 (1981):  458-60|Sorrell TC, Collignon PJ "A prospective study of adverse reactions associated with vancomycin therapy." J Antimicrob Chemother 16 (1985):  235-41|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31188, 12074, 'Vancomycin', 'Ototoxicity', 'Intravenous use of vancomycin may cause damage to the auditory branch of the eighth cranial nerve.  Permanent hearing loss has been reported.  Tinnitus sometimes precedes the onset of deafness, which may progress despite withdrawal of the drug.  Therapy with vancomycin, particularly if prolonged (> 10 days), should be administered cautiously in patients with preexisting auditory impairment or tinnitus, since it may delay the recognition or confound the diagnosis of a drug-induced ototoxic effect.  To minimize the risk of toxicity, the usual dosage should not be exceeded, use with other ototoxic agents should be avoided, and serum drug concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Ototoxicity has generally been associated with serum vancomycin levels of 80 to 100 mcg/mL, although toxic reactions have also been reported at levels as low as 25 mcg/mL.  Serial audiograms should be obtained in patients old enough to be tested, and the dosage reduced or therapy withdrawn promptly if signs and symptoms of toxicity develop.Oral vancomycin is generally not associated with systemic toxicity due to poor absorption from the gastrointestinal tract.  However, clinically significant serum concentrations have been reported in some patients following multiple oral doses of vancomycin for active Clostridium difficile pseudomembranous colitis.  Therefore, when vancomycin is administered orally, clinicians may want to heed the usual warnings and precautions associated with intravenous use of the drug.', '3', 'Traber PG, Levine DP "Vancomycin ototoxicity in a patient with normal renal function." Ann Intern Med 95 (1981):  458-60|Sorrell TC, Collignon PJ "A prospective study of adverse reactions associated with vancomycin therapy." J Antimicrob Chemother 16 (1985):  235-41|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31189, 18077, 'Vancomycin', 'Ototoxicity', 'Intravenous use of vancomycin may cause damage to the auditory branch of the eighth cranial nerve.  Permanent hearing loss has been reported.  Tinnitus sometimes precedes the onset of deafness, which may progress despite withdrawal of the drug.  Therapy with vancomycin, particularly if prolonged (> 10 days), should be administered cautiously in patients with preexisting auditory impairment or tinnitus, since it may delay the recognition or confound the diagnosis of a drug-induced ototoxic effect.  To minimize the risk of toxicity, the usual dosage should not be exceeded, use with other ototoxic agents should be avoided, and serum drug concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Ototoxicity has generally been associated with serum vancomycin levels of 80 to 100 mcg/mL, although toxic reactions have also been reported at levels as low as 25 mcg/mL.  Serial audiograms should be obtained in patients old enough to be tested, and the dosage reduced or therapy withdrawn promptly if signs and symptoms of toxicity develop.Oral vancomycin is generally not associated with systemic toxicity due to poor absorption from the gastrointestinal tract.  However, clinically significant serum concentrations have been reported in some patients following multiple oral doses of vancomycin for active Clostridium difficile pseudomembranous colitis.  Therefore, when vancomycin is administered orally, clinicians may want to heed the usual warnings and precautions associated with intravenous use of the drug.', '3', 'Traber PG, Levine DP "Vancomycin ototoxicity in a patient with normal renal function." Ann Intern Med 95 (1981):  458-60|Sorrell TC, Collignon PJ "A prospective study of adverse reactions associated with vancomycin therapy." J Antimicrob Chemother 16 (1985):  235-41|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31190, 18078, 'Vancomycin', 'Ototoxicity', 'Intravenous use of vancomycin may cause damage to the auditory branch of the eighth cranial nerve.  Permanent hearing loss has been reported.  Tinnitus sometimes precedes the onset of deafness, which may progress despite withdrawal of the drug.  Therapy with vancomycin, particularly if prolonged (> 10 days), should be administered cautiously in patients with preexisting auditory impairment or tinnitus, since it may delay the recognition or confound the diagnosis of a drug-induced ototoxic effect.  To minimize the risk of toxicity, the usual dosage should not be exceeded, use with other ototoxic agents should be avoided, and serum drug concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Ototoxicity has generally been associated with serum vancomycin levels of 80 to 100 mcg/mL, although toxic reactions have also been reported at levels as low as 25 mcg/mL.  Serial audiograms should be obtained in patients old enough to be tested, and the dosage reduced or therapy withdrawn promptly if signs and symptoms of toxicity develop.Oral vancomycin is generally not associated with systemic toxicity due to poor absorption from the gastrointestinal tract.  However, clinically significant serum concentrations have been reported in some patients following multiple oral doses of vancomycin for active Clostridium difficile pseudomembranous colitis.  Therefore, when vancomycin is administered orally, clinicians may want to heed the usual warnings and precautions associated with intravenous use of the drug.', '3', 'Traber PG, Levine DP "Vancomycin ototoxicity in a patient with normal renal function." Ann Intern Med 95 (1981):  458-60|Sorrell TC, Collignon PJ "A prospective study of adverse reactions associated with vancomycin therapy." J Antimicrob Chemother 16 (1985):  235-41|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31191, 21315, 'Vancomycin', 'Ototoxicity', 'Intravenous use of vancomycin may cause damage to the auditory branch of the eighth cranial nerve.  Permanent hearing loss has been reported.  Tinnitus sometimes precedes the onset of deafness, which may progress despite withdrawal of the drug.  Therapy with vancomycin, particularly if prolonged (> 10 days), should be administered cautiously in patients with preexisting auditory impairment or tinnitus, since it may delay the recognition or confound the diagnosis of a drug-induced ototoxic effect.  To minimize the risk of toxicity, the usual dosage should not be exceeded, use with other ototoxic agents should be avoided, and serum drug concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Ototoxicity has generally been associated with serum vancomycin levels of 80 to 100 mcg/mL, although toxic reactions have also been reported at levels as low as 25 mcg/mL.  Serial audiograms should be obtained in patients old enough to be tested, and the dosage reduced or therapy withdrawn promptly if signs and symptoms of toxicity develop.Oral vancomycin is generally not associated with systemic toxicity due to poor absorption from the gastrointestinal tract.  However, clinically significant serum concentrations have been reported in some patients following multiple oral doses of vancomycin for active Clostridium difficile pseudomembranous colitis.  Therefore, when vancomycin is administered orally, clinicians may want to heed the usual warnings and precautions associated with intravenous use of the drug.', '3', 'Traber PG, Levine DP "Vancomycin ototoxicity in a patient with normal renal function." Ann Intern Med 95 (1981):  458-60|Sorrell TC, Collignon PJ "A prospective study of adverse reactions associated with vancomycin therapy." J Antimicrob Chemother 16 (1985):  235-41|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31192, 28959, 'Vancomycin', 'Ototoxicity', 'Intravenous use of vancomycin may cause damage to the auditory branch of the eighth cranial nerve.  Permanent hearing loss has been reported.  Tinnitus sometimes precedes the onset of deafness, which may progress despite withdrawal of the drug.  Therapy with vancomycin, particularly if prolonged (> 10 days), should be administered cautiously in patients with preexisting auditory impairment or tinnitus, since it may delay the recognition or confound the diagnosis of a drug-induced ototoxic effect.  To minimize the risk of toxicity, the usual dosage should not be exceeded, use with other ototoxic agents should be avoided, and serum drug concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Ototoxicity has generally been associated with serum vancomycin levels of 80 to 100 mcg/mL, although toxic reactions have also been reported at levels as low as 25 mcg/mL.  Serial audiograms should be obtained in patients old enough to be tested, and the dosage reduced or therapy withdrawn promptly if signs and symptoms of toxicity develop.Oral vancomycin is generally not associated with systemic toxicity due to poor absorption from the gastrointestinal tract.  However, clinically significant serum concentrations have been reported in some patients following multiple oral doses of vancomycin for active Clostridium difficile pseudomembranous colitis.  Therefore, when vancomycin is administered orally, clinicians may want to heed the usual warnings and precautions associated with intravenous use of the drug.', '3', 'Traber PG, Levine DP "Vancomycin ototoxicity in a patient with normal renal function." Ann Intern Med 95 (1981):  458-60|Sorrell TC, Collignon PJ "A prospective study of adverse reactions associated with vancomycin therapy." J Antimicrob Chemother 16 (1985):  235-41|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31193, 28961, 'Vancomycin', 'Ototoxicity', 'Intravenous use of vancomycin may cause damage to the auditory branch of the eighth cranial nerve.  Permanent hearing loss has been reported.  Tinnitus sometimes precedes the onset of deafness, which may progress despite withdrawal of the drug.  Therapy with vancomycin, particularly if prolonged (> 10 days), should be administered cautiously in patients with preexisting auditory impairment or tinnitus, since it may delay the recognition or confound the diagnosis of a drug-induced ototoxic effect.  To minimize the risk of toxicity, the usual dosage should not be exceeded, use with other ototoxic agents should be avoided, and serum drug concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Ototoxicity has generally been associated with serum vancomycin levels of 80 to 100 mcg/mL, although toxic reactions have also been reported at levels as low as 25 mcg/mL.  Serial audiograms should be obtained in patients old enough to be tested, and the dosage reduced or therapy withdrawn promptly if signs and symptoms of toxicity develop.Oral vancomycin is generally not associated with systemic toxicity due to poor absorption from the gastrointestinal tract.  However, clinically significant serum concentrations have been reported in some patients following multiple oral doses of vancomycin for active Clostridium difficile pseudomembranous colitis.  Therefore, when vancomycin is administered orally, clinicians may want to heed the usual warnings and precautions associated with intravenous use of the drug.', '3', 'Traber PG, Levine DP "Vancomycin ototoxicity in a patient with normal renal function." Ann Intern Med 95 (1981):  458-60|Sorrell TC, Collignon PJ "A prospective study of adverse reactions associated with vancomycin therapy." J Antimicrob Chemother 16 (1985):  235-41|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31194, 28964, 'Vancomycin', 'Ototoxicity', 'Intravenous use of vancomycin may cause damage to the auditory branch of the eighth cranial nerve.  Permanent hearing loss has been reported.  Tinnitus sometimes precedes the onset of deafness, which may progress despite withdrawal of the drug.  Therapy with vancomycin, particularly if prolonged (> 10 days), should be administered cautiously in patients with preexisting auditory impairment or tinnitus, since it may delay the recognition or confound the diagnosis of a drug-induced ototoxic effect.  To minimize the risk of toxicity, the usual dosage should not be exceeded, use with other ototoxic agents should be avoided, and serum drug concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Ototoxicity has generally been associated with serum vancomycin levels of 80 to 100 mcg/mL, although toxic reactions have also been reported at levels as low as 25 mcg/mL.  Serial audiograms should be obtained in patients old enough to be tested, and the dosage reduced or therapy withdrawn promptly if signs and symptoms of toxicity develop.Oral vancomycin is generally not associated with systemic toxicity due to poor absorption from the gastrointestinal tract.  However, clinically significant serum concentrations have been reported in some patients following multiple oral doses of vancomycin for active Clostridium difficile pseudomembranous colitis.  Therefore, when vancomycin is administered orally, clinicians may want to heed the usual warnings and precautions associated with intravenous use of the drug.', '3', 'Traber PG, Levine DP "Vancomycin ototoxicity in a patient with normal renal function." Ann Intern Med 95 (1981):  458-60|Sorrell TC, Collignon PJ "A prospective study of adverse reactions associated with vancomycin therapy." J Antimicrob Chemother 16 (1985):  235-41|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31195, 28966, 'Vancomycin', 'Ototoxicity', 'Intravenous use of vancomycin may cause damage to the auditory branch of the eighth cranial nerve.  Permanent hearing loss has been reported.  Tinnitus sometimes precedes the onset of deafness, which may progress despite withdrawal of the drug.  Therapy with vancomycin, particularly if prolonged (> 10 days), should be administered cautiously in patients with preexisting auditory impairment or tinnitus, since it may delay the recognition or confound the diagnosis of a drug-induced ototoxic effect.  To minimize the risk of toxicity, the usual dosage should not be exceeded, use with other ototoxic agents should be avoided, and serum drug concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Ototoxicity has generally been associated with serum vancomycin levels of 80 to 100 mcg/mL, although toxic reactions have also been reported at levels as low as 25 mcg/mL.  Serial audiograms should be obtained in patients old enough to be tested, and the dosage reduced or therapy withdrawn promptly if signs and symptoms of toxicity develop.Oral vancomycin is generally not associated with systemic toxicity due to poor absorption from the gastrointestinal tract.  However, clinically significant serum concentrations have been reported in some patients following multiple oral doses of vancomycin for active Clostridium difficile pseudomembranous colitis.  Therefore, when vancomycin is administered orally, clinicians may want to heed the usual warnings and precautions associated with intravenous use of the drug.', '3', 'Traber PG, Levine DP "Vancomycin ototoxicity in a patient with normal renal function." Ann Intern Med 95 (1981):  458-60|Sorrell TC, Collignon PJ "A prospective study of adverse reactions associated with vancomycin therapy." J Antimicrob Chemother 16 (1985):  235-41|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31196, 28967, 'Vancomycin', 'Ototoxicity', 'Intravenous use of vancomycin may cause damage to the auditory branch of the eighth cranial nerve.  Permanent hearing loss has been reported.  Tinnitus sometimes precedes the onset of deafness, which may progress despite withdrawal of the drug.  Therapy with vancomycin, particularly if prolonged (> 10 days), should be administered cautiously in patients with preexisting auditory impairment or tinnitus, since it may delay the recognition or confound the diagnosis of a drug-induced ototoxic effect.  To minimize the risk of toxicity, the usual dosage should not be exceeded, use with other ototoxic agents should be avoided, and serum drug concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Ototoxicity has generally been associated with serum vancomycin levels of 80 to 100 mcg/mL, although toxic reactions have also been reported at levels as low as 25 mcg/mL.  Serial audiograms should be obtained in patients old enough to be tested, and the dosage reduced or therapy withdrawn promptly if signs and symptoms of toxicity develop.Oral vancomycin is generally not associated with systemic toxicity due to poor absorption from the gastrointestinal tract.  However, clinically significant serum concentrations have been reported in some patients following multiple oral doses of vancomycin for active Clostridium difficile pseudomembranous colitis.  Therefore, when vancomycin is administered orally, clinicians may want to heed the usual warnings and precautions associated with intravenous use of the drug.', '3', 'Traber PG, Levine DP "Vancomycin ototoxicity in a patient with normal renal function." Ann Intern Med 95 (1981):  458-60|Sorrell TC, Collignon PJ "A prospective study of adverse reactions associated with vancomycin therapy." J Antimicrob Chemother 16 (1985):  235-41|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31197, 29204, 'Vancomycin', 'Ototoxicity', 'Intravenous use of vancomycin may cause damage to the auditory branch of the eighth cranial nerve.  Permanent hearing loss has been reported.  Tinnitus sometimes precedes the onset of deafness, which may progress despite withdrawal of the drug.  Therapy with vancomycin, particularly if prolonged (> 10 days), should be administered cautiously in patients with preexisting auditory impairment or tinnitus, since it may delay the recognition or confound the diagnosis of a drug-induced ototoxic effect.  To minimize the risk of toxicity, the usual dosage should not be exceeded, use with other ototoxic agents should be avoided, and serum drug concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Ototoxicity has generally been associated with serum vancomycin levels of 80 to 100 mcg/mL, although toxic reactions have also been reported at levels as low as 25 mcg/mL.  Serial audiograms should be obtained in patients old enough to be tested, and the dosage reduced or therapy withdrawn promptly if signs and symptoms of toxicity develop.Oral vancomycin is generally not associated with systemic toxicity due to poor absorption from the gastrointestinal tract.  However, clinically significant serum concentrations have been reported in some patients following multiple oral doses of vancomycin for active Clostridium difficile pseudomembranous colitis.  Therefore, when vancomycin is administered orally, clinicians may want to heed the usual warnings and precautions associated with intravenous use of the drug.', '3', 'Traber PG, Levine DP "Vancomycin ototoxicity in a patient with normal renal function." Ann Intern Med 95 (1981):  458-60|Sorrell TC, Collignon PJ "A prospective study of adverse reactions associated with vancomycin therapy." J Antimicrob Chemother 16 (1985):  235-41|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31198, 31576, 'Vancomycin', 'Ototoxicity', 'Intravenous use of vancomycin may cause damage to the auditory branch of the eighth cranial nerve.  Permanent hearing loss has been reported.  Tinnitus sometimes precedes the onset of deafness, which may progress despite withdrawal of the drug.  Therapy with vancomycin, particularly if prolonged (> 10 days), should be administered cautiously in patients with preexisting auditory impairment or tinnitus, since it may delay the recognition or confound the diagnosis of a drug-induced ototoxic effect.  To minimize the risk of toxicity, the usual dosage should not be exceeded, use with other ototoxic agents should be avoided, and serum drug concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Ototoxicity has generally been associated with serum vancomycin levels of 80 to 100 mcg/mL, although toxic reactions have also been reported at levels as low as 25 mcg/mL.  Serial audiograms should be obtained in patients old enough to be tested, and the dosage reduced or therapy withdrawn promptly if signs and symptoms of toxicity develop.Oral vancomycin is generally not associated with systemic toxicity due to poor absorption from the gastrointestinal tract.  However, clinically significant serum concentrations have been reported in some patients following multiple oral doses of vancomycin for active Clostridium difficile pseudomembranous colitis.  Therefore, when vancomycin is administered orally, clinicians may want to heed the usual warnings and precautions associated with intravenous use of the drug.', '3', 'Traber PG, Levine DP "Vancomycin ototoxicity in a patient with normal renal function." Ann Intern Med 95 (1981):  458-60|Sorrell TC, Collignon PJ "A prospective study of adverse reactions associated with vancomycin therapy." J Antimicrob Chemother 16 (1985):  235-41|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31199, 32122, 'Vancomycin', 'Ototoxicity', 'Intravenous use of vancomycin may cause damage to the auditory branch of the eighth cranial nerve.  Permanent hearing loss has been reported.  Tinnitus sometimes precedes the onset of deafness, which may progress despite withdrawal of the drug.  Therapy with vancomycin, particularly if prolonged (> 10 days), should be administered cautiously in patients with preexisting auditory impairment or tinnitus, since it may delay the recognition or confound the diagnosis of a drug-induced ototoxic effect.  To minimize the risk of toxicity, the usual dosage should not be exceeded, use with other ototoxic agents should be avoided, and serum drug concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Ototoxicity has generally been associated with serum vancomycin levels of 80 to 100 mcg/mL, although toxic reactions have also been reported at levels as low as 25 mcg/mL.  Serial audiograms should be obtained in patients old enough to be tested, and the dosage reduced or therapy withdrawn promptly if signs and symptoms of toxicity develop.Oral vancomycin is generally not associated with systemic toxicity due to poor absorption from the gastrointestinal tract.  However, clinically significant serum concentrations have been reported in some patients following multiple oral doses of vancomycin for active Clostridium difficile pseudomembranous colitis.  Therefore, when vancomycin is administered orally, clinicians may want to heed the usual warnings and precautions associated with intravenous use of the drug.', '3', 'Traber PG, Levine DP "Vancomycin ototoxicity in a patient with normal renal function." Ann Intern Med 95 (1981):  458-60|Sorrell TC, Collignon PJ "A prospective study of adverse reactions associated with vancomycin therapy." J Antimicrob Chemother 16 (1985):  235-41|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31200, 32293, 'Vancomycin', 'Ototoxicity', 'Intravenous use of vancomycin may cause damage to the auditory branch of the eighth cranial nerve.  Permanent hearing loss has been reported.  Tinnitus sometimes precedes the onset of deafness, which may progress despite withdrawal of the drug.  Therapy with vancomycin, particularly if prolonged (> 10 days), should be administered cautiously in patients with preexisting auditory impairment or tinnitus, since it may delay the recognition or confound the diagnosis of a drug-induced ototoxic effect.  To minimize the risk of toxicity, the usual dosage should not be exceeded, use with other ototoxic agents should be avoided, and serum drug concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Ototoxicity has generally been associated with serum vancomycin levels of 80 to 100 mcg/mL, although toxic reactions have also been reported at levels as low as 25 mcg/mL.  Serial audiograms should be obtained in patients old enough to be tested, and the dosage reduced or therapy withdrawn promptly if signs and symptoms of toxicity develop.Oral vancomycin is generally not associated with systemic toxicity due to poor absorption from the gastrointestinal tract.  However, clinically significant serum concentrations have been reported in some patients following multiple oral doses of vancomycin for active Clostridium difficile pseudomembranous colitis.  Therefore, when vancomycin is administered orally, clinicians may want to heed the usual warnings and precautions associated with intravenous use of the drug.', '3', 'Traber PG, Levine DP "Vancomycin ototoxicity in a patient with normal renal function." Ann Intern Med 95 (1981):  458-60|Sorrell TC, Collignon PJ "A prospective study of adverse reactions associated with vancomycin therapy." J Antimicrob Chemother 16 (1985):  235-41|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31201, 33827, 'Vancomycin', 'Ototoxicity', 'Intravenous use of vancomycin may cause damage to the auditory branch of the eighth cranial nerve.  Permanent hearing loss has been reported.  Tinnitus sometimes precedes the onset of deafness, which may progress despite withdrawal of the drug.  Therapy with vancomycin, particularly if prolonged (> 10 days), should be administered cautiously in patients with preexisting auditory impairment or tinnitus, since it may delay the recognition or confound the diagnosis of a drug-induced ototoxic effect.  To minimize the risk of toxicity, the usual dosage should not be exceeded, use with other ototoxic agents should be avoided, and serum drug concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Ototoxicity has generally been associated with serum vancomycin levels of 80 to 100 mcg/mL, although toxic reactions have also been reported at levels as low as 25 mcg/mL.  Serial audiograms should be obtained in patients old enough to be tested, and the dosage reduced or therapy withdrawn promptly if signs and symptoms of toxicity develop.Oral vancomycin is generally not associated with systemic toxicity due to poor absorption from the gastrointestinal tract.  However, clinically significant serum concentrations have been reported in some patients following multiple oral doses of vancomycin for active Clostridium difficile pseudomembranous colitis.  Therefore, when vancomycin is administered orally, clinicians may want to heed the usual warnings and precautions associated with intravenous use of the drug.', '3', 'Traber PG, Levine DP "Vancomycin ototoxicity in a patient with normal renal function." Ann Intern Med 95 (1981):  458-60|Sorrell TC, Collignon PJ "A prospective study of adverse reactions associated with vancomycin therapy." J Antimicrob Chemother 16 (1985):  235-41|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31202, 33828, 'Vancomycin', 'Ototoxicity', 'Intravenous use of vancomycin may cause damage to the auditory branch of the eighth cranial nerve.  Permanent hearing loss has been reported.  Tinnitus sometimes precedes the onset of deafness, which may progress despite withdrawal of the drug.  Therapy with vancomycin, particularly if prolonged (> 10 days), should be administered cautiously in patients with preexisting auditory impairment or tinnitus, since it may delay the recognition or confound the diagnosis of a drug-induced ototoxic effect.  To minimize the risk of toxicity, the usual dosage should not be exceeded, use with other ototoxic agents should be avoided, and serum drug concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Ototoxicity has generally been associated with serum vancomycin levels of 80 to 100 mcg/mL, although toxic reactions have also been reported at levels as low as 25 mcg/mL.  Serial audiograms should be obtained in patients old enough to be tested, and the dosage reduced or therapy withdrawn promptly if signs and symptoms of toxicity develop.Oral vancomycin is generally not associated with systemic toxicity due to poor absorption from the gastrointestinal tract.  However, clinically significant serum concentrations have been reported in some patients following multiple oral doses of vancomycin for active Clostridium difficile pseudomembranous colitis.  Therefore, when vancomycin is administered orally, clinicians may want to heed the usual warnings and precautions associated with intravenous use of the drug.', '3', 'Traber PG, Levine DP "Vancomycin ototoxicity in a patient with normal renal function." Ann Intern Med 95 (1981):  458-60|Sorrell TC, Collignon PJ "A prospective study of adverse reactions associated with vancomycin therapy." J Antimicrob Chemother 16 (1985):  235-41|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31203, 12071, 'Vancomycin', 'Kidney Diseases', 'Intravenous use of vancomycin may be associated with oto- and nephrotoxic effects.  Eighth cranial nerve damage may manifest as tinnitus and varying degrees of hearing impairment.  Nephrotoxicity is usually evidenced by transient elevations in BUN or serum creatinine concentrations, as well as the presence of hyaline and granular casts and albumin in the urine.  Rarely, acute interstitial nephritis has been reported.  Although vancomycin-induced nephrotoxicity is generally reversible following discontinuation of the drug, death from uremia has occurred.  Therapy with vancomycin should be administered cautiously at reduced dosages in patients with renal impairment, since they may be at increased risk for oto- and nephrotoxicity due to drug accumulation.  To minimize the risk of toxicity, the usual dosage should not be exceeded, use with other neuro- and nephrotoxic agents should be avoided, and serum drug concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Oto- and nephrotoxicity has generally been associated with serum vancomycin levels of 80 to 100 mcg/mL, although toxic reactions have also been reported at levels as low as 25 mcg/mL.  Renal and eighth cranial nerve function should be closely monitored, and the dosage reduced or therapy withdrawn if toxicity develops.Oral vancomycin is generally not associated with systemic toxicity due to poor absorption from the gastrointestinal tract.  However, clinically significant serum concentrations have been reported in some patients following multiple oral doses of vancomycin for active Clostridium difficile pseudomembranous colitis.  The risk for systemic adverse effects may be greatest in patients with preexisting renal impairment.  Therefore, when vancomycin is administered orally, clinicians may want to heed the usual warnings and precautions associated with intravenous use of the drug.', '3', 'Moellering RC, Krogstad DJ, Greenblatt DJ "Pharmacokinetics of vancomycin in normal subjects and in patients with reduced renal function." Rev Infect Dis 3  Suppl (1981):  s230-5|Eisenberg ES, Robbins N, Lenci M "Vancomycin and interstitial nephritis." Ann Intern Med 95 (1981):  658|Masur H, Francioli P, Ruddy M, Murray HW "Vancomycin serum levels and toxicity in chronic hemodialysis patients with staphylococcus aureus bacteremia." Clin Nephrol 20 (1983):  85-8|Dean RP, Wagner DJ, Tolpin MD "Vancomycin/aminoglycoside nephrotoxicity." J Pediatr 106 (1985):  861-2|Sorrell TC, Collignon PJ "A prospective study of adverse reactions associated with vancomycin therapy." J Antimicrob Chemother 16 (1985):  235-41|Cimino MA, Rotstein C, Slaughter RL, Emrich LJ "Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy." Am J Med 83 (1987):  1091-7|Bergman MM, Glew RH, Ebert TH "Acute intetstitial nephritis associated with vancomycin therapy." Arch Intern Med 148 (1988):  2139-40|Ratner SJ "Vancomycin-induced interstitial nephritis." Am J Med 84 (1988):  561-2|Downs NJ, Neihart RE, Dolezal JM, Hodges GR "Mild nephrotoxicity associated with vancomycin use." Arch Intern Med 149 (1989):  1777-81|Codding CE, Ramseyer L, Allon M, Pitha J, Rodriguez M "Tubulointerstitial nephritis due to vancomycin." Am J Kidney Dis 14 (1989):  512-5|Rodvold KA, Blum RA, Fischer JH, et al. "Vancomycin pharmacokinetics in patients with various degrees of renal function." Antimicrob Agents Chemother 32 (1988):  848-52|Matzke GR, McGory RW, Halstenson CE, Keane WF "Pharmacokinetics of vancomycin in patients with various degrees of renal function." Antimicrob Agents Chemother 25 (1984):  433-7|Tan CC, Lee HS, Ti TY, Lee JC "Pharmacokinetics of intravenous vancomycin in patients with end-stage renal failure." Ther Drug Monit 12 (1990):  29-34|Macias WL, Mueller BA, Scarim SK "Vancomycin pharmacokinetics in acute renal failure: preservation of nonrenal clearance." Clin Pharmacol Ther 50 (1991):  688-94|Lindholm DD, Murray JS "Persistence of vancomycin in the blood during renal failure and its treatment by hemodialysis." N Engl J Med 274 (1966):  1047-51|Cunha BA, Quintilliani R, Deglin JM, Izard MW, Nightingale CH "Pharmacokinetics of vancomycin in anuria." Rev Infect Dis 3 Suppl (1981):  s269-72|Moellering RC, Krogstad DJ, Greenblatt DJ "Vancomycin therapy in patients with impaired renal function: a nomogram for dosage." Ann Intern Med 94 (1981):  343-6|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):|Wai AO, Lo AMS, Abdo A, Marra F "Vancomycin-induced acute interstitial nephritis." Ann Pharmacother 32 (1998):  1160-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31204, 12072, 'Vancomycin', 'Kidney Diseases', 'Intravenous use of vancomycin may be associated with oto- and nephrotoxic effects.  Eighth cranial nerve damage may manifest as tinnitus and varying degrees of hearing impairment.  Nephrotoxicity is usually evidenced by transient elevations in BUN or serum creatinine concentrations, as well as the presence of hyaline and granular casts and albumin in the urine.  Rarely, acute interstitial nephritis has been reported.  Although vancomycin-induced nephrotoxicity is generally reversible following discontinuation of the drug, death from uremia has occurred.  Therapy with vancomycin should be administered cautiously at reduced dosages in patients with renal impairment, since they may be at increased risk for oto- and nephrotoxicity due to drug accumulation.  To minimize the risk of toxicity, the usual dosage should not be exceeded, use with other neuro- and nephrotoxic agents should be avoided, and serum drug concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Oto- and nephrotoxicity has generally been associated with serum vancomycin levels of 80 to 100 mcg/mL, although toxic reactions have also been reported at levels as low as 25 mcg/mL.  Renal and eighth cranial nerve function should be closely monitored, and the dosage reduced or therapy withdrawn if toxicity develops.Oral vancomycin is generally not associated with systemic toxicity due to poor absorption from the gastrointestinal tract.  However, clinically significant serum concentrations have been reported in some patients following multiple oral doses of vancomycin for active Clostridium difficile pseudomembranous colitis.  The risk for systemic adverse effects may be greatest in patients with preexisting renal impairment.  Therefore, when vancomycin is administered orally, clinicians may want to heed the usual warnings and precautions associated with intravenous use of the drug.', '3', 'Moellering RC, Krogstad DJ, Greenblatt DJ "Pharmacokinetics of vancomycin in normal subjects and in patients with reduced renal function." Rev Infect Dis 3  Suppl (1981):  s230-5|Eisenberg ES, Robbins N, Lenci M "Vancomycin and interstitial nephritis." Ann Intern Med 95 (1981):  658|Masur H, Francioli P, Ruddy M, Murray HW "Vancomycin serum levels and toxicity in chronic hemodialysis patients with staphylococcus aureus bacteremia." Clin Nephrol 20 (1983):  85-8|Dean RP, Wagner DJ, Tolpin MD "Vancomycin/aminoglycoside nephrotoxicity." J Pediatr 106 (1985):  861-2|Sorrell TC, Collignon PJ "A prospective study of adverse reactions associated with vancomycin therapy." J Antimicrob Chemother 16 (1985):  235-41|Cimino MA, Rotstein C, Slaughter RL, Emrich LJ "Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy." Am J Med 83 (1987):  1091-7|Bergman MM, Glew RH, Ebert TH "Acute intetstitial nephritis associated with vancomycin therapy." Arch Intern Med 148 (1988):  2139-40|Ratner SJ "Vancomycin-induced interstitial nephritis." Am J Med 84 (1988):  561-2|Downs NJ, Neihart RE, Dolezal JM, Hodges GR "Mild nephrotoxicity associated with vancomycin use." Arch Intern Med 149 (1989):  1777-81|Codding CE, Ramseyer L, Allon M, Pitha J, Rodriguez M "Tubulointerstitial nephritis due to vancomycin." Am J Kidney Dis 14 (1989):  512-5|Rodvold KA, Blum RA, Fischer JH, et al. "Vancomycin pharmacokinetics in patients with various degrees of renal function." Antimicrob Agents Chemother 32 (1988):  848-52|Matzke GR, McGory RW, Halstenson CE, Keane WF "Pharmacokinetics of vancomycin in patients with various degrees of renal function." Antimicrob Agents Chemother 25 (1984):  433-7|Tan CC, Lee HS, Ti TY, Lee JC "Pharmacokinetics of intravenous vancomycin in patients with end-stage renal failure." Ther Drug Monit 12 (1990):  29-34|Macias WL, Mueller BA, Scarim SK "Vancomycin pharmacokinetics in acute renal failure: preservation of nonrenal clearance." Clin Pharmacol Ther 50 (1991):  688-94|Lindholm DD, Murray JS "Persistence of vancomycin in the blood during renal failure and its treatment by hemodialysis." N Engl J Med 274 (1966):  1047-51|Cunha BA, Quintilliani R, Deglin JM, Izard MW, Nightingale CH "Pharmacokinetics of vancomycin in anuria." Rev Infect Dis 3 Suppl (1981):  s269-72|Moellering RC, Krogstad DJ, Greenblatt DJ "Vancomycin therapy in patients with impaired renal function: a nomogram for dosage." Ann Intern Med 94 (1981):  343-6|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):|Wai AO, Lo AMS, Abdo A, Marra F "Vancomycin-induced acute interstitial nephritis." Ann Pharmacother 32 (1998):  1160-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31205, 12074, 'Vancomycin', 'Kidney Diseases', 'Intravenous use of vancomycin may be associated with oto- and nephrotoxic effects.  Eighth cranial nerve damage may manifest as tinnitus and varying degrees of hearing impairment.  Nephrotoxicity is usually evidenced by transient elevations in BUN or serum creatinine concentrations, as well as the presence of hyaline and granular casts and albumin in the urine.  Rarely, acute interstitial nephritis has been reported.  Although vancomycin-induced nephrotoxicity is generally reversible following discontinuation of the drug, death from uremia has occurred.  Therapy with vancomycin should be administered cautiously at reduced dosages in patients with renal impairment, since they may be at increased risk for oto- and nephrotoxicity due to drug accumulation.  To minimize the risk of toxicity, the usual dosage should not be exceeded, use with other neuro- and nephrotoxic agents should be avoided, and serum drug concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Oto- and nephrotoxicity has generally been associated with serum vancomycin levels of 80 to 100 mcg/mL, although toxic reactions have also been reported at levels as low as 25 mcg/mL.  Renal and eighth cranial nerve function should be closely monitored, and the dosage reduced or therapy withdrawn if toxicity develops.Oral vancomycin is generally not associated with systemic toxicity due to poor absorption from the gastrointestinal tract.  However, clinically significant serum concentrations have been reported in some patients following multiple oral doses of vancomycin for active Clostridium difficile pseudomembranous colitis.  The risk for systemic adverse effects may be greatest in patients with preexisting renal impairment.  Therefore, when vancomycin is administered orally, clinicians may want to heed the usual warnings and precautions associated with intravenous use of the drug.', '3', 'Moellering RC, Krogstad DJ, Greenblatt DJ "Pharmacokinetics of vancomycin in normal subjects and in patients with reduced renal function." Rev Infect Dis 3  Suppl (1981):  s230-5|Eisenberg ES, Robbins N, Lenci M "Vancomycin and interstitial nephritis." Ann Intern Med 95 (1981):  658|Masur H, Francioli P, Ruddy M, Murray HW "Vancomycin serum levels and toxicity in chronic hemodialysis patients with staphylococcus aureus bacteremia." Clin Nephrol 20 (1983):  85-8|Dean RP, Wagner DJ, Tolpin MD "Vancomycin/aminoglycoside nephrotoxicity." J Pediatr 106 (1985):  861-2|Sorrell TC, Collignon PJ "A prospective study of adverse reactions associated with vancomycin therapy." J Antimicrob Chemother 16 (1985):  235-41|Cimino MA, Rotstein C, Slaughter RL, Emrich LJ "Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy." Am J Med 83 (1987):  1091-7|Bergman MM, Glew RH, Ebert TH "Acute intetstitial nephritis associated with vancomycin therapy." Arch Intern Med 148 (1988):  2139-40|Ratner SJ "Vancomycin-induced interstitial nephritis." Am J Med 84 (1988):  561-2|Downs NJ, Neihart RE, Dolezal JM, Hodges GR "Mild nephrotoxicity associated with vancomycin use." Arch Intern Med 149 (1989):  1777-81|Codding CE, Ramseyer L, Allon M, Pitha J, Rodriguez M "Tubulointerstitial nephritis due to vancomycin." Am J Kidney Dis 14 (1989):  512-5|Rodvold KA, Blum RA, Fischer JH, et al. "Vancomycin pharmacokinetics in patients with various degrees of renal function." Antimicrob Agents Chemother 32 (1988):  848-52|Matzke GR, McGory RW, Halstenson CE, Keane WF "Pharmacokinetics of vancomycin in patients with various degrees of renal function." Antimicrob Agents Chemother 25 (1984):  433-7|Tan CC, Lee HS, Ti TY, Lee JC "Pharmacokinetics of intravenous vancomycin in patients with end-stage renal failure." Ther Drug Monit 12 (1990):  29-34|Macias WL, Mueller BA, Scarim SK "Vancomycin pharmacokinetics in acute renal failure: preservation of nonrenal clearance." Clin Pharmacol Ther 50 (1991):  688-94|Lindholm DD, Murray JS "Persistence of vancomycin in the blood during renal failure and its treatment by hemodialysis." N Engl J Med 274 (1966):  1047-51|Cunha BA, Quintilliani R, Deglin JM, Izard MW, Nightingale CH "Pharmacokinetics of vancomycin in anuria." Rev Infect Dis 3 Suppl (1981):  s269-72|Moellering RC, Krogstad DJ, Greenblatt DJ "Vancomycin therapy in patients with impaired renal function: a nomogram for dosage." Ann Intern Med 94 (1981):  343-6|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):|Wai AO, Lo AMS, Abdo A, Marra F "Vancomycin-induced acute interstitial nephritis." Ann Pharmacother 32 (1998):  1160-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31206, 18077, 'Vancomycin', 'Kidney Diseases', 'Intravenous use of vancomycin may be associated with oto- and nephrotoxic effects.  Eighth cranial nerve damage may manifest as tinnitus and varying degrees of hearing impairment.  Nephrotoxicity is usually evidenced by transient elevations in BUN or serum creatinine concentrations, as well as the presence of hyaline and granular casts and albumin in the urine.  Rarely, acute interstitial nephritis has been reported.  Although vancomycin-induced nephrotoxicity is generally reversible following discontinuation of the drug, death from uremia has occurred.  Therapy with vancomycin should be administered cautiously at reduced dosages in patients with renal impairment, since they may be at increased risk for oto- and nephrotoxicity due to drug accumulation.  To minimize the risk of toxicity, the usual dosage should not be exceeded, use with other neuro- and nephrotoxic agents should be avoided, and serum drug concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Oto- and nephrotoxicity has generally been associated with serum vancomycin levels of 80 to 100 mcg/mL, although toxic reactions have also been reported at levels as low as 25 mcg/mL.  Renal and eighth cranial nerve function should be closely monitored, and the dosage reduced or therapy withdrawn if toxicity develops.Oral vancomycin is generally not associated with systemic toxicity due to poor absorption from the gastrointestinal tract.  However, clinically significant serum concentrations have been reported in some patients following multiple oral doses of vancomycin for active Clostridium difficile pseudomembranous colitis.  The risk for systemic adverse effects may be greatest in patients with preexisting renal impairment.  Therefore, when vancomycin is administered orally, clinicians may want to heed the usual warnings and precautions associated with intravenous use of the drug.', '3', 'Moellering RC, Krogstad DJ, Greenblatt DJ "Pharmacokinetics of vancomycin in normal subjects and in patients with reduced renal function." Rev Infect Dis 3  Suppl (1981):  s230-5|Eisenberg ES, Robbins N, Lenci M "Vancomycin and interstitial nephritis." Ann Intern Med 95 (1981):  658|Masur H, Francioli P, Ruddy M, Murray HW "Vancomycin serum levels and toxicity in chronic hemodialysis patients with staphylococcus aureus bacteremia." Clin Nephrol 20 (1983):  85-8|Dean RP, Wagner DJ, Tolpin MD "Vancomycin/aminoglycoside nephrotoxicity." J Pediatr 106 (1985):  861-2|Sorrell TC, Collignon PJ "A prospective study of adverse reactions associated with vancomycin therapy." J Antimicrob Chemother 16 (1985):  235-41|Cimino MA, Rotstein C, Slaughter RL, Emrich LJ "Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy." Am J Med 83 (1987):  1091-7|Bergman MM, Glew RH, Ebert TH "Acute intetstitial nephritis associated with vancomycin therapy." Arch Intern Med 148 (1988):  2139-40|Ratner SJ "Vancomycin-induced interstitial nephritis." Am J Med 84 (1988):  561-2|Downs NJ, Neihart RE, Dolezal JM, Hodges GR "Mild nephrotoxicity associated with vancomycin use." Arch Intern Med 149 (1989):  1777-81|Codding CE, Ramseyer L, Allon M, Pitha J, Rodriguez M "Tubulointerstitial nephritis due to vancomycin." Am J Kidney Dis 14 (1989):  512-5|Rodvold KA, Blum RA, Fischer JH, et al. "Vancomycin pharmacokinetics in patients with various degrees of renal function." Antimicrob Agents Chemother 32 (1988):  848-52|Matzke GR, McGory RW, Halstenson CE, Keane WF "Pharmacokinetics of vancomycin in patients with various degrees of renal function." Antimicrob Agents Chemother 25 (1984):  433-7|Tan CC, Lee HS, Ti TY, Lee JC "Pharmacokinetics of intravenous vancomycin in patients with end-stage renal failure." Ther Drug Monit 12 (1990):  29-34|Macias WL, Mueller BA, Scarim SK "Vancomycin pharmacokinetics in acute renal failure: preservation of nonrenal clearance." Clin Pharmacol Ther 50 (1991):  688-94|Lindholm DD, Murray JS "Persistence of vancomycin in the blood during renal failure and its treatment by hemodialysis." N Engl J Med 274 (1966):  1047-51|Cunha BA, Quintilliani R, Deglin JM, Izard MW, Nightingale CH "Pharmacokinetics of vancomycin in anuria." Rev Infect Dis 3 Suppl (1981):  s269-72|Moellering RC, Krogstad DJ, Greenblatt DJ "Vancomycin therapy in patients with impaired renal function: a nomogram for dosage." Ann Intern Med 94 (1981):  343-6|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):|Wai AO, Lo AMS, Abdo A, Marra F "Vancomycin-induced acute interstitial nephritis." Ann Pharmacother 32 (1998):  1160-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31207, 18078, 'Vancomycin', 'Kidney Diseases', 'Intravenous use of vancomycin may be associated with oto- and nephrotoxic effects.  Eighth cranial nerve damage may manifest as tinnitus and varying degrees of hearing impairment.  Nephrotoxicity is usually evidenced by transient elevations in BUN or serum creatinine concentrations, as well as the presence of hyaline and granular casts and albumin in the urine.  Rarely, acute interstitial nephritis has been reported.  Although vancomycin-induced nephrotoxicity is generally reversible following discontinuation of the drug, death from uremia has occurred.  Therapy with vancomycin should be administered cautiously at reduced dosages in patients with renal impairment, since they may be at increased risk for oto- and nephrotoxicity due to drug accumulation.  To minimize the risk of toxicity, the usual dosage should not be exceeded, use with other neuro- and nephrotoxic agents should be avoided, and serum drug concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Oto- and nephrotoxicity has generally been associated with serum vancomycin levels of 80 to 100 mcg/mL, although toxic reactions have also been reported at levels as low as 25 mcg/mL.  Renal and eighth cranial nerve function should be closely monitored, and the dosage reduced or therapy withdrawn if toxicity develops.Oral vancomycin is generally not associated with systemic toxicity due to poor absorption from the gastrointestinal tract.  However, clinically significant serum concentrations have been reported in some patients following multiple oral doses of vancomycin for active Clostridium difficile pseudomembranous colitis.  The risk for systemic adverse effects may be greatest in patients with preexisting renal impairment.  Therefore, when vancomycin is administered orally, clinicians may want to heed the usual warnings and precautions associated with intravenous use of the drug.', '3', 'Moellering RC, Krogstad DJ, Greenblatt DJ "Pharmacokinetics of vancomycin in normal subjects and in patients with reduced renal function." Rev Infect Dis 3  Suppl (1981):  s230-5|Eisenberg ES, Robbins N, Lenci M "Vancomycin and interstitial nephritis." Ann Intern Med 95 (1981):  658|Masur H, Francioli P, Ruddy M, Murray HW "Vancomycin serum levels and toxicity in chronic hemodialysis patients with staphylococcus aureus bacteremia." Clin Nephrol 20 (1983):  85-8|Dean RP, Wagner DJ, Tolpin MD "Vancomycin/aminoglycoside nephrotoxicity." J Pediatr 106 (1985):  861-2|Sorrell TC, Collignon PJ "A prospective study of adverse reactions associated with vancomycin therapy." J Antimicrob Chemother 16 (1985):  235-41|Cimino MA, Rotstein C, Slaughter RL, Emrich LJ "Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy." Am J Med 83 (1987):  1091-7|Bergman MM, Glew RH, Ebert TH "Acute intetstitial nephritis associated with vancomycin therapy." Arch Intern Med 148 (1988):  2139-40|Ratner SJ "Vancomycin-induced interstitial nephritis." Am J Med 84 (1988):  561-2|Downs NJ, Neihart RE, Dolezal JM, Hodges GR "Mild nephrotoxicity associated with vancomycin use." Arch Intern Med 149 (1989):  1777-81|Codding CE, Ramseyer L, Allon M, Pitha J, Rodriguez M "Tubulointerstitial nephritis due to vancomycin." Am J Kidney Dis 14 (1989):  512-5|Rodvold KA, Blum RA, Fischer JH, et al. "Vancomycin pharmacokinetics in patients with various degrees of renal function." Antimicrob Agents Chemother 32 (1988):  848-52|Matzke GR, McGory RW, Halstenson CE, Keane WF "Pharmacokinetics of vancomycin in patients with various degrees of renal function." Antimicrob Agents Chemother 25 (1984):  433-7|Tan CC, Lee HS, Ti TY, Lee JC "Pharmacokinetics of intravenous vancomycin in patients with end-stage renal failure." Ther Drug Monit 12 (1990):  29-34|Macias WL, Mueller BA, Scarim SK "Vancomycin pharmacokinetics in acute renal failure: preservation of nonrenal clearance." Clin Pharmacol Ther 50 (1991):  688-94|Lindholm DD, Murray JS "Persistence of vancomycin in the blood during renal failure and its treatment by hemodialysis." N Engl J Med 274 (1966):  1047-51|Cunha BA, Quintilliani R, Deglin JM, Izard MW, Nightingale CH "Pharmacokinetics of vancomycin in anuria." Rev Infect Dis 3 Suppl (1981):  s269-72|Moellering RC, Krogstad DJ, Greenblatt DJ "Vancomycin therapy in patients with impaired renal function: a nomogram for dosage." Ann Intern Med 94 (1981):  343-6|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):|Wai AO, Lo AMS, Abdo A, Marra F "Vancomycin-induced acute interstitial nephritis." Ann Pharmacother 32 (1998):  1160-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31208, 21315, 'Vancomycin', 'Kidney Diseases', 'Intravenous use of vancomycin may be associated with oto- and nephrotoxic effects.  Eighth cranial nerve damage may manifest as tinnitus and varying degrees of hearing impairment.  Nephrotoxicity is usually evidenced by transient elevations in BUN or serum creatinine concentrations, as well as the presence of hyaline and granular casts and albumin in the urine.  Rarely, acute interstitial nephritis has been reported.  Although vancomycin-induced nephrotoxicity is generally reversible following discontinuation of the drug, death from uremia has occurred.  Therapy with vancomycin should be administered cautiously at reduced dosages in patients with renal impairment, since they may be at increased risk for oto- and nephrotoxicity due to drug accumulation.  To minimize the risk of toxicity, the usual dosage should not be exceeded, use with other neuro- and nephrotoxic agents should be avoided, and serum drug concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Oto- and nephrotoxicity has generally been associated with serum vancomycin levels of 80 to 100 mcg/mL, although toxic reactions have also been reported at levels as low as 25 mcg/mL.  Renal and eighth cranial nerve function should be closely monitored, and the dosage reduced or therapy withdrawn if toxicity develops.Oral vancomycin is generally not associated with systemic toxicity due to poor absorption from the gastrointestinal tract.  However, clinically significant serum concentrations have been reported in some patients following multiple oral doses of vancomycin for active Clostridium difficile pseudomembranous colitis.  The risk for systemic adverse effects may be greatest in patients with preexisting renal impairment.  Therefore, when vancomycin is administered orally, clinicians may want to heed the usual warnings and precautions associated with intravenous use of the drug.', '3', 'Moellering RC, Krogstad DJ, Greenblatt DJ "Pharmacokinetics of vancomycin in normal subjects and in patients with reduced renal function." Rev Infect Dis 3  Suppl (1981):  s230-5|Eisenberg ES, Robbins N, Lenci M "Vancomycin and interstitial nephritis." Ann Intern Med 95 (1981):  658|Masur H, Francioli P, Ruddy M, Murray HW "Vancomycin serum levels and toxicity in chronic hemodialysis patients with staphylococcus aureus bacteremia." Clin Nephrol 20 (1983):  85-8|Dean RP, Wagner DJ, Tolpin MD "Vancomycin/aminoglycoside nephrotoxicity." J Pediatr 106 (1985):  861-2|Sorrell TC, Collignon PJ "A prospective study of adverse reactions associated with vancomycin therapy." J Antimicrob Chemother 16 (1985):  235-41|Cimino MA, Rotstein C, Slaughter RL, Emrich LJ "Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy." Am J Med 83 (1987):  1091-7|Bergman MM, Glew RH, Ebert TH "Acute intetstitial nephritis associated with vancomycin therapy." Arch Intern Med 148 (1988):  2139-40|Ratner SJ "Vancomycin-induced interstitial nephritis." Am J Med 84 (1988):  561-2|Downs NJ, Neihart RE, Dolezal JM, Hodges GR "Mild nephrotoxicity associated with vancomycin use." Arch Intern Med 149 (1989):  1777-81|Codding CE, Ramseyer L, Allon M, Pitha J, Rodriguez M "Tubulointerstitial nephritis due to vancomycin." Am J Kidney Dis 14 (1989):  512-5|Rodvold KA, Blum RA, Fischer JH, et al. "Vancomycin pharmacokinetics in patients with various degrees of renal function." Antimicrob Agents Chemother 32 (1988):  848-52|Matzke GR, McGory RW, Halstenson CE, Keane WF "Pharmacokinetics of vancomycin in patients with various degrees of renal function." Antimicrob Agents Chemother 25 (1984):  433-7|Tan CC, Lee HS, Ti TY, Lee JC "Pharmacokinetics of intravenous vancomycin in patients with end-stage renal failure." Ther Drug Monit 12 (1990):  29-34|Macias WL, Mueller BA, Scarim SK "Vancomycin pharmacokinetics in acute renal failure: preservation of nonrenal clearance." Clin Pharmacol Ther 50 (1991):  688-94|Lindholm DD, Murray JS "Persistence of vancomycin in the blood during renal failure and its treatment by hemodialysis." N Engl J Med 274 (1966):  1047-51|Cunha BA, Quintilliani R, Deglin JM, Izard MW, Nightingale CH "Pharmacokinetics of vancomycin in anuria." Rev Infect Dis 3 Suppl (1981):  s269-72|Moellering RC, Krogstad DJ, Greenblatt DJ "Vancomycin therapy in patients with impaired renal function: a nomogram for dosage." Ann Intern Med 94 (1981):  343-6|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):|Wai AO, Lo AMS, Abdo A, Marra F "Vancomycin-induced acute interstitial nephritis." Ann Pharmacother 32 (1998):  1160-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31209, 28959, 'Vancomycin', 'Kidney Diseases', 'Intravenous use of vancomycin may be associated with oto- and nephrotoxic effects.  Eighth cranial nerve damage may manifest as tinnitus and varying degrees of hearing impairment.  Nephrotoxicity is usually evidenced by transient elevations in BUN or serum creatinine concentrations, as well as the presence of hyaline and granular casts and albumin in the urine.  Rarely, acute interstitial nephritis has been reported.  Although vancomycin-induced nephrotoxicity is generally reversible following discontinuation of the drug, death from uremia has occurred.  Therapy with vancomycin should be administered cautiously at reduced dosages in patients with renal impairment, since they may be at increased risk for oto- and nephrotoxicity due to drug accumulation.  To minimize the risk of toxicity, the usual dosage should not be exceeded, use with other neuro- and nephrotoxic agents should be avoided, and serum drug concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Oto- and nephrotoxicity has generally been associated with serum vancomycin levels of 80 to 100 mcg/mL, although toxic reactions have also been reported at levels as low as 25 mcg/mL.  Renal and eighth cranial nerve function should be closely monitored, and the dosage reduced or therapy withdrawn if toxicity develops.Oral vancomycin is generally not associated with systemic toxicity due to poor absorption from the gastrointestinal tract.  However, clinically significant serum concentrations have been reported in some patients following multiple oral doses of vancomycin for active Clostridium difficile pseudomembranous colitis.  The risk for systemic adverse effects may be greatest in patients with preexisting renal impairment.  Therefore, when vancomycin is administered orally, clinicians may want to heed the usual warnings and precautions associated with intravenous use of the drug.', '3', 'Moellering RC, Krogstad DJ, Greenblatt DJ "Pharmacokinetics of vancomycin in normal subjects and in patients with reduced renal function." Rev Infect Dis 3  Suppl (1981):  s230-5|Eisenberg ES, Robbins N, Lenci M "Vancomycin and interstitial nephritis." Ann Intern Med 95 (1981):  658|Masur H, Francioli P, Ruddy M, Murray HW "Vancomycin serum levels and toxicity in chronic hemodialysis patients with staphylococcus aureus bacteremia." Clin Nephrol 20 (1983):  85-8|Dean RP, Wagner DJ, Tolpin MD "Vancomycin/aminoglycoside nephrotoxicity." J Pediatr 106 (1985):  861-2|Sorrell TC, Collignon PJ "A prospective study of adverse reactions associated with vancomycin therapy." J Antimicrob Chemother 16 (1985):  235-41|Cimino MA, Rotstein C, Slaughter RL, Emrich LJ "Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy." Am J Med 83 (1987):  1091-7|Bergman MM, Glew RH, Ebert TH "Acute intetstitial nephritis associated with vancomycin therapy." Arch Intern Med 148 (1988):  2139-40|Ratner SJ "Vancomycin-induced interstitial nephritis." Am J Med 84 (1988):  561-2|Downs NJ, Neihart RE, Dolezal JM, Hodges GR "Mild nephrotoxicity associated with vancomycin use." Arch Intern Med 149 (1989):  1777-81|Codding CE, Ramseyer L, Allon M, Pitha J, Rodriguez M "Tubulointerstitial nephritis due to vancomycin." Am J Kidney Dis 14 (1989):  512-5|Rodvold KA, Blum RA, Fischer JH, et al. "Vancomycin pharmacokinetics in patients with various degrees of renal function." Antimicrob Agents Chemother 32 (1988):  848-52|Matzke GR, McGory RW, Halstenson CE, Keane WF "Pharmacokinetics of vancomycin in patients with various degrees of renal function." Antimicrob Agents Chemother 25 (1984):  433-7|Tan CC, Lee HS, Ti TY, Lee JC "Pharmacokinetics of intravenous vancomycin in patients with end-stage renal failure." Ther Drug Monit 12 (1990):  29-34|Macias WL, Mueller BA, Scarim SK "Vancomycin pharmacokinetics in acute renal failure: preservation of nonrenal clearance." Clin Pharmacol Ther 50 (1991):  688-94|Lindholm DD, Murray JS "Persistence of vancomycin in the blood during renal failure and its treatment by hemodialysis." N Engl J Med 274 (1966):  1047-51|Cunha BA, Quintilliani R, Deglin JM, Izard MW, Nightingale CH "Pharmacokinetics of vancomycin in anuria." Rev Infect Dis 3 Suppl (1981):  s269-72|Moellering RC, Krogstad DJ, Greenblatt DJ "Vancomycin therapy in patients with impaired renal function: a nomogram for dosage." Ann Intern Med 94 (1981):  343-6|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):|Wai AO, Lo AMS, Abdo A, Marra F "Vancomycin-induced acute interstitial nephritis." Ann Pharmacother 32 (1998):  1160-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31210, 28961, 'Vancomycin', 'Kidney Diseases', 'Intravenous use of vancomycin may be associated with oto- and nephrotoxic effects.  Eighth cranial nerve damage may manifest as tinnitus and varying degrees of hearing impairment.  Nephrotoxicity is usually evidenced by transient elevations in BUN or serum creatinine concentrations, as well as the presence of hyaline and granular casts and albumin in the urine.  Rarely, acute interstitial nephritis has been reported.  Although vancomycin-induced nephrotoxicity is generally reversible following discontinuation of the drug, death from uremia has occurred.  Therapy with vancomycin should be administered cautiously at reduced dosages in patients with renal impairment, since they may be at increased risk for oto- and nephrotoxicity due to drug accumulation.  To minimize the risk of toxicity, the usual dosage should not be exceeded, use with other neuro- and nephrotoxic agents should be avoided, and serum drug concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Oto- and nephrotoxicity has generally been associated with serum vancomycin levels of 80 to 100 mcg/mL, although toxic reactions have also been reported at levels as low as 25 mcg/mL.  Renal and eighth cranial nerve function should be closely monitored, and the dosage reduced or therapy withdrawn if toxicity develops.Oral vancomycin is generally not associated with systemic toxicity due to poor absorption from the gastrointestinal tract.  However, clinically significant serum concentrations have been reported in some patients following multiple oral doses of vancomycin for active Clostridium difficile pseudomembranous colitis.  The risk for systemic adverse effects may be greatest in patients with preexisting renal impairment.  Therefore, when vancomycin is administered orally, clinicians may want to heed the usual warnings and precautions associated with intravenous use of the drug.', '3', 'Moellering RC, Krogstad DJ, Greenblatt DJ "Pharmacokinetics of vancomycin in normal subjects and in patients with reduced renal function." Rev Infect Dis 3  Suppl (1981):  s230-5|Eisenberg ES, Robbins N, Lenci M "Vancomycin and interstitial nephritis." Ann Intern Med 95 (1981):  658|Masur H, Francioli P, Ruddy M, Murray HW "Vancomycin serum levels and toxicity in chronic hemodialysis patients with staphylococcus aureus bacteremia." Clin Nephrol 20 (1983):  85-8|Dean RP, Wagner DJ, Tolpin MD "Vancomycin/aminoglycoside nephrotoxicity." J Pediatr 106 (1985):  861-2|Sorrell TC, Collignon PJ "A prospective study of adverse reactions associated with vancomycin therapy." J Antimicrob Chemother 16 (1985):  235-41|Cimino MA, Rotstein C, Slaughter RL, Emrich LJ "Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy." Am J Med 83 (1987):  1091-7|Bergman MM, Glew RH, Ebert TH "Acute intetstitial nephritis associated with vancomycin therapy." Arch Intern Med 148 (1988):  2139-40|Ratner SJ "Vancomycin-induced interstitial nephritis." Am J Med 84 (1988):  561-2|Downs NJ, Neihart RE, Dolezal JM, Hodges GR "Mild nephrotoxicity associated with vancomycin use." Arch Intern Med 149 (1989):  1777-81|Codding CE, Ramseyer L, Allon M, Pitha J, Rodriguez M "Tubulointerstitial nephritis due to vancomycin." Am J Kidney Dis 14 (1989):  512-5|Rodvold KA, Blum RA, Fischer JH, et al. "Vancomycin pharmacokinetics in patients with various degrees of renal function." Antimicrob Agents Chemother 32 (1988):  848-52|Matzke GR, McGory RW, Halstenson CE, Keane WF "Pharmacokinetics of vancomycin in patients with various degrees of renal function." Antimicrob Agents Chemother 25 (1984):  433-7|Tan CC, Lee HS, Ti TY, Lee JC "Pharmacokinetics of intravenous vancomycin in patients with end-stage renal failure." Ther Drug Monit 12 (1990):  29-34|Macias WL, Mueller BA, Scarim SK "Vancomycin pharmacokinetics in acute renal failure: preservation of nonrenal clearance." Clin Pharmacol Ther 50 (1991):  688-94|Lindholm DD, Murray JS "Persistence of vancomycin in the blood during renal failure and its treatment by hemodialysis." N Engl J Med 274 (1966):  1047-51|Cunha BA, Quintilliani R, Deglin JM, Izard MW, Nightingale CH "Pharmacokinetics of vancomycin in anuria." Rev Infect Dis 3 Suppl (1981):  s269-72|Moellering RC, Krogstad DJ, Greenblatt DJ "Vancomycin therapy in patients with impaired renal function: a nomogram for dosage." Ann Intern Med 94 (1981):  343-6|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):|Wai AO, Lo AMS, Abdo A, Marra F "Vancomycin-induced acute interstitial nephritis." Ann Pharmacother 32 (1998):  1160-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31211, 28964, 'Vancomycin', 'Kidney Diseases', 'Intravenous use of vancomycin may be associated with oto- and nephrotoxic effects.  Eighth cranial nerve damage may manifest as tinnitus and varying degrees of hearing impairment.  Nephrotoxicity is usually evidenced by transient elevations in BUN or serum creatinine concentrations, as well as the presence of hyaline and granular casts and albumin in the urine.  Rarely, acute interstitial nephritis has been reported.  Although vancomycin-induced nephrotoxicity is generally reversible following discontinuation of the drug, death from uremia has occurred.  Therapy with vancomycin should be administered cautiously at reduced dosages in patients with renal impairment, since they may be at increased risk for oto- and nephrotoxicity due to drug accumulation.  To minimize the risk of toxicity, the usual dosage should not be exceeded, use with other neuro- and nephrotoxic agents should be avoided, and serum drug concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Oto- and nephrotoxicity has generally been associated with serum vancomycin levels of 80 to 100 mcg/mL, although toxic reactions have also been reported at levels as low as 25 mcg/mL.  Renal and eighth cranial nerve function should be closely monitored, and the dosage reduced or therapy withdrawn if toxicity develops.Oral vancomycin is generally not associated with systemic toxicity due to poor absorption from the gastrointestinal tract.  However, clinically significant serum concentrations have been reported in some patients following multiple oral doses of vancomycin for active Clostridium difficile pseudomembranous colitis.  The risk for systemic adverse effects may be greatest in patients with preexisting renal impairment.  Therefore, when vancomycin is administered orally, clinicians may want to heed the usual warnings and precautions associated with intravenous use of the drug.', '3', 'Moellering RC, Krogstad DJ, Greenblatt DJ "Pharmacokinetics of vancomycin in normal subjects and in patients with reduced renal function." Rev Infect Dis 3  Suppl (1981):  s230-5|Eisenberg ES, Robbins N, Lenci M "Vancomycin and interstitial nephritis." Ann Intern Med 95 (1981):  658|Masur H, Francioli P, Ruddy M, Murray HW "Vancomycin serum levels and toxicity in chronic hemodialysis patients with staphylococcus aureus bacteremia." Clin Nephrol 20 (1983):  85-8|Dean RP, Wagner DJ, Tolpin MD "Vancomycin/aminoglycoside nephrotoxicity." J Pediatr 106 (1985):  861-2|Sorrell TC, Collignon PJ "A prospective study of adverse reactions associated with vancomycin therapy." J Antimicrob Chemother 16 (1985):  235-41|Cimino MA, Rotstein C, Slaughter RL, Emrich LJ "Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy." Am J Med 83 (1987):  1091-7|Bergman MM, Glew RH, Ebert TH "Acute intetstitial nephritis associated with vancomycin therapy." Arch Intern Med 148 (1988):  2139-40|Ratner SJ "Vancomycin-induced interstitial nephritis." Am J Med 84 (1988):  561-2|Downs NJ, Neihart RE, Dolezal JM, Hodges GR "Mild nephrotoxicity associated with vancomycin use." Arch Intern Med 149 (1989):  1777-81|Codding CE, Ramseyer L, Allon M, Pitha J, Rodriguez M "Tubulointerstitial nephritis due to vancomycin." Am J Kidney Dis 14 (1989):  512-5|Rodvold KA, Blum RA, Fischer JH, et al. "Vancomycin pharmacokinetics in patients with various degrees of renal function." Antimicrob Agents Chemother 32 (1988):  848-52|Matzke GR, McGory RW, Halstenson CE, Keane WF "Pharmacokinetics of vancomycin in patients with various degrees of renal function." Antimicrob Agents Chemother 25 (1984):  433-7|Tan CC, Lee HS, Ti TY, Lee JC "Pharmacokinetics of intravenous vancomycin in patients with end-stage renal failure." Ther Drug Monit 12 (1990):  29-34|Macias WL, Mueller BA, Scarim SK "Vancomycin pharmacokinetics in acute renal failure: preservation of nonrenal clearance." Clin Pharmacol Ther 50 (1991):  688-94|Lindholm DD, Murray JS "Persistence of vancomycin in the blood during renal failure and its treatment by hemodialysis." N Engl J Med 274 (1966):  1047-51|Cunha BA, Quintilliani R, Deglin JM, Izard MW, Nightingale CH "Pharmacokinetics of vancomycin in anuria." Rev Infect Dis 3 Suppl (1981):  s269-72|Moellering RC, Krogstad DJ, Greenblatt DJ "Vancomycin therapy in patients with impaired renal function: a nomogram for dosage." Ann Intern Med 94 (1981):  343-6|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):|Wai AO, Lo AMS, Abdo A, Marra F "Vancomycin-induced acute interstitial nephritis." Ann Pharmacother 32 (1998):  1160-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31212, 28966, 'Vancomycin', 'Kidney Diseases', 'Intravenous use of vancomycin may be associated with oto- and nephrotoxic effects.  Eighth cranial nerve damage may manifest as tinnitus and varying degrees of hearing impairment.  Nephrotoxicity is usually evidenced by transient elevations in BUN or serum creatinine concentrations, as well as the presence of hyaline and granular casts and albumin in the urine.  Rarely, acute interstitial nephritis has been reported.  Although vancomycin-induced nephrotoxicity is generally reversible following discontinuation of the drug, death from uremia has occurred.  Therapy with vancomycin should be administered cautiously at reduced dosages in patients with renal impairment, since they may be at increased risk for oto- and nephrotoxicity due to drug accumulation.  To minimize the risk of toxicity, the usual dosage should not be exceeded, use with other neuro- and nephrotoxic agents should be avoided, and serum drug concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Oto- and nephrotoxicity has generally been associated with serum vancomycin levels of 80 to 100 mcg/mL, although toxic reactions have also been reported at levels as low as 25 mcg/mL.  Renal and eighth cranial nerve function should be closely monitored, and the dosage reduced or therapy withdrawn if toxicity develops.Oral vancomycin is generally not associated with systemic toxicity due to poor absorption from the gastrointestinal tract.  However, clinically significant serum concentrations have been reported in some patients following multiple oral doses of vancomycin for active Clostridium difficile pseudomembranous colitis.  The risk for systemic adverse effects may be greatest in patients with preexisting renal impairment.  Therefore, when vancomycin is administered orally, clinicians may want to heed the usual warnings and precautions associated with intravenous use of the drug.', '3', 'Moellering RC, Krogstad DJ, Greenblatt DJ "Pharmacokinetics of vancomycin in normal subjects and in patients with reduced renal function." Rev Infect Dis 3  Suppl (1981):  s230-5|Eisenberg ES, Robbins N, Lenci M "Vancomycin and interstitial nephritis." Ann Intern Med 95 (1981):  658|Masur H, Francioli P, Ruddy M, Murray HW "Vancomycin serum levels and toxicity in chronic hemodialysis patients with staphylococcus aureus bacteremia." Clin Nephrol 20 (1983):  85-8|Dean RP, Wagner DJ, Tolpin MD "Vancomycin/aminoglycoside nephrotoxicity." J Pediatr 106 (1985):  861-2|Sorrell TC, Collignon PJ "A prospective study of adverse reactions associated with vancomycin therapy." J Antimicrob Chemother 16 (1985):  235-41|Cimino MA, Rotstein C, Slaughter RL, Emrich LJ "Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy." Am J Med 83 (1987):  1091-7|Bergman MM, Glew RH, Ebert TH "Acute intetstitial nephritis associated with vancomycin therapy." Arch Intern Med 148 (1988):  2139-40|Ratner SJ "Vancomycin-induced interstitial nephritis." Am J Med 84 (1988):  561-2|Downs NJ, Neihart RE, Dolezal JM, Hodges GR "Mild nephrotoxicity associated with vancomycin use." Arch Intern Med 149 (1989):  1777-81|Codding CE, Ramseyer L, Allon M, Pitha J, Rodriguez M "Tubulointerstitial nephritis due to vancomycin." Am J Kidney Dis 14 (1989):  512-5|Rodvold KA, Blum RA, Fischer JH, et al. "Vancomycin pharmacokinetics in patients with various degrees of renal function." Antimicrob Agents Chemother 32 (1988):  848-52|Matzke GR, McGory RW, Halstenson CE, Keane WF "Pharmacokinetics of vancomycin in patients with various degrees of renal function." Antimicrob Agents Chemother 25 (1984):  433-7|Tan CC, Lee HS, Ti TY, Lee JC "Pharmacokinetics of intravenous vancomycin in patients with end-stage renal failure." Ther Drug Monit 12 (1990):  29-34|Macias WL, Mueller BA, Scarim SK "Vancomycin pharmacokinetics in acute renal failure: preservation of nonrenal clearance." Clin Pharmacol Ther 50 (1991):  688-94|Lindholm DD, Murray JS "Persistence of vancomycin in the blood during renal failure and its treatment by hemodialysis." N Engl J Med 274 (1966):  1047-51|Cunha BA, Quintilliani R, Deglin JM, Izard MW, Nightingale CH "Pharmacokinetics of vancomycin in anuria." Rev Infect Dis 3 Suppl (1981):  s269-72|Moellering RC, Krogstad DJ, Greenblatt DJ "Vancomycin therapy in patients with impaired renal function: a nomogram for dosage." Ann Intern Med 94 (1981):  343-6|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):|Wai AO, Lo AMS, Abdo A, Marra F "Vancomycin-induced acute interstitial nephritis." Ann Pharmacother 32 (1998):  1160-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31213, 28967, 'Vancomycin', 'Kidney Diseases', 'Intravenous use of vancomycin may be associated with oto- and nephrotoxic effects.  Eighth cranial nerve damage may manifest as tinnitus and varying degrees of hearing impairment.  Nephrotoxicity is usually evidenced by transient elevations in BUN or serum creatinine concentrations, as well as the presence of hyaline and granular casts and albumin in the urine.  Rarely, acute interstitial nephritis has been reported.  Although vancomycin-induced nephrotoxicity is generally reversible following discontinuation of the drug, death from uremia has occurred.  Therapy with vancomycin should be administered cautiously at reduced dosages in patients with renal impairment, since they may be at increased risk for oto- and nephrotoxicity due to drug accumulation.  To minimize the risk of toxicity, the usual dosage should not be exceeded, use with other neuro- and nephrotoxic agents should be avoided, and serum drug concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Oto- and nephrotoxicity has generally been associated with serum vancomycin levels of 80 to 100 mcg/mL, although toxic reactions have also been reported at levels as low as 25 mcg/mL.  Renal and eighth cranial nerve function should be closely monitored, and the dosage reduced or therapy withdrawn if toxicity develops.Oral vancomycin is generally not associated with systemic toxicity due to poor absorption from the gastrointestinal tract.  However, clinically significant serum concentrations have been reported in some patients following multiple oral doses of vancomycin for active Clostridium difficile pseudomembranous colitis.  The risk for systemic adverse effects may be greatest in patients with preexisting renal impairment.  Therefore, when vancomycin is administered orally, clinicians may want to heed the usual warnings and precautions associated with intravenous use of the drug.', '3', 'Moellering RC, Krogstad DJ, Greenblatt DJ "Pharmacokinetics of vancomycin in normal subjects and in patients with reduced renal function." Rev Infect Dis 3  Suppl (1981):  s230-5|Eisenberg ES, Robbins N, Lenci M "Vancomycin and interstitial nephritis." Ann Intern Med 95 (1981):  658|Masur H, Francioli P, Ruddy M, Murray HW "Vancomycin serum levels and toxicity in chronic hemodialysis patients with staphylococcus aureus bacteremia." Clin Nephrol 20 (1983):  85-8|Dean RP, Wagner DJ, Tolpin MD "Vancomycin/aminoglycoside nephrotoxicity." J Pediatr 106 (1985):  861-2|Sorrell TC, Collignon PJ "A prospective study of adverse reactions associated with vancomycin therapy." J Antimicrob Chemother 16 (1985):  235-41|Cimino MA, Rotstein C, Slaughter RL, Emrich LJ "Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy." Am J Med 83 (1987):  1091-7|Bergman MM, Glew RH, Ebert TH "Acute intetstitial nephritis associated with vancomycin therapy." Arch Intern Med 148 (1988):  2139-40|Ratner SJ "Vancomycin-induced interstitial nephritis." Am J Med 84 (1988):  561-2|Downs NJ, Neihart RE, Dolezal JM, Hodges GR "Mild nephrotoxicity associated with vancomycin use." Arch Intern Med 149 (1989):  1777-81|Codding CE, Ramseyer L, Allon M, Pitha J, Rodriguez M "Tubulointerstitial nephritis due to vancomycin." Am J Kidney Dis 14 (1989):  512-5|Rodvold KA, Blum RA, Fischer JH, et al. "Vancomycin pharmacokinetics in patients with various degrees of renal function." Antimicrob Agents Chemother 32 (1988):  848-52|Matzke GR, McGory RW, Halstenson CE, Keane WF "Pharmacokinetics of vancomycin in patients with various degrees of renal function." Antimicrob Agents Chemother 25 (1984):  433-7|Tan CC, Lee HS, Ti TY, Lee JC "Pharmacokinetics of intravenous vancomycin in patients with end-stage renal failure." Ther Drug Monit 12 (1990):  29-34|Macias WL, Mueller BA, Scarim SK "Vancomycin pharmacokinetics in acute renal failure: preservation of nonrenal clearance." Clin Pharmacol Ther 50 (1991):  688-94|Lindholm DD, Murray JS "Persistence of vancomycin in the blood during renal failure and its treatment by hemodialysis." N Engl J Med 274 (1966):  1047-51|Cunha BA, Quintilliani R, Deglin JM, Izard MW, Nightingale CH "Pharmacokinetics of vancomycin in anuria." Rev Infect Dis 3 Suppl (1981):  s269-72|Moellering RC, Krogstad DJ, Greenblatt DJ "Vancomycin therapy in patients with impaired renal function: a nomogram for dosage." Ann Intern Med 94 (1981):  343-6|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):|Wai AO, Lo AMS, Abdo A, Marra F "Vancomycin-induced acute interstitial nephritis." Ann Pharmacother 32 (1998):  1160-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31214, 29204, 'Vancomycin', 'Kidney Diseases', 'Intravenous use of vancomycin may be associated with oto- and nephrotoxic effects.  Eighth cranial nerve damage may manifest as tinnitus and varying degrees of hearing impairment.  Nephrotoxicity is usually evidenced by transient elevations in BUN or serum creatinine concentrations, as well as the presence of hyaline and granular casts and albumin in the urine.  Rarely, acute interstitial nephritis has been reported.  Although vancomycin-induced nephrotoxicity is generally reversible following discontinuation of the drug, death from uremia has occurred.  Therapy with vancomycin should be administered cautiously at reduced dosages in patients with renal impairment, since they may be at increased risk for oto- and nephrotoxicity due to drug accumulation.  To minimize the risk of toxicity, the usual dosage should not be exceeded, use with other neuro- and nephrotoxic agents should be avoided, and serum drug concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Oto- and nephrotoxicity has generally been associated with serum vancomycin levels of 80 to 100 mcg/mL, although toxic reactions have also been reported at levels as low as 25 mcg/mL.  Renal and eighth cranial nerve function should be closely monitored, and the dosage reduced or therapy withdrawn if toxicity develops.Oral vancomycin is generally not associated with systemic toxicity due to poor absorption from the gastrointestinal tract.  However, clinically significant serum concentrations have been reported in some patients following multiple oral doses of vancomycin for active Clostridium difficile pseudomembranous colitis.  The risk for systemic adverse effects may be greatest in patients with preexisting renal impairment.  Therefore, when vancomycin is administered orally, clinicians may want to heed the usual warnings and precautions associated with intravenous use of the drug.', '3', 'Moellering RC, Krogstad DJ, Greenblatt DJ "Pharmacokinetics of vancomycin in normal subjects and in patients with reduced renal function." Rev Infect Dis 3  Suppl (1981):  s230-5|Eisenberg ES, Robbins N, Lenci M "Vancomycin and interstitial nephritis." Ann Intern Med 95 (1981):  658|Masur H, Francioli P, Ruddy M, Murray HW "Vancomycin serum levels and toxicity in chronic hemodialysis patients with staphylococcus aureus bacteremia." Clin Nephrol 20 (1983):  85-8|Dean RP, Wagner DJ, Tolpin MD "Vancomycin/aminoglycoside nephrotoxicity." J Pediatr 106 (1985):  861-2|Sorrell TC, Collignon PJ "A prospective study of adverse reactions associated with vancomycin therapy." J Antimicrob Chemother 16 (1985):  235-41|Cimino MA, Rotstein C, Slaughter RL, Emrich LJ "Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy." Am J Med 83 (1987):  1091-7|Bergman MM, Glew RH, Ebert TH "Acute intetstitial nephritis associated with vancomycin therapy." Arch Intern Med 148 (1988):  2139-40|Ratner SJ "Vancomycin-induced interstitial nephritis." Am J Med 84 (1988):  561-2|Downs NJ, Neihart RE, Dolezal JM, Hodges GR "Mild nephrotoxicity associated with vancomycin use." Arch Intern Med 149 (1989):  1777-81|Codding CE, Ramseyer L, Allon M, Pitha J, Rodriguez M "Tubulointerstitial nephritis due to vancomycin." Am J Kidney Dis 14 (1989):  512-5|Rodvold KA, Blum RA, Fischer JH, et al. "Vancomycin pharmacokinetics in patients with various degrees of renal function." Antimicrob Agents Chemother 32 (1988):  848-52|Matzke GR, McGory RW, Halstenson CE, Keane WF "Pharmacokinetics of vancomycin in patients with various degrees of renal function." Antimicrob Agents Chemother 25 (1984):  433-7|Tan CC, Lee HS, Ti TY, Lee JC "Pharmacokinetics of intravenous vancomycin in patients with end-stage renal failure." Ther Drug Monit 12 (1990):  29-34|Macias WL, Mueller BA, Scarim SK "Vancomycin pharmacokinetics in acute renal failure: preservation of nonrenal clearance." Clin Pharmacol Ther 50 (1991):  688-94|Lindholm DD, Murray JS "Persistence of vancomycin in the blood during renal failure and its treatment by hemodialysis." N Engl J Med 274 (1966):  1047-51|Cunha BA, Quintilliani R, Deglin JM, Izard MW, Nightingale CH "Pharmacokinetics of vancomycin in anuria." Rev Infect Dis 3 Suppl (1981):  s269-72|Moellering RC, Krogstad DJ, Greenblatt DJ "Vancomycin therapy in patients with impaired renal function: a nomogram for dosage." Ann Intern Med 94 (1981):  343-6|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):|Wai AO, Lo AMS, Abdo A, Marra F "Vancomycin-induced acute interstitial nephritis." Ann Pharmacother 32 (1998):  1160-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31215, 31576, 'Vancomycin', 'Kidney Diseases', 'Intravenous use of vancomycin may be associated with oto- and nephrotoxic effects.  Eighth cranial nerve damage may manifest as tinnitus and varying degrees of hearing impairment.  Nephrotoxicity is usually evidenced by transient elevations in BUN or serum creatinine concentrations, as well as the presence of hyaline and granular casts and albumin in the urine.  Rarely, acute interstitial nephritis has been reported.  Although vancomycin-induced nephrotoxicity is generally reversible following discontinuation of the drug, death from uremia has occurred.  Therapy with vancomycin should be administered cautiously at reduced dosages in patients with renal impairment, since they may be at increased risk for oto- and nephrotoxicity due to drug accumulation.  To minimize the risk of toxicity, the usual dosage should not be exceeded, use with other neuro- and nephrotoxic agents should be avoided, and serum drug concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Oto- and nephrotoxicity has generally been associated with serum vancomycin levels of 80 to 100 mcg/mL, although toxic reactions have also been reported at levels as low as 25 mcg/mL.  Renal and eighth cranial nerve function should be closely monitored, and the dosage reduced or therapy withdrawn if toxicity develops.Oral vancomycin is generally not associated with systemic toxicity due to poor absorption from the gastrointestinal tract.  However, clinically significant serum concentrations have been reported in some patients following multiple oral doses of vancomycin for active Clostridium difficile pseudomembranous colitis.  The risk for systemic adverse effects may be greatest in patients with preexisting renal impairment.  Therefore, when vancomycin is administered orally, clinicians may want to heed the usual warnings and precautions associated with intravenous use of the drug.', '3', 'Moellering RC, Krogstad DJ, Greenblatt DJ "Pharmacokinetics of vancomycin in normal subjects and in patients with reduced renal function." Rev Infect Dis 3  Suppl (1981):  s230-5|Eisenberg ES, Robbins N, Lenci M "Vancomycin and interstitial nephritis." Ann Intern Med 95 (1981):  658|Masur H, Francioli P, Ruddy M, Murray HW "Vancomycin serum levels and toxicity in chronic hemodialysis patients with staphylococcus aureus bacteremia." Clin Nephrol 20 (1983):  85-8|Dean RP, Wagner DJ, Tolpin MD "Vancomycin/aminoglycoside nephrotoxicity." J Pediatr 106 (1985):  861-2|Sorrell TC, Collignon PJ "A prospective study of adverse reactions associated with vancomycin therapy." J Antimicrob Chemother 16 (1985):  235-41|Cimino MA, Rotstein C, Slaughter RL, Emrich LJ "Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy." Am J Med 83 (1987):  1091-7|Bergman MM, Glew RH, Ebert TH "Acute intetstitial nephritis associated with vancomycin therapy." Arch Intern Med 148 (1988):  2139-40|Ratner SJ "Vancomycin-induced interstitial nephritis." Am J Med 84 (1988):  561-2|Downs NJ, Neihart RE, Dolezal JM, Hodges GR "Mild nephrotoxicity associated with vancomycin use." Arch Intern Med 149 (1989):  1777-81|Codding CE, Ramseyer L, Allon M, Pitha J, Rodriguez M "Tubulointerstitial nephritis due to vancomycin." Am J Kidney Dis 14 (1989):  512-5|Rodvold KA, Blum RA, Fischer JH, et al. "Vancomycin pharmacokinetics in patients with various degrees of renal function." Antimicrob Agents Chemother 32 (1988):  848-52|Matzke GR, McGory RW, Halstenson CE, Keane WF "Pharmacokinetics of vancomycin in patients with various degrees of renal function." Antimicrob Agents Chemother 25 (1984):  433-7|Tan CC, Lee HS, Ti TY, Lee JC "Pharmacokinetics of intravenous vancomycin in patients with end-stage renal failure." Ther Drug Monit 12 (1990):  29-34|Macias WL, Mueller BA, Scarim SK "Vancomycin pharmacokinetics in acute renal failure: preservation of nonrenal clearance." Clin Pharmacol Ther 50 (1991):  688-94|Lindholm DD, Murray JS "Persistence of vancomycin in the blood during renal failure and its treatment by hemodialysis." N Engl J Med 274 (1966):  1047-51|Cunha BA, Quintilliani R, Deglin JM, Izard MW, Nightingale CH "Pharmacokinetics of vancomycin in anuria." Rev Infect Dis 3 Suppl (1981):  s269-72|Moellering RC, Krogstad DJ, Greenblatt DJ "Vancomycin therapy in patients with impaired renal function: a nomogram for dosage." Ann Intern Med 94 (1981):  343-6|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):|Wai AO, Lo AMS, Abdo A, Marra F "Vancomycin-induced acute interstitial nephritis." Ann Pharmacother 32 (1998):  1160-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31216, 32122, 'Vancomycin', 'Kidney Diseases', 'Intravenous use of vancomycin may be associated with oto- and nephrotoxic effects.  Eighth cranial nerve damage may manifest as tinnitus and varying degrees of hearing impairment.  Nephrotoxicity is usually evidenced by transient elevations in BUN or serum creatinine concentrations, as well as the presence of hyaline and granular casts and albumin in the urine.  Rarely, acute interstitial nephritis has been reported.  Although vancomycin-induced nephrotoxicity is generally reversible following discontinuation of the drug, death from uremia has occurred.  Therapy with vancomycin should be administered cautiously at reduced dosages in patients with renal impairment, since they may be at increased risk for oto- and nephrotoxicity due to drug accumulation.  To minimize the risk of toxicity, the usual dosage should not be exceeded, use with other neuro- and nephrotoxic agents should be avoided, and serum drug concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Oto- and nephrotoxicity has generally been associated with serum vancomycin levels of 80 to 100 mcg/mL, although toxic reactions have also been reported at levels as low as 25 mcg/mL.  Renal and eighth cranial nerve function should be closely monitored, and the dosage reduced or therapy withdrawn if toxicity develops.Oral vancomycin is generally not associated with systemic toxicity due to poor absorption from the gastrointestinal tract.  However, clinically significant serum concentrations have been reported in some patients following multiple oral doses of vancomycin for active Clostridium difficile pseudomembranous colitis.  The risk for systemic adverse effects may be greatest in patients with preexisting renal impairment.  Therefore, when vancomycin is administered orally, clinicians may want to heed the usual warnings and precautions associated with intravenous use of the drug.', '3', 'Moellering RC, Krogstad DJ, Greenblatt DJ "Pharmacokinetics of vancomycin in normal subjects and in patients with reduced renal function." Rev Infect Dis 3  Suppl (1981):  s230-5|Eisenberg ES, Robbins N, Lenci M "Vancomycin and interstitial nephritis." Ann Intern Med 95 (1981):  658|Masur H, Francioli P, Ruddy M, Murray HW "Vancomycin serum levels and toxicity in chronic hemodialysis patients with staphylococcus aureus bacteremia." Clin Nephrol 20 (1983):  85-8|Dean RP, Wagner DJ, Tolpin MD "Vancomycin/aminoglycoside nephrotoxicity." J Pediatr 106 (1985):  861-2|Sorrell TC, Collignon PJ "A prospective study of adverse reactions associated with vancomycin therapy." J Antimicrob Chemother 16 (1985):  235-41|Cimino MA, Rotstein C, Slaughter RL, Emrich LJ "Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy." Am J Med 83 (1987):  1091-7|Bergman MM, Glew RH, Ebert TH "Acute intetstitial nephritis associated with vancomycin therapy." Arch Intern Med 148 (1988):  2139-40|Ratner SJ "Vancomycin-induced interstitial nephritis." Am J Med 84 (1988):  561-2|Downs NJ, Neihart RE, Dolezal JM, Hodges GR "Mild nephrotoxicity associated with vancomycin use." Arch Intern Med 149 (1989):  1777-81|Codding CE, Ramseyer L, Allon M, Pitha J, Rodriguez M "Tubulointerstitial nephritis due to vancomycin." Am J Kidney Dis 14 (1989):  512-5|Rodvold KA, Blum RA, Fischer JH, et al. "Vancomycin pharmacokinetics in patients with various degrees of renal function." Antimicrob Agents Chemother 32 (1988):  848-52|Matzke GR, McGory RW, Halstenson CE, Keane WF "Pharmacokinetics of vancomycin in patients with various degrees of renal function." Antimicrob Agents Chemother 25 (1984):  433-7|Tan CC, Lee HS, Ti TY, Lee JC "Pharmacokinetics of intravenous vancomycin in patients with end-stage renal failure." Ther Drug Monit 12 (1990):  29-34|Macias WL, Mueller BA, Scarim SK "Vancomycin pharmacokinetics in acute renal failure: preservation of nonrenal clearance." Clin Pharmacol Ther 50 (1991):  688-94|Lindholm DD, Murray JS "Persistence of vancomycin in the blood during renal failure and its treatment by hemodialysis." N Engl J Med 274 (1966):  1047-51|Cunha BA, Quintilliani R, Deglin JM, Izard MW, Nightingale CH "Pharmacokinetics of vancomycin in anuria." Rev Infect Dis 3 Suppl (1981):  s269-72|Moellering RC, Krogstad DJ, Greenblatt DJ "Vancomycin therapy in patients with impaired renal function: a nomogram for dosage." Ann Intern Med 94 (1981):  343-6|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):|Wai AO, Lo AMS, Abdo A, Marra F "Vancomycin-induced acute interstitial nephritis." Ann Pharmacother 32 (1998):  1160-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31217, 32293, 'Vancomycin', 'Kidney Diseases', 'Intravenous use of vancomycin may be associated with oto- and nephrotoxic effects.  Eighth cranial nerve damage may manifest as tinnitus and varying degrees of hearing impairment.  Nephrotoxicity is usually evidenced by transient elevations in BUN or serum creatinine concentrations, as well as the presence of hyaline and granular casts and albumin in the urine.  Rarely, acute interstitial nephritis has been reported.  Although vancomycin-induced nephrotoxicity is generally reversible following discontinuation of the drug, death from uremia has occurred.  Therapy with vancomycin should be administered cautiously at reduced dosages in patients with renal impairment, since they may be at increased risk for oto- and nephrotoxicity due to drug accumulation.  To minimize the risk of toxicity, the usual dosage should not be exceeded, use with other neuro- and nephrotoxic agents should be avoided, and serum drug concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Oto- and nephrotoxicity has generally been associated with serum vancomycin levels of 80 to 100 mcg/mL, although toxic reactions have also been reported at levels as low as 25 mcg/mL.  Renal and eighth cranial nerve function should be closely monitored, and the dosage reduced or therapy withdrawn if toxicity develops.Oral vancomycin is generally not associated with systemic toxicity due to poor absorption from the gastrointestinal tract.  However, clinically significant serum concentrations have been reported in some patients following multiple oral doses of vancomycin for active Clostridium difficile pseudomembranous colitis.  The risk for systemic adverse effects may be greatest in patients with preexisting renal impairment.  Therefore, when vancomycin is administered orally, clinicians may want to heed the usual warnings and precautions associated with intravenous use of the drug.', '3', 'Moellering RC, Krogstad DJ, Greenblatt DJ "Pharmacokinetics of vancomycin in normal subjects and in patients with reduced renal function." Rev Infect Dis 3  Suppl (1981):  s230-5|Eisenberg ES, Robbins N, Lenci M "Vancomycin and interstitial nephritis." Ann Intern Med 95 (1981):  658|Masur H, Francioli P, Ruddy M, Murray HW "Vancomycin serum levels and toxicity in chronic hemodialysis patients with staphylococcus aureus bacteremia." Clin Nephrol 20 (1983):  85-8|Dean RP, Wagner DJ, Tolpin MD "Vancomycin/aminoglycoside nephrotoxicity." J Pediatr 106 (1985):  861-2|Sorrell TC, Collignon PJ "A prospective study of adverse reactions associated with vancomycin therapy." J Antimicrob Chemother 16 (1985):  235-41|Cimino MA, Rotstein C, Slaughter RL, Emrich LJ "Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy." Am J Med 83 (1987):  1091-7|Bergman MM, Glew RH, Ebert TH "Acute intetstitial nephritis associated with vancomycin therapy." Arch Intern Med 148 (1988):  2139-40|Ratner SJ "Vancomycin-induced interstitial nephritis." Am J Med 84 (1988):  561-2|Downs NJ, Neihart RE, Dolezal JM, Hodges GR "Mild nephrotoxicity associated with vancomycin use." Arch Intern Med 149 (1989):  1777-81|Codding CE, Ramseyer L, Allon M, Pitha J, Rodriguez M "Tubulointerstitial nephritis due to vancomycin." Am J Kidney Dis 14 (1989):  512-5|Rodvold KA, Blum RA, Fischer JH, et al. "Vancomycin pharmacokinetics in patients with various degrees of renal function." Antimicrob Agents Chemother 32 (1988):  848-52|Matzke GR, McGory RW, Halstenson CE, Keane WF "Pharmacokinetics of vancomycin in patients with various degrees of renal function." Antimicrob Agents Chemother 25 (1984):  433-7|Tan CC, Lee HS, Ti TY, Lee JC "Pharmacokinetics of intravenous vancomycin in patients with end-stage renal failure." Ther Drug Monit 12 (1990):  29-34|Macias WL, Mueller BA, Scarim SK "Vancomycin pharmacokinetics in acute renal failure: preservation of nonrenal clearance." Clin Pharmacol Ther 50 (1991):  688-94|Lindholm DD, Murray JS "Persistence of vancomycin in the blood during renal failure and its treatment by hemodialysis." N Engl J Med 274 (1966):  1047-51|Cunha BA, Quintilliani R, Deglin JM, Izard MW, Nightingale CH "Pharmacokinetics of vancomycin in anuria." Rev Infect Dis 3 Suppl (1981):  s269-72|Moellering RC, Krogstad DJ, Greenblatt DJ "Vancomycin therapy in patients with impaired renal function: a nomogram for dosage." Ann Intern Med 94 (1981):  343-6|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):|Wai AO, Lo AMS, Abdo A, Marra F "Vancomycin-induced acute interstitial nephritis." Ann Pharmacother 32 (1998):  1160-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31218, 33827, 'Vancomycin', 'Kidney Diseases', 'Intravenous use of vancomycin may be associated with oto- and nephrotoxic effects.  Eighth cranial nerve damage may manifest as tinnitus and varying degrees of hearing impairment.  Nephrotoxicity is usually evidenced by transient elevations in BUN or serum creatinine concentrations, as well as the presence of hyaline and granular casts and albumin in the urine.  Rarely, acute interstitial nephritis has been reported.  Although vancomycin-induced nephrotoxicity is generally reversible following discontinuation of the drug, death from uremia has occurred.  Therapy with vancomycin should be administered cautiously at reduced dosages in patients with renal impairment, since they may be at increased risk for oto- and nephrotoxicity due to drug accumulation.  To minimize the risk of toxicity, the usual dosage should not be exceeded, use with other neuro- and nephrotoxic agents should be avoided, and serum drug concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Oto- and nephrotoxicity has generally been associated with serum vancomycin levels of 80 to 100 mcg/mL, although toxic reactions have also been reported at levels as low as 25 mcg/mL.  Renal and eighth cranial nerve function should be closely monitored, and the dosage reduced or therapy withdrawn if toxicity develops.Oral vancomycin is generally not associated with systemic toxicity due to poor absorption from the gastrointestinal tract.  However, clinically significant serum concentrations have been reported in some patients following multiple oral doses of vancomycin for active Clostridium difficile pseudomembranous colitis.  The risk for systemic adverse effects may be greatest in patients with preexisting renal impairment.  Therefore, when vancomycin is administered orally, clinicians may want to heed the usual warnings and precautions associated with intravenous use of the drug.', '3', 'Moellering RC, Krogstad DJ, Greenblatt DJ "Pharmacokinetics of vancomycin in normal subjects and in patients with reduced renal function." Rev Infect Dis 3  Suppl (1981):  s230-5|Eisenberg ES, Robbins N, Lenci M "Vancomycin and interstitial nephritis." Ann Intern Med 95 (1981):  658|Masur H, Francioli P, Ruddy M, Murray HW "Vancomycin serum levels and toxicity in chronic hemodialysis patients with staphylococcus aureus bacteremia." Clin Nephrol 20 (1983):  85-8|Dean RP, Wagner DJ, Tolpin MD "Vancomycin/aminoglycoside nephrotoxicity." J Pediatr 106 (1985):  861-2|Sorrell TC, Collignon PJ "A prospective study of adverse reactions associated with vancomycin therapy." J Antimicrob Chemother 16 (1985):  235-41|Cimino MA, Rotstein C, Slaughter RL, Emrich LJ "Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy." Am J Med 83 (1987):  1091-7|Bergman MM, Glew RH, Ebert TH "Acute intetstitial nephritis associated with vancomycin therapy." Arch Intern Med 148 (1988):  2139-40|Ratner SJ "Vancomycin-induced interstitial nephritis." Am J Med 84 (1988):  561-2|Downs NJ, Neihart RE, Dolezal JM, Hodges GR "Mild nephrotoxicity associated with vancomycin use." Arch Intern Med 149 (1989):  1777-81|Codding CE, Ramseyer L, Allon M, Pitha J, Rodriguez M "Tubulointerstitial nephritis due to vancomycin." Am J Kidney Dis 14 (1989):  512-5|Rodvold KA, Blum RA, Fischer JH, et al. "Vancomycin pharmacokinetics in patients with various degrees of renal function." Antimicrob Agents Chemother 32 (1988):  848-52|Matzke GR, McGory RW, Halstenson CE, Keane WF "Pharmacokinetics of vancomycin in patients with various degrees of renal function." Antimicrob Agents Chemother 25 (1984):  433-7|Tan CC, Lee HS, Ti TY, Lee JC "Pharmacokinetics of intravenous vancomycin in patients with end-stage renal failure." Ther Drug Monit 12 (1990):  29-34|Macias WL, Mueller BA, Scarim SK "Vancomycin pharmacokinetics in acute renal failure: preservation of nonrenal clearance." Clin Pharmacol Ther 50 (1991):  688-94|Lindholm DD, Murray JS "Persistence of vancomycin in the blood during renal failure and its treatment by hemodialysis." N Engl J Med 274 (1966):  1047-51|Cunha BA, Quintilliani R, Deglin JM, Izard MW, Nightingale CH "Pharmacokinetics of vancomycin in anuria." Rev Infect Dis 3 Suppl (1981):  s269-72|Moellering RC, Krogstad DJ, Greenblatt DJ "Vancomycin therapy in patients with impaired renal function: a nomogram for dosage." Ann Intern Med 94 (1981):  343-6|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):|Wai AO, Lo AMS, Abdo A, Marra F "Vancomycin-induced acute interstitial nephritis." Ann Pharmacother 32 (1998):  1160-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31219, 33828, 'Vancomycin', 'Kidney Diseases', 'Intravenous use of vancomycin may be associated with oto- and nephrotoxic effects.  Eighth cranial nerve damage may manifest as tinnitus and varying degrees of hearing impairment.  Nephrotoxicity is usually evidenced by transient elevations in BUN or serum creatinine concentrations, as well as the presence of hyaline and granular casts and albumin in the urine.  Rarely, acute interstitial nephritis has been reported.  Although vancomycin-induced nephrotoxicity is generally reversible following discontinuation of the drug, death from uremia has occurred.  Therapy with vancomycin should be administered cautiously at reduced dosages in patients with renal impairment, since they may be at increased risk for oto- and nephrotoxicity due to drug accumulation.  To minimize the risk of toxicity, the usual dosage should not be exceeded, use with other neuro- and nephrotoxic agents should be avoided, and serum drug concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Oto- and nephrotoxicity has generally been associated with serum vancomycin levels of 80 to 100 mcg/mL, although toxic reactions have also been reported at levels as low as 25 mcg/mL.  Renal and eighth cranial nerve function should be closely monitored, and the dosage reduced or therapy withdrawn if toxicity develops.Oral vancomycin is generally not associated with systemic toxicity due to poor absorption from the gastrointestinal tract.  However, clinically significant serum concentrations have been reported in some patients following multiple oral doses of vancomycin for active Clostridium difficile pseudomembranous colitis.  The risk for systemic adverse effects may be greatest in patients with preexisting renal impairment.  Therefore, when vancomycin is administered orally, clinicians may want to heed the usual warnings and precautions associated with intravenous use of the drug.', '3', 'Moellering RC, Krogstad DJ, Greenblatt DJ "Pharmacokinetics of vancomycin in normal subjects and in patients with reduced renal function." Rev Infect Dis 3  Suppl (1981):  s230-5|Eisenberg ES, Robbins N, Lenci M "Vancomycin and interstitial nephritis." Ann Intern Med 95 (1981):  658|Masur H, Francioli P, Ruddy M, Murray HW "Vancomycin serum levels and toxicity in chronic hemodialysis patients with staphylococcus aureus bacteremia." Clin Nephrol 20 (1983):  85-8|Dean RP, Wagner DJ, Tolpin MD "Vancomycin/aminoglycoside nephrotoxicity." J Pediatr 106 (1985):  861-2|Sorrell TC, Collignon PJ "A prospective study of adverse reactions associated with vancomycin therapy." J Antimicrob Chemother 16 (1985):  235-41|Cimino MA, Rotstein C, Slaughter RL, Emrich LJ "Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy." Am J Med 83 (1987):  1091-7|Bergman MM, Glew RH, Ebert TH "Acute intetstitial nephritis associated with vancomycin therapy." Arch Intern Med 148 (1988):  2139-40|Ratner SJ "Vancomycin-induced interstitial nephritis." Am J Med 84 (1988):  561-2|Downs NJ, Neihart RE, Dolezal JM, Hodges GR "Mild nephrotoxicity associated with vancomycin use." Arch Intern Med 149 (1989):  1777-81|Codding CE, Ramseyer L, Allon M, Pitha J, Rodriguez M "Tubulointerstitial nephritis due to vancomycin." Am J Kidney Dis 14 (1989):  512-5|Rodvold KA, Blum RA, Fischer JH, et al. "Vancomycin pharmacokinetics in patients with various degrees of renal function." Antimicrob Agents Chemother 32 (1988):  848-52|Matzke GR, McGory RW, Halstenson CE, Keane WF "Pharmacokinetics of vancomycin in patients with various degrees of renal function." Antimicrob Agents Chemother 25 (1984):  433-7|Tan CC, Lee HS, Ti TY, Lee JC "Pharmacokinetics of intravenous vancomycin in patients with end-stage renal failure." Ther Drug Monit 12 (1990):  29-34|Macias WL, Mueller BA, Scarim SK "Vancomycin pharmacokinetics in acute renal failure: preservation of nonrenal clearance." Clin Pharmacol Ther 50 (1991):  688-94|Lindholm DD, Murray JS "Persistence of vancomycin in the blood during renal failure and its treatment by hemodialysis." N Engl J Med 274 (1966):  1047-51|Cunha BA, Quintilliani R, Deglin JM, Izard MW, Nightingale CH "Pharmacokinetics of vancomycin in anuria." Rev Infect Dis 3 Suppl (1981):  s269-72|Moellering RC, Krogstad DJ, Greenblatt DJ "Vancomycin therapy in patients with impaired renal function: a nomogram for dosage." Ann Intern Med 94 (1981):  343-6|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):|Wai AO, Lo AMS, Abdo A, Marra F "Vancomycin-induced acute interstitial nephritis." Ann Pharmacother 32 (1998):  1160-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31220, 12071, 'Vancomycin', 'Neutropenia', 'Reversible neutropenia has been reported with intravenous use of vancomycin, usually starting one week or more after initiation of therapy or after a total dosage of more than 25 g.  Thrombocytopenia and agranulocytosis (granulocytes < 500/mm3) has occurred rarely.  Patients with preexisting neutropenia should be monitored closely during vancomycin therapy for further decreases in leukocyte counts, and therapy discontinued if appropriate.', '2', 'Kauffman CA, Severance PJ, Silva J, Huard TK "Neutropenia associated with vancomycin therapy." South Med J 75 (1982):  1131-3|Farwell AP, Kendall LG, Vakil RD, Glew RH "Delayed appearance of vancomycin-induced neutropenia in a patient with chronic renal failure." South Med J 77 (1984):  664-5|Mackett RL, Guay DR "Vancomycin-induced neutropenia." Can Med Assoc J 132 (1985):  39-40|Koo KB, Bachand RL, Chow AW "Vancomycin-induced neutropenia." Drug Intell Clin Pharm 20 (1986):  780-2|Adrouny A, Meguerditchian S, Koo CH, et al. "Agranulocytosis related to vancomycin therapy." Am J Med 81 (1986):  1059-61|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):|Mandl DL, Garrison MW, Palpant SD "Agranulocytosis induced by vancomycin or ticarcillin/clavulanate." Ann Pharmacother 31 (1997):  1321-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31221, 12072, 'Vancomycin', 'Neutropenia', 'Reversible neutropenia has been reported with intravenous use of vancomycin, usually starting one week or more after initiation of therapy or after a total dosage of more than 25 g.  Thrombocytopenia and agranulocytosis (granulocytes < 500/mm3) has occurred rarely.  Patients with preexisting neutropenia should be monitored closely during vancomycin therapy for further decreases in leukocyte counts, and therapy discontinued if appropriate.', '2', 'Kauffman CA, Severance PJ, Silva J, Huard TK "Neutropenia associated with vancomycin therapy." South Med J 75 (1982):  1131-3|Farwell AP, Kendall LG, Vakil RD, Glew RH "Delayed appearance of vancomycin-induced neutropenia in a patient with chronic renal failure." South Med J 77 (1984):  664-5|Mackett RL, Guay DR "Vancomycin-induced neutropenia." Can Med Assoc J 132 (1985):  39-40|Koo KB, Bachand RL, Chow AW "Vancomycin-induced neutropenia." Drug Intell Clin Pharm 20 (1986):  780-2|Adrouny A, Meguerditchian S, Koo CH, et al. "Agranulocytosis related to vancomycin therapy." Am J Med 81 (1986):  1059-61|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):|Mandl DL, Garrison MW, Palpant SD "Agranulocytosis induced by vancomycin or ticarcillin/clavulanate." Ann Pharmacother 31 (1997):  1321-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31222, 12074, 'Vancomycin', 'Neutropenia', 'Reversible neutropenia has been reported with intravenous use of vancomycin, usually starting one week or more after initiation of therapy or after a total dosage of more than 25 g.  Thrombocytopenia and agranulocytosis (granulocytes < 500/mm3) has occurred rarely.  Patients with preexisting neutropenia should be monitored closely during vancomycin therapy for further decreases in leukocyte counts, and therapy discontinued if appropriate.', '2', 'Kauffman CA, Severance PJ, Silva J, Huard TK "Neutropenia associated with vancomycin therapy." South Med J 75 (1982):  1131-3|Farwell AP, Kendall LG, Vakil RD, Glew RH "Delayed appearance of vancomycin-induced neutropenia in a patient with chronic renal failure." South Med J 77 (1984):  664-5|Mackett RL, Guay DR "Vancomycin-induced neutropenia." Can Med Assoc J 132 (1985):  39-40|Koo KB, Bachand RL, Chow AW "Vancomycin-induced neutropenia." Drug Intell Clin Pharm 20 (1986):  780-2|Adrouny A, Meguerditchian S, Koo CH, et al. "Agranulocytosis related to vancomycin therapy." Am J Med 81 (1986):  1059-61|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):|Mandl DL, Garrison MW, Palpant SD "Agranulocytosis induced by vancomycin or ticarcillin/clavulanate." Ann Pharmacother 31 (1997):  1321-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31223, 18077, 'Vancomycin', 'Neutropenia', 'Reversible neutropenia has been reported with intravenous use of vancomycin, usually starting one week or more after initiation of therapy or after a total dosage of more than 25 g.  Thrombocytopenia and agranulocytosis (granulocytes < 500/mm3) has occurred rarely.  Patients with preexisting neutropenia should be monitored closely during vancomycin therapy for further decreases in leukocyte counts, and therapy discontinued if appropriate.', '2', 'Kauffman CA, Severance PJ, Silva J, Huard TK "Neutropenia associated with vancomycin therapy." South Med J 75 (1982):  1131-3|Farwell AP, Kendall LG, Vakil RD, Glew RH "Delayed appearance of vancomycin-induced neutropenia in a patient with chronic renal failure." South Med J 77 (1984):  664-5|Mackett RL, Guay DR "Vancomycin-induced neutropenia." Can Med Assoc J 132 (1985):  39-40|Koo KB, Bachand RL, Chow AW "Vancomycin-induced neutropenia." Drug Intell Clin Pharm 20 (1986):  780-2|Adrouny A, Meguerditchian S, Koo CH, et al. "Agranulocytosis related to vancomycin therapy." Am J Med 81 (1986):  1059-61|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):|Mandl DL, Garrison MW, Palpant SD "Agranulocytosis induced by vancomycin or ticarcillin/clavulanate." Ann Pharmacother 31 (1997):  1321-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31224, 18078, 'Vancomycin', 'Neutropenia', 'Reversible neutropenia has been reported with intravenous use of vancomycin, usually starting one week or more after initiation of therapy or after a total dosage of more than 25 g.  Thrombocytopenia and agranulocytosis (granulocytes < 500/mm3) has occurred rarely.  Patients with preexisting neutropenia should be monitored closely during vancomycin therapy for further decreases in leukocyte counts, and therapy discontinued if appropriate.', '2', 'Kauffman CA, Severance PJ, Silva J, Huard TK "Neutropenia associated with vancomycin therapy." South Med J 75 (1982):  1131-3|Farwell AP, Kendall LG, Vakil RD, Glew RH "Delayed appearance of vancomycin-induced neutropenia in a patient with chronic renal failure." South Med J 77 (1984):  664-5|Mackett RL, Guay DR "Vancomycin-induced neutropenia." Can Med Assoc J 132 (1985):  39-40|Koo KB, Bachand RL, Chow AW "Vancomycin-induced neutropenia." Drug Intell Clin Pharm 20 (1986):  780-2|Adrouny A, Meguerditchian S, Koo CH, et al. "Agranulocytosis related to vancomycin therapy." Am J Med 81 (1986):  1059-61|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):|Mandl DL, Garrison MW, Palpant SD "Agranulocytosis induced by vancomycin or ticarcillin/clavulanate." Ann Pharmacother 31 (1997):  1321-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31225, 21315, 'Vancomycin', 'Neutropenia', 'Reversible neutropenia has been reported with intravenous use of vancomycin, usually starting one week or more after initiation of therapy or after a total dosage of more than 25 g.  Thrombocytopenia and agranulocytosis (granulocytes < 500/mm3) has occurred rarely.  Patients with preexisting neutropenia should be monitored closely during vancomycin therapy for further decreases in leukocyte counts, and therapy discontinued if appropriate.', '2', 'Kauffman CA, Severance PJ, Silva J, Huard TK "Neutropenia associated with vancomycin therapy." South Med J 75 (1982):  1131-3|Farwell AP, Kendall LG, Vakil RD, Glew RH "Delayed appearance of vancomycin-induced neutropenia in a patient with chronic renal failure." South Med J 77 (1984):  664-5|Mackett RL, Guay DR "Vancomycin-induced neutropenia." Can Med Assoc J 132 (1985):  39-40|Koo KB, Bachand RL, Chow AW "Vancomycin-induced neutropenia." Drug Intell Clin Pharm 20 (1986):  780-2|Adrouny A, Meguerditchian S, Koo CH, et al. "Agranulocytosis related to vancomycin therapy." Am J Med 81 (1986):  1059-61|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):|Mandl DL, Garrison MW, Palpant SD "Agranulocytosis induced by vancomycin or ticarcillin/clavulanate." Ann Pharmacother 31 (1997):  1321-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31226, 28959, 'Vancomycin', 'Neutropenia', 'Reversible neutropenia has been reported with intravenous use of vancomycin, usually starting one week or more after initiation of therapy or after a total dosage of more than 25 g.  Thrombocytopenia and agranulocytosis (granulocytes < 500/mm3) has occurred rarely.  Patients with preexisting neutropenia should be monitored closely during vancomycin therapy for further decreases in leukocyte counts, and therapy discontinued if appropriate.', '2', 'Kauffman CA, Severance PJ, Silva J, Huard TK "Neutropenia associated with vancomycin therapy." South Med J 75 (1982):  1131-3|Farwell AP, Kendall LG, Vakil RD, Glew RH "Delayed appearance of vancomycin-induced neutropenia in a patient with chronic renal failure." South Med J 77 (1984):  664-5|Mackett RL, Guay DR "Vancomycin-induced neutropenia." Can Med Assoc J 132 (1985):  39-40|Koo KB, Bachand RL, Chow AW "Vancomycin-induced neutropenia." Drug Intell Clin Pharm 20 (1986):  780-2|Adrouny A, Meguerditchian S, Koo CH, et al. "Agranulocytosis related to vancomycin therapy." Am J Med 81 (1986):  1059-61|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):|Mandl DL, Garrison MW, Palpant SD "Agranulocytosis induced by vancomycin or ticarcillin/clavulanate." Ann Pharmacother 31 (1997):  1321-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31227, 28961, 'Vancomycin', 'Neutropenia', 'Reversible neutropenia has been reported with intravenous use of vancomycin, usually starting one week or more after initiation of therapy or after a total dosage of more than 25 g.  Thrombocytopenia and agranulocytosis (granulocytes < 500/mm3) has occurred rarely.  Patients with preexisting neutropenia should be monitored closely during vancomycin therapy for further decreases in leukocyte counts, and therapy discontinued if appropriate.', '2', 'Kauffman CA, Severance PJ, Silva J, Huard TK "Neutropenia associated with vancomycin therapy." South Med J 75 (1982):  1131-3|Farwell AP, Kendall LG, Vakil RD, Glew RH "Delayed appearance of vancomycin-induced neutropenia in a patient with chronic renal failure." South Med J 77 (1984):  664-5|Mackett RL, Guay DR "Vancomycin-induced neutropenia." Can Med Assoc J 132 (1985):  39-40|Koo KB, Bachand RL, Chow AW "Vancomycin-induced neutropenia." Drug Intell Clin Pharm 20 (1986):  780-2|Adrouny A, Meguerditchian S, Koo CH, et al. "Agranulocytosis related to vancomycin therapy." Am J Med 81 (1986):  1059-61|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):|Mandl DL, Garrison MW, Palpant SD "Agranulocytosis induced by vancomycin or ticarcillin/clavulanate." Ann Pharmacother 31 (1997):  1321-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31228, 28964, 'Vancomycin', 'Neutropenia', 'Reversible neutropenia has been reported with intravenous use of vancomycin, usually starting one week or more after initiation of therapy or after a total dosage of more than 25 g.  Thrombocytopenia and agranulocytosis (granulocytes < 500/mm3) has occurred rarely.  Patients with preexisting neutropenia should be monitored closely during vancomycin therapy for further decreases in leukocyte counts, and therapy discontinued if appropriate.', '2', 'Kauffman CA, Severance PJ, Silva J, Huard TK "Neutropenia associated with vancomycin therapy." South Med J 75 (1982):  1131-3|Farwell AP, Kendall LG, Vakil RD, Glew RH "Delayed appearance of vancomycin-induced neutropenia in a patient with chronic renal failure." South Med J 77 (1984):  664-5|Mackett RL, Guay DR "Vancomycin-induced neutropenia." Can Med Assoc J 132 (1985):  39-40|Koo KB, Bachand RL, Chow AW "Vancomycin-induced neutropenia." Drug Intell Clin Pharm 20 (1986):  780-2|Adrouny A, Meguerditchian S, Koo CH, et al. "Agranulocytosis related to vancomycin therapy." Am J Med 81 (1986):  1059-61|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):|Mandl DL, Garrison MW, Palpant SD "Agranulocytosis induced by vancomycin or ticarcillin/clavulanate." Ann Pharmacother 31 (1997):  1321-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31229, 28966, 'Vancomycin', 'Neutropenia', 'Reversible neutropenia has been reported with intravenous use of vancomycin, usually starting one week or more after initiation of therapy or after a total dosage of more than 25 g.  Thrombocytopenia and agranulocytosis (granulocytes < 500/mm3) has occurred rarely.  Patients with preexisting neutropenia should be monitored closely during vancomycin therapy for further decreases in leukocyte counts, and therapy discontinued if appropriate.', '2', 'Kauffman CA, Severance PJ, Silva J, Huard TK "Neutropenia associated with vancomycin therapy." South Med J 75 (1982):  1131-3|Farwell AP, Kendall LG, Vakil RD, Glew RH "Delayed appearance of vancomycin-induced neutropenia in a patient with chronic renal failure." South Med J 77 (1984):  664-5|Mackett RL, Guay DR "Vancomycin-induced neutropenia." Can Med Assoc J 132 (1985):  39-40|Koo KB, Bachand RL, Chow AW "Vancomycin-induced neutropenia." Drug Intell Clin Pharm 20 (1986):  780-2|Adrouny A, Meguerditchian S, Koo CH, et al. "Agranulocytosis related to vancomycin therapy." Am J Med 81 (1986):  1059-61|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):|Mandl DL, Garrison MW, Palpant SD "Agranulocytosis induced by vancomycin or ticarcillin/clavulanate." Ann Pharmacother 31 (1997):  1321-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31230, 28967, 'Vancomycin', 'Neutropenia', 'Reversible neutropenia has been reported with intravenous use of vancomycin, usually starting one week or more after initiation of therapy or after a total dosage of more than 25 g.  Thrombocytopenia and agranulocytosis (granulocytes < 500/mm3) has occurred rarely.  Patients with preexisting neutropenia should be monitored closely during vancomycin therapy for further decreases in leukocyte counts, and therapy discontinued if appropriate.', '2', 'Kauffman CA, Severance PJ, Silva J, Huard TK "Neutropenia associated with vancomycin therapy." South Med J 75 (1982):  1131-3|Farwell AP, Kendall LG, Vakil RD, Glew RH "Delayed appearance of vancomycin-induced neutropenia in a patient with chronic renal failure." South Med J 77 (1984):  664-5|Mackett RL, Guay DR "Vancomycin-induced neutropenia." Can Med Assoc J 132 (1985):  39-40|Koo KB, Bachand RL, Chow AW "Vancomycin-induced neutropenia." Drug Intell Clin Pharm 20 (1986):  780-2|Adrouny A, Meguerditchian S, Koo CH, et al. "Agranulocytosis related to vancomycin therapy." Am J Med 81 (1986):  1059-61|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):|Mandl DL, Garrison MW, Palpant SD "Agranulocytosis induced by vancomycin or ticarcillin/clavulanate." Ann Pharmacother 31 (1997):  1321-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31231, 29204, 'Vancomycin', 'Neutropenia', 'Reversible neutropenia has been reported with intravenous use of vancomycin, usually starting one week or more after initiation of therapy or after a total dosage of more than 25 g.  Thrombocytopenia and agranulocytosis (granulocytes < 500/mm3) has occurred rarely.  Patients with preexisting neutropenia should be monitored closely during vancomycin therapy for further decreases in leukocyte counts, and therapy discontinued if appropriate.', '2', 'Kauffman CA, Severance PJ, Silva J, Huard TK "Neutropenia associated with vancomycin therapy." South Med J 75 (1982):  1131-3|Farwell AP, Kendall LG, Vakil RD, Glew RH "Delayed appearance of vancomycin-induced neutropenia in a patient with chronic renal failure." South Med J 77 (1984):  664-5|Mackett RL, Guay DR "Vancomycin-induced neutropenia." Can Med Assoc J 132 (1985):  39-40|Koo KB, Bachand RL, Chow AW "Vancomycin-induced neutropenia." Drug Intell Clin Pharm 20 (1986):  780-2|Adrouny A, Meguerditchian S, Koo CH, et al. "Agranulocytosis related to vancomycin therapy." Am J Med 81 (1986):  1059-61|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):|Mandl DL, Garrison MW, Palpant SD "Agranulocytosis induced by vancomycin or ticarcillin/clavulanate." Ann Pharmacother 31 (1997):  1321-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31232, 31576, 'Vancomycin', 'Neutropenia', 'Reversible neutropenia has been reported with intravenous use of vancomycin, usually starting one week or more after initiation of therapy or after a total dosage of more than 25 g.  Thrombocytopenia and agranulocytosis (granulocytes < 500/mm3) has occurred rarely.  Patients with preexisting neutropenia should be monitored closely during vancomycin therapy for further decreases in leukocyte counts, and therapy discontinued if appropriate.', '2', 'Kauffman CA, Severance PJ, Silva J, Huard TK "Neutropenia associated with vancomycin therapy." South Med J 75 (1982):  1131-3|Farwell AP, Kendall LG, Vakil RD, Glew RH "Delayed appearance of vancomycin-induced neutropenia in a patient with chronic renal failure." South Med J 77 (1984):  664-5|Mackett RL, Guay DR "Vancomycin-induced neutropenia." Can Med Assoc J 132 (1985):  39-40|Koo KB, Bachand RL, Chow AW "Vancomycin-induced neutropenia." Drug Intell Clin Pharm 20 (1986):  780-2|Adrouny A, Meguerditchian S, Koo CH, et al. "Agranulocytosis related to vancomycin therapy." Am J Med 81 (1986):  1059-61|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):|Mandl DL, Garrison MW, Palpant SD "Agranulocytosis induced by vancomycin or ticarcillin/clavulanate." Ann Pharmacother 31 (1997):  1321-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31233, 32122, 'Vancomycin', 'Neutropenia', 'Reversible neutropenia has been reported with intravenous use of vancomycin, usually starting one week or more after initiation of therapy or after a total dosage of more than 25 g.  Thrombocytopenia and agranulocytosis (granulocytes < 500/mm3) has occurred rarely.  Patients with preexisting neutropenia should be monitored closely during vancomycin therapy for further decreases in leukocyte counts, and therapy discontinued if appropriate.', '2', 'Kauffman CA, Severance PJ, Silva J, Huard TK "Neutropenia associated with vancomycin therapy." South Med J 75 (1982):  1131-3|Farwell AP, Kendall LG, Vakil RD, Glew RH "Delayed appearance of vancomycin-induced neutropenia in a patient with chronic renal failure." South Med J 77 (1984):  664-5|Mackett RL, Guay DR "Vancomycin-induced neutropenia." Can Med Assoc J 132 (1985):  39-40|Koo KB, Bachand RL, Chow AW "Vancomycin-induced neutropenia." Drug Intell Clin Pharm 20 (1986):  780-2|Adrouny A, Meguerditchian S, Koo CH, et al. "Agranulocytosis related to vancomycin therapy." Am J Med 81 (1986):  1059-61|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):|Mandl DL, Garrison MW, Palpant SD "Agranulocytosis induced by vancomycin or ticarcillin/clavulanate." Ann Pharmacother 31 (1997):  1321-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31234, 32293, 'Vancomycin', 'Neutropenia', 'Reversible neutropenia has been reported with intravenous use of vancomycin, usually starting one week or more after initiation of therapy or after a total dosage of more than 25 g.  Thrombocytopenia and agranulocytosis (granulocytes < 500/mm3) has occurred rarely.  Patients with preexisting neutropenia should be monitored closely during vancomycin therapy for further decreases in leukocyte counts, and therapy discontinued if appropriate.', '2', 'Kauffman CA, Severance PJ, Silva J, Huard TK "Neutropenia associated with vancomycin therapy." South Med J 75 (1982):  1131-3|Farwell AP, Kendall LG, Vakil RD, Glew RH "Delayed appearance of vancomycin-induced neutropenia in a patient with chronic renal failure." South Med J 77 (1984):  664-5|Mackett RL, Guay DR "Vancomycin-induced neutropenia." Can Med Assoc J 132 (1985):  39-40|Koo KB, Bachand RL, Chow AW "Vancomycin-induced neutropenia." Drug Intell Clin Pharm 20 (1986):  780-2|Adrouny A, Meguerditchian S, Koo CH, et al. "Agranulocytosis related to vancomycin therapy." Am J Med 81 (1986):  1059-61|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):|Mandl DL, Garrison MW, Palpant SD "Agranulocytosis induced by vancomycin or ticarcillin/clavulanate." Ann Pharmacother 31 (1997):  1321-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31235, 33827, 'Vancomycin', 'Neutropenia', 'Reversible neutropenia has been reported with intravenous use of vancomycin, usually starting one week or more after initiation of therapy or after a total dosage of more than 25 g.  Thrombocytopenia and agranulocytosis (granulocytes < 500/mm3) has occurred rarely.  Patients with preexisting neutropenia should be monitored closely during vancomycin therapy for further decreases in leukocyte counts, and therapy discontinued if appropriate.', '2', 'Kauffman CA, Severance PJ, Silva J, Huard TK "Neutropenia associated with vancomycin therapy." South Med J 75 (1982):  1131-3|Farwell AP, Kendall LG, Vakil RD, Glew RH "Delayed appearance of vancomycin-induced neutropenia in a patient with chronic renal failure." South Med J 77 (1984):  664-5|Mackett RL, Guay DR "Vancomycin-induced neutropenia." Can Med Assoc J 132 (1985):  39-40|Koo KB, Bachand RL, Chow AW "Vancomycin-induced neutropenia." Drug Intell Clin Pharm 20 (1986):  780-2|Adrouny A, Meguerditchian S, Koo CH, et al. "Agranulocytosis related to vancomycin therapy." Am J Med 81 (1986):  1059-61|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):|Mandl DL, Garrison MW, Palpant SD "Agranulocytosis induced by vancomycin or ticarcillin/clavulanate." Ann Pharmacother 31 (1997):  1321-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31236, 33828, 'Vancomycin', 'Neutropenia', 'Reversible neutropenia has been reported with intravenous use of vancomycin, usually starting one week or more after initiation of therapy or after a total dosage of more than 25 g.  Thrombocytopenia and agranulocytosis (granulocytes < 500/mm3) has occurred rarely.  Patients with preexisting neutropenia should be monitored closely during vancomycin therapy for further decreases in leukocyte counts, and therapy discontinued if appropriate.', '2', 'Kauffman CA, Severance PJ, Silva J, Huard TK "Neutropenia associated with vancomycin therapy." South Med J 75 (1982):  1131-3|Farwell AP, Kendall LG, Vakil RD, Glew RH "Delayed appearance of vancomycin-induced neutropenia in a patient with chronic renal failure." South Med J 77 (1984):  664-5|Mackett RL, Guay DR "Vancomycin-induced neutropenia." Can Med Assoc J 132 (1985):  39-40|Koo KB, Bachand RL, Chow AW "Vancomycin-induced neutropenia." Drug Intell Clin Pharm 20 (1986):  780-2|Adrouny A, Meguerditchian S, Koo CH, et al. "Agranulocytosis related to vancomycin therapy." Am J Med 81 (1986):  1059-61|"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):|Mandl DL, Garrison MW, Palpant SD "Agranulocytosis induced by vancomycin or ticarcillin/clavulanate." Ann Pharmacother 31 (1997):  1321-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31237, 12071, 'Vancomycin', 'Gastroenteritis', 'Vancomycin is potentially oto- and nephrotoxic.  While it is poorly absorbed from the gastrointestinal tract, significant systemic absorption may occur if intestinal mucosal integrity is compromised.  Therapy with oral vancomycin should be administered cautiously in patients with inflammatory or ulcerative gastrointestinal diseases because of the potential for enhanced absorption of the drug.', '2', '"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31238, 12072, 'Vancomycin', 'Gastroenteritis', 'Vancomycin is potentially oto- and nephrotoxic.  While it is poorly absorbed from the gastrointestinal tract, significant systemic absorption may occur if intestinal mucosal integrity is compromised.  Therapy with oral vancomycin should be administered cautiously in patients with inflammatory or ulcerative gastrointestinal diseases because of the potential for enhanced absorption of the drug.', '2', '"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31239, 12074, 'Vancomycin', 'Gastroenteritis', 'Vancomycin is potentially oto- and nephrotoxic.  While it is poorly absorbed from the gastrointestinal tract, significant systemic absorption may occur if intestinal mucosal integrity is compromised.  Therapy with oral vancomycin should be administered cautiously in patients with inflammatory or ulcerative gastrointestinal diseases because of the potential for enhanced absorption of the drug.', '2', '"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31240, 18077, 'Vancomycin', 'Gastroenteritis', 'Vancomycin is potentially oto- and nephrotoxic.  While it is poorly absorbed from the gastrointestinal tract, significant systemic absorption may occur if intestinal mucosal integrity is compromised.  Therapy with oral vancomycin should be administered cautiously in patients with inflammatory or ulcerative gastrointestinal diseases because of the potential for enhanced absorption of the drug.', '2', '"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31241, 18078, 'Vancomycin', 'Gastroenteritis', 'Vancomycin is potentially oto- and nephrotoxic.  While it is poorly absorbed from the gastrointestinal tract, significant systemic absorption may occur if intestinal mucosal integrity is compromised.  Therapy with oral vancomycin should be administered cautiously in patients with inflammatory or ulcerative gastrointestinal diseases because of the potential for enhanced absorption of the drug.', '2', '"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31242, 21315, 'Vancomycin', 'Gastroenteritis', 'Vancomycin is potentially oto- and nephrotoxic.  While it is poorly absorbed from the gastrointestinal tract, significant systemic absorption may occur if intestinal mucosal integrity is compromised.  Therapy with oral vancomycin should be administered cautiously in patients with inflammatory or ulcerative gastrointestinal diseases because of the potential for enhanced absorption of the drug.', '2', '"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31243, 28959, 'Vancomycin', 'Gastroenteritis', 'Vancomycin is potentially oto- and nephrotoxic.  While it is poorly absorbed from the gastrointestinal tract, significant systemic absorption may occur if intestinal mucosal integrity is compromised.  Therapy with oral vancomycin should be administered cautiously in patients with inflammatory or ulcerative gastrointestinal diseases because of the potential for enhanced absorption of the drug.', '2', '"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31244, 28961, 'Vancomycin', 'Gastroenteritis', 'Vancomycin is potentially oto- and nephrotoxic.  While it is poorly absorbed from the gastrointestinal tract, significant systemic absorption may occur if intestinal mucosal integrity is compromised.  Therapy with oral vancomycin should be administered cautiously in patients with inflammatory or ulcerative gastrointestinal diseases because of the potential for enhanced absorption of the drug.', '2', '"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31245, 28964, 'Vancomycin', 'Gastroenteritis', 'Vancomycin is potentially oto- and nephrotoxic.  While it is poorly absorbed from the gastrointestinal tract, significant systemic absorption may occur if intestinal mucosal integrity is compromised.  Therapy with oral vancomycin should be administered cautiously in patients with inflammatory or ulcerative gastrointestinal diseases because of the potential for enhanced absorption of the drug.', '2', '"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31246, 28966, 'Vancomycin', 'Gastroenteritis', 'Vancomycin is potentially oto- and nephrotoxic.  While it is poorly absorbed from the gastrointestinal tract, significant systemic absorption may occur if intestinal mucosal integrity is compromised.  Therapy with oral vancomycin should be administered cautiously in patients with inflammatory or ulcerative gastrointestinal diseases because of the potential for enhanced absorption of the drug.', '2', '"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31247, 28967, 'Vancomycin', 'Gastroenteritis', 'Vancomycin is potentially oto- and nephrotoxic.  While it is poorly absorbed from the gastrointestinal tract, significant systemic absorption may occur if intestinal mucosal integrity is compromised.  Therapy with oral vancomycin should be administered cautiously in patients with inflammatory or ulcerative gastrointestinal diseases because of the potential for enhanced absorption of the drug.', '2', '"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31248, 29204, 'Vancomycin', 'Gastroenteritis', 'Vancomycin is potentially oto- and nephrotoxic.  While it is poorly absorbed from the gastrointestinal tract, significant systemic absorption may occur if intestinal mucosal integrity is compromised.  Therapy with oral vancomycin should be administered cautiously in patients with inflammatory or ulcerative gastrointestinal diseases because of the potential for enhanced absorption of the drug.', '2', '"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31249, 31576, 'Vancomycin', 'Gastroenteritis', 'Vancomycin is potentially oto- and nephrotoxic.  While it is poorly absorbed from the gastrointestinal tract, significant systemic absorption may occur if intestinal mucosal integrity is compromised.  Therapy with oral vancomycin should be administered cautiously in patients with inflammatory or ulcerative gastrointestinal diseases because of the potential for enhanced absorption of the drug.', '2', '"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31250, 32122, 'Vancomycin', 'Gastroenteritis', 'Vancomycin is potentially oto- and nephrotoxic.  While it is poorly absorbed from the gastrointestinal tract, significant systemic absorption may occur if intestinal mucosal integrity is compromised.  Therapy with oral vancomycin should be administered cautiously in patients with inflammatory or ulcerative gastrointestinal diseases because of the potential for enhanced absorption of the drug.', '2', '"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31251, 32293, 'Vancomycin', 'Gastroenteritis', 'Vancomycin is potentially oto- and nephrotoxic.  While it is poorly absorbed from the gastrointestinal tract, significant systemic absorption may occur if intestinal mucosal integrity is compromised.  Therapy with oral vancomycin should be administered cautiously in patients with inflammatory or ulcerative gastrointestinal diseases because of the potential for enhanced absorption of the drug.', '2', '"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31252, 33827, 'Vancomycin', 'Gastroenteritis', 'Vancomycin is potentially oto- and nephrotoxic.  While it is poorly absorbed from the gastrointestinal tract, significant systemic absorption may occur if intestinal mucosal integrity is compromised.  Therapy with oral vancomycin should be administered cautiously in patients with inflammatory or ulcerative gastrointestinal diseases because of the potential for enhanced absorption of the drug.', '2', '"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31253, 33828, 'Vancomycin', 'Gastroenteritis', 'Vancomycin is potentially oto- and nephrotoxic.  While it is poorly absorbed from the gastrointestinal tract, significant systemic absorption may occur if intestinal mucosal integrity is compromised.  Therapy with oral vancomycin should be administered cautiously in patients with inflammatory or ulcerative gastrointestinal diseases because of the potential for enhanced absorption of the drug.', '2', '"Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31254, 12309, 'Vincristine', 'Respiratory Insufficiency', 'Acute shortness of breath and bronchospasm, some severe and life-threatening, have been reported with the use of vinca alkaloids.  These reactions were observed most often during combination therapy with mitomycin C, occurring within minutes to several hours after administration of the vinca alkaloid or up to 2 weeks following the mitomycin dose.  Therapy with vinca alkaloids should be administered cautiously in patients with preexisting pulmonary dysfunction.  Aggressive treatment may be necessary, including use of supplemental oxygen, bronchodilators, and/or corticosteroids.  In patients who develop progressive dyspnea requiring chronic therapy, vinca alkaloid should not be readministered.', '3', '"Product Information. Velban (vinblastine)." Lilly, Eli and Company  (2001):|"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31255, 12310, 'Vincristine', 'Respiratory Insufficiency', 'Acute shortness of breath and bronchospasm, some severe and life-threatening, have been reported with the use of vinca alkaloids.  These reactions were observed most often during combination therapy with mitomycin C, occurring within minutes to several hours after administration of the vinca alkaloid or up to 2 weeks following the mitomycin dose.  Therapy with vinca alkaloids should be administered cautiously in patients with preexisting pulmonary dysfunction.  Aggressive treatment may be necessary, including use of supplemental oxygen, bronchodilators, and/or corticosteroids.  In patients who develop progressive dyspnea requiring chronic therapy, vinca alkaloid should not be readministered.', '3', '"Product Information. Velban (vinblastine)." Lilly, Eli and Company  (2001):|"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31256, 12311, 'Vincristine', 'Respiratory Insufficiency', 'Acute shortness of breath and bronchospasm, some severe and life-threatening, have been reported with the use of vinca alkaloids.  These reactions were observed most often during combination therapy with mitomycin C, occurring within minutes to several hours after administration of the vinca alkaloid or up to 2 weeks following the mitomycin dose.  Therapy with vinca alkaloids should be administered cautiously in patients with preexisting pulmonary dysfunction.  Aggressive treatment may be necessary, including use of supplemental oxygen, bronchodilators, and/or corticosteroids.  In patients who develop progressive dyspnea requiring chronic therapy, vinca alkaloid should not be readministered.', '3', '"Product Information. Velban (vinblastine)." Lilly, Eli and Company  (2001):|"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31257, 12318, 'Vincristine', 'Respiratory Insufficiency', 'Acute shortness of breath and bronchospasm, some severe and life-threatening, have been reported with the use of vinca alkaloids.  These reactions were observed most often during combination therapy with mitomycin C, occurring within minutes to several hours after administration of the vinca alkaloid or up to 2 weeks following the mitomycin dose.  Therapy with vinca alkaloids should be administered cautiously in patients with preexisting pulmonary dysfunction.  Aggressive treatment may be necessary, including use of supplemental oxygen, bronchodilators, and/or corticosteroids.  In patients who develop progressive dyspnea requiring chronic therapy, vinca alkaloid should not be readministered.', '3', '"Product Information. Velban (vinblastine)." Lilly, Eli and Company  (2001):|"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31258, 12319, 'Vincristine', 'Respiratory Insufficiency', 'Acute shortness of breath and bronchospasm, some severe and life-threatening, have been reported with the use of vinca alkaloids.  These reactions were observed most often during combination therapy with mitomycin C, occurring within minutes to several hours after administration of the vinca alkaloid or up to 2 weeks following the mitomycin dose.  Therapy with vinca alkaloids should be administered cautiously in patients with preexisting pulmonary dysfunction.  Aggressive treatment may be necessary, including use of supplemental oxygen, bronchodilators, and/or corticosteroids.  In patients who develop progressive dyspnea requiring chronic therapy, vinca alkaloid should not be readministered.', '3', '"Product Information. Velban (vinblastine)." Lilly, Eli and Company  (2001):|"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31259, 12309, 'Vincristine', 'Neurologic Manifestations', 'The use of vincristine is contraindicated in patients with demyelinating conditions including Charcot-Marie-Tooth syndrome.  Neurotoxicity associated with vincristine therapy is dose-related and frequently sequential.  Sensorimotor (paresthesia, decreased deep- tendon reflex, ataxia, paralysis), autonomic (constipation and adynamic ileus), and CNS (mental status changes, seizures, coma) neurotoxicity have been reported.  Patients with existing neuromuscular or neurologic diseases may be at increased risk for toxicity with vincristine therapy.  Therapy with vincristine should be administered cautiously and dosage reduction considered in patients with neurologic dysfunction.', '3', 'Postma TJ, Benard BA, Huijgens PC, Ossenkoppele GJ, Heimans JJ "Long-term effects of vincristine on the peripheral nervous system." J Neurooncol 15 (1993):  23-7|Rosenthal S, Kaufman S "Vincristine neurotoxicity." Ann Intern Med 80 (1974):  733-7|Delaney P "Vincristine-induced laryngeal nerve paralysis." Neurology 32 (1982):  1285-8|Annino DJ Jr, MacArthur CJ, Friedman EM "Vincristine-induced recurrent laryngeal nerve paralysis." Laryngoscope 102 (1992):  1260-2|Warrier RP, Tan T, Patel Y, Yu LC, Quarls K, Shenoy S "Vincristine neurotoxicity." Indian Pediatr 29 (1992):  370-3|Watkins SM, Griffin JP "High incidence of vincristine-induced neuropathy in lymphomas." Br Med J 1 (1978):  610-2|Martin J, Mainwaring D "Letter: Coma and convulsions associated with vincristine therapy." Br Med J 4 (1973):  782-3|Johnson FL, Bernstein ID, Hartmann JR, Chard RL Jr "Seizures associated with vincristine sulfate therapy." J Pediatr 82 (1973):  699-702|Tormey DC "Neurotoxicity of vincristine." Lancet 1 (1973):  1312|Weiden PL, Wright SE "Vincristine neurotoxicity." N Engl J Med 286 (1972):  1369-70|Jalihal S, Roebuck N "Acute vincristine neurotoxicity." Lancet 1 (1985):  637|"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Marqibo (vinCRIStine liposome)." Talon Therapeutics Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31260, 12310, 'Vincristine', 'Neurologic Manifestations', 'The use of vincristine is contraindicated in patients with demyelinating conditions including Charcot-Marie-Tooth syndrome.  Neurotoxicity associated with vincristine therapy is dose-related and frequently sequential.  Sensorimotor (paresthesia, decreased deep- tendon reflex, ataxia, paralysis), autonomic (constipation and adynamic ileus), and CNS (mental status changes, seizures, coma) neurotoxicity have been reported.  Patients with existing neuromuscular or neurologic diseases may be at increased risk for toxicity with vincristine therapy.  Therapy with vincristine should be administered cautiously and dosage reduction considered in patients with neurologic dysfunction.', '3', 'Postma TJ, Benard BA, Huijgens PC, Ossenkoppele GJ, Heimans JJ "Long-term effects of vincristine on the peripheral nervous system." J Neurooncol 15 (1993):  23-7|Rosenthal S, Kaufman S "Vincristine neurotoxicity." Ann Intern Med 80 (1974):  733-7|Delaney P "Vincristine-induced laryngeal nerve paralysis." Neurology 32 (1982):  1285-8|Annino DJ Jr, MacArthur CJ, Friedman EM "Vincristine-induced recurrent laryngeal nerve paralysis." Laryngoscope 102 (1992):  1260-2|Warrier RP, Tan T, Patel Y, Yu LC, Quarls K, Shenoy S "Vincristine neurotoxicity." Indian Pediatr 29 (1992):  370-3|Watkins SM, Griffin JP "High incidence of vincristine-induced neuropathy in lymphomas." Br Med J 1 (1978):  610-2|Martin J, Mainwaring D "Letter: Coma and convulsions associated with vincristine therapy." Br Med J 4 (1973):  782-3|Johnson FL, Bernstein ID, Hartmann JR, Chard RL Jr "Seizures associated with vincristine sulfate therapy." J Pediatr 82 (1973):  699-702|Tormey DC "Neurotoxicity of vincristine." Lancet 1 (1973):  1312|Weiden PL, Wright SE "Vincristine neurotoxicity." N Engl J Med 286 (1972):  1369-70|Jalihal S, Roebuck N "Acute vincristine neurotoxicity." Lancet 1 (1985):  637|"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Marqibo (vinCRIStine liposome)." Talon Therapeutics Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31261, 12311, 'Vincristine', 'Neurologic Manifestations', 'The use of vincristine is contraindicated in patients with demyelinating conditions including Charcot-Marie-Tooth syndrome.  Neurotoxicity associated with vincristine therapy is dose-related and frequently sequential.  Sensorimotor (paresthesia, decreased deep- tendon reflex, ataxia, paralysis), autonomic (constipation and adynamic ileus), and CNS (mental status changes, seizures, coma) neurotoxicity have been reported.  Patients with existing neuromuscular or neurologic diseases may be at increased risk for toxicity with vincristine therapy.  Therapy with vincristine should be administered cautiously and dosage reduction considered in patients with neurologic dysfunction.', '3', 'Postma TJ, Benard BA, Huijgens PC, Ossenkoppele GJ, Heimans JJ "Long-term effects of vincristine on the peripheral nervous system." J Neurooncol 15 (1993):  23-7|Rosenthal S, Kaufman S "Vincristine neurotoxicity." Ann Intern Med 80 (1974):  733-7|Delaney P "Vincristine-induced laryngeal nerve paralysis." Neurology 32 (1982):  1285-8|Annino DJ Jr, MacArthur CJ, Friedman EM "Vincristine-induced recurrent laryngeal nerve paralysis." Laryngoscope 102 (1992):  1260-2|Warrier RP, Tan T, Patel Y, Yu LC, Quarls K, Shenoy S "Vincristine neurotoxicity." Indian Pediatr 29 (1992):  370-3|Watkins SM, Griffin JP "High incidence of vincristine-induced neuropathy in lymphomas." Br Med J 1 (1978):  610-2|Martin J, Mainwaring D "Letter: Coma and convulsions associated with vincristine therapy." Br Med J 4 (1973):  782-3|Johnson FL, Bernstein ID, Hartmann JR, Chard RL Jr "Seizures associated with vincristine sulfate therapy." J Pediatr 82 (1973):  699-702|Tormey DC "Neurotoxicity of vincristine." Lancet 1 (1973):  1312|Weiden PL, Wright SE "Vincristine neurotoxicity." N Engl J Med 286 (1972):  1369-70|Jalihal S, Roebuck N "Acute vincristine neurotoxicity." Lancet 1 (1985):  637|"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Marqibo (vinCRIStine liposome)." Talon Therapeutics Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31262, 12318, 'Vincristine', 'Neurologic Manifestations', 'The use of vincristine is contraindicated in patients with demyelinating conditions including Charcot-Marie-Tooth syndrome.  Neurotoxicity associated with vincristine therapy is dose-related and frequently sequential.  Sensorimotor (paresthesia, decreased deep- tendon reflex, ataxia, paralysis), autonomic (constipation and adynamic ileus), and CNS (mental status changes, seizures, coma) neurotoxicity have been reported.  Patients with existing neuromuscular or neurologic diseases may be at increased risk for toxicity with vincristine therapy.  Therapy with vincristine should be administered cautiously and dosage reduction considered in patients with neurologic dysfunction.', '3', 'Postma TJ, Benard BA, Huijgens PC, Ossenkoppele GJ, Heimans JJ "Long-term effects of vincristine on the peripheral nervous system." J Neurooncol 15 (1993):  23-7|Rosenthal S, Kaufman S "Vincristine neurotoxicity." Ann Intern Med 80 (1974):  733-7|Delaney P "Vincristine-induced laryngeal nerve paralysis." Neurology 32 (1982):  1285-8|Annino DJ Jr, MacArthur CJ, Friedman EM "Vincristine-induced recurrent laryngeal nerve paralysis." Laryngoscope 102 (1992):  1260-2|Warrier RP, Tan T, Patel Y, Yu LC, Quarls K, Shenoy S "Vincristine neurotoxicity." Indian Pediatr 29 (1992):  370-3|Watkins SM, Griffin JP "High incidence of vincristine-induced neuropathy in lymphomas." Br Med J 1 (1978):  610-2|Martin J, Mainwaring D "Letter: Coma and convulsions associated with vincristine therapy." Br Med J 4 (1973):  782-3|Johnson FL, Bernstein ID, Hartmann JR, Chard RL Jr "Seizures associated with vincristine sulfate therapy." J Pediatr 82 (1973):  699-702|Tormey DC "Neurotoxicity of vincristine." Lancet 1 (1973):  1312|Weiden PL, Wright SE "Vincristine neurotoxicity." N Engl J Med 286 (1972):  1369-70|Jalihal S, Roebuck N "Acute vincristine neurotoxicity." Lancet 1 (1985):  637|"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Marqibo (vinCRIStine liposome)." Talon Therapeutics Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31263, 12319, 'Vincristine', 'Neurologic Manifestations', 'The use of vincristine is contraindicated in patients with demyelinating conditions including Charcot-Marie-Tooth syndrome.  Neurotoxicity associated with vincristine therapy is dose-related and frequently sequential.  Sensorimotor (paresthesia, decreased deep- tendon reflex, ataxia, paralysis), autonomic (constipation and adynamic ileus), and CNS (mental status changes, seizures, coma) neurotoxicity have been reported.  Patients with existing neuromuscular or neurologic diseases may be at increased risk for toxicity with vincristine therapy.  Therapy with vincristine should be administered cautiously and dosage reduction considered in patients with neurologic dysfunction.', '3', 'Postma TJ, Benard BA, Huijgens PC, Ossenkoppele GJ, Heimans JJ "Long-term effects of vincristine on the peripheral nervous system." J Neurooncol 15 (1993):  23-7|Rosenthal S, Kaufman S "Vincristine neurotoxicity." Ann Intern Med 80 (1974):  733-7|Delaney P "Vincristine-induced laryngeal nerve paralysis." Neurology 32 (1982):  1285-8|Annino DJ Jr, MacArthur CJ, Friedman EM "Vincristine-induced recurrent laryngeal nerve paralysis." Laryngoscope 102 (1992):  1260-2|Warrier RP, Tan T, Patel Y, Yu LC, Quarls K, Shenoy S "Vincristine neurotoxicity." Indian Pediatr 29 (1992):  370-3|Watkins SM, Griffin JP "High incidence of vincristine-induced neuropathy in lymphomas." Br Med J 1 (1978):  610-2|Martin J, Mainwaring D "Letter: Coma and convulsions associated with vincristine therapy." Br Med J 4 (1973):  782-3|Johnson FL, Bernstein ID, Hartmann JR, Chard RL Jr "Seizures associated with vincristine sulfate therapy." J Pediatr 82 (1973):  699-702|Tormey DC "Neurotoxicity of vincristine." Lancet 1 (1973):  1312|Weiden PL, Wright SE "Vincristine neurotoxicity." N Engl J Med 286 (1972):  1369-70|Jalihal S, Roebuck N "Acute vincristine neurotoxicity." Lancet 1 (1985):  637|"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Marqibo (vinCRIStine liposome)." Talon Therapeutics Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31264, 12309, 'Vincristine', 'Constipation', 'Vincristine can cause constipation.  Ileus, bowel obstruction, and colonic pseudo-obstruction have occurred.  When using this agent in people at risk of constipation, appropriate measures should be instituted to prevent such complications.  A routine prophylactic regimen against constipation is recommended for all patients receiving vincristine.', '2', '"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Marqibo (vinCRIStine liposome)." Talon Therapeutics Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31265, 12310, 'Vincristine', 'Constipation', 'Vincristine can cause constipation.  Ileus, bowel obstruction, and colonic pseudo-obstruction have occurred.  When using this agent in people at risk of constipation, appropriate measures should be instituted to prevent such complications.  A routine prophylactic regimen against constipation is recommended for all patients receiving vincristine.', '2', '"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Marqibo (vinCRIStine liposome)." Talon Therapeutics Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31266, 12311, 'Vincristine', 'Constipation', 'Vincristine can cause constipation.  Ileus, bowel obstruction, and colonic pseudo-obstruction have occurred.  When using this agent in people at risk of constipation, appropriate measures should be instituted to prevent such complications.  A routine prophylactic regimen against constipation is recommended for all patients receiving vincristine.', '2', '"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Marqibo (vinCRIStine liposome)." Talon Therapeutics Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31267, 12318, 'Vincristine', 'Constipation', 'Vincristine can cause constipation.  Ileus, bowel obstruction, and colonic pseudo-obstruction have occurred.  When using this agent in people at risk of constipation, appropriate measures should be instituted to prevent such complications.  A routine prophylactic regimen against constipation is recommended for all patients receiving vincristine.', '2', '"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Marqibo (vinCRIStine liposome)." Talon Therapeutics Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31268, 12319, 'Vincristine', 'Constipation', 'Vincristine can cause constipation.  Ileus, bowel obstruction, and colonic pseudo-obstruction have occurred.  When using this agent in people at risk of constipation, appropriate measures should be instituted to prevent such complications.  A routine prophylactic regimen against constipation is recommended for all patients receiving vincristine.', '2', '"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Marqibo (vinCRIStine liposome)." Talon Therapeutics Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31269, 12309, 'Vincristine', 'Liver Diseases', 'Vincristine is primarily metabolized by the liver.  The influence of severe hepatic impairment on the safety and efficacy of vincristine has not been evaluated.  Additionally, fatal liver toxicity and elevated levels of aspartate aminotransferase have occurred in clinical trials.  Vincristine should be reduced or interrupted if there is evidence of hepatic toxicity.  Therapy with vincristine should be administered cautiously and dosages reduced in patients with compromised hepatic function.  Close clinical monitoring of hepatic function is recommended.', '2', 'Jackson DV, Jr  Castle MC, Bender RA "Biliary excretion of vincristine." Clin Pharmacol Ther 24 (1978):  101-7|Van den Berg HW, Desai ZR, Wilson R, Kennedy G, Bridges JM, Shanks RG "The pharmacokinetics of vincristine in man: reduced drug clearance associated with raised serum alkaline phosphatase and dose-limited elimination." Cancer Chemother Pharmacol 8 (1982):  215-9|"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Marqibo (vinCRIStine liposome)." Talon Therapeutics Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31270, 12310, 'Vincristine', 'Liver Diseases', 'Vincristine is primarily metabolized by the liver.  The influence of severe hepatic impairment on the safety and efficacy of vincristine has not been evaluated.  Additionally, fatal liver toxicity and elevated levels of aspartate aminotransferase have occurred in clinical trials.  Vincristine should be reduced or interrupted if there is evidence of hepatic toxicity.  Therapy with vincristine should be administered cautiously and dosages reduced in patients with compromised hepatic function.  Close clinical monitoring of hepatic function is recommended.', '2', 'Jackson DV, Jr  Castle MC, Bender RA "Biliary excretion of vincristine." Clin Pharmacol Ther 24 (1978):  101-7|Van den Berg HW, Desai ZR, Wilson R, Kennedy G, Bridges JM, Shanks RG "The pharmacokinetics of vincristine in man: reduced drug clearance associated with raised serum alkaline phosphatase and dose-limited elimination." Cancer Chemother Pharmacol 8 (1982):  215-9|"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Marqibo (vinCRIStine liposome)." Talon Therapeutics Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31271, 12311, 'Vincristine', 'Liver Diseases', 'Vincristine is primarily metabolized by the liver.  The influence of severe hepatic impairment on the safety and efficacy of vincristine has not been evaluated.  Additionally, fatal liver toxicity and elevated levels of aspartate aminotransferase have occurred in clinical trials.  Vincristine should be reduced or interrupted if there is evidence of hepatic toxicity.  Therapy with vincristine should be administered cautiously and dosages reduced in patients with compromised hepatic function.  Close clinical monitoring of hepatic function is recommended.', '2', 'Jackson DV, Jr  Castle MC, Bender RA "Biliary excretion of vincristine." Clin Pharmacol Ther 24 (1978):  101-7|Van den Berg HW, Desai ZR, Wilson R, Kennedy G, Bridges JM, Shanks RG "The pharmacokinetics of vincristine in man: reduced drug clearance associated with raised serum alkaline phosphatase and dose-limited elimination." Cancer Chemother Pharmacol 8 (1982):  215-9|"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Marqibo (vinCRIStine liposome)." Talon Therapeutics Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31272, 12318, 'Vincristine', 'Liver Diseases', 'Vincristine is primarily metabolized by the liver.  The influence of severe hepatic impairment on the safety and efficacy of vincristine has not been evaluated.  Additionally, fatal liver toxicity and elevated levels of aspartate aminotransferase have occurred in clinical trials.  Vincristine should be reduced or interrupted if there is evidence of hepatic toxicity.  Therapy with vincristine should be administered cautiously and dosages reduced in patients with compromised hepatic function.  Close clinical monitoring of hepatic function is recommended.', '2', 'Jackson DV, Jr  Castle MC, Bender RA "Biliary excretion of vincristine." Clin Pharmacol Ther 24 (1978):  101-7|Van den Berg HW, Desai ZR, Wilson R, Kennedy G, Bridges JM, Shanks RG "The pharmacokinetics of vincristine in man: reduced drug clearance associated with raised serum alkaline phosphatase and dose-limited elimination." Cancer Chemother Pharmacol 8 (1982):  215-9|"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Marqibo (vinCRIStine liposome)." Talon Therapeutics Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31273, 12319, 'Vincristine', 'Liver Diseases', 'Vincristine is primarily metabolized by the liver.  The influence of severe hepatic impairment on the safety and efficacy of vincristine has not been evaluated.  Additionally, fatal liver toxicity and elevated levels of aspartate aminotransferase have occurred in clinical trials.  Vincristine should be reduced or interrupted if there is evidence of hepatic toxicity.  Therapy with vincristine should be administered cautiously and dosages reduced in patients with compromised hepatic function.  Close clinical monitoring of hepatic function is recommended.', '2', 'Jackson DV, Jr  Castle MC, Bender RA "Biliary excretion of vincristine." Clin Pharmacol Ther 24 (1978):  101-7|Van den Berg HW, Desai ZR, Wilson R, Kennedy G, Bridges JM, Shanks RG "The pharmacokinetics of vincristine in man: reduced drug clearance associated with raised serum alkaline phosphatase and dose-limited elimination." Cancer Chemother Pharmacol 8 (1982):  215-9|"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Marqibo (vinCRIStine liposome)." Talon Therapeutics Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31274, 12309, 'Vincristine', 'Infections', 'Vincristine induces mild, dose-related myelosuppression. The use of vincristine may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during therapy with vincristine.  Clinical monitoring of hematopoetic function is recommended.', '2', '"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Marqibo (vinCRIStine liposome)." Talon Therapeutics Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31275, 12310, 'Vincristine', 'Infections', 'Vincristine induces mild, dose-related myelosuppression. The use of vincristine may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during therapy with vincristine.  Clinical monitoring of hematopoetic function is recommended.', '2', '"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Marqibo (vinCRIStine liposome)." Talon Therapeutics Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31276, 12311, 'Vincristine', 'Infections', 'Vincristine induces mild, dose-related myelosuppression. The use of vincristine may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during therapy with vincristine.  Clinical monitoring of hematopoetic function is recommended.', '2', '"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Marqibo (vinCRIStine liposome)." Talon Therapeutics Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31277, 12318, 'Vincristine', 'Infections', 'Vincristine induces mild, dose-related myelosuppression. The use of vincristine may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during therapy with vincristine.  Clinical monitoring of hematopoetic function is recommended.', '2', '"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Marqibo (vinCRIStine liposome)." Talon Therapeutics Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31278, 12319, 'Vincristine', 'Infections', 'Vincristine induces mild, dose-related myelosuppression. The use of vincristine may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during therapy with vincristine.  Clinical monitoring of hematopoetic function is recommended.', '2', '"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Marqibo (vinCRIStine liposome)." Talon Therapeutics Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31279, 12309, 'Vincristine', 'Bone Marrow Failure Disorders', 'Vincristine induces dose-related myelosuppression.  Leukopenia, thrombocytopenia, and anemia have been reported, however vincristine does not appear to have a consistent or significant effect on platelets or red blood cells.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Therapy with vincristine should be administered cautiously in patients with compromised bone marrow reserve.  Monitor complete blood counts prior to each dose.  If Grade 3 or 4 neutropenia, thrombocytopenia, or anemia develops, consider a dose modification or reduction as well as supportive care measures.', '2', 'Young JA, Howell SB, Green MR "Pharmacokinetics and toxicity of 5-day continuous infusion of vinblastine." Cancer Chemother Pharmacol 12 (1984):  43-5|Chong CD  Logothetis CJ  Savaraj N  Fritsche HA  Gietner AM  Samuels ML "The correlation of vinblastine pharmacokinetics to toxicity in  testicular cancer patients." J Clin Pharmacol 28 (1988):  714-8|Neville AJ  Rand CA  Barr RD "Vinblastine-induced erythrocytotoxicity." Scand J Haematol 28 (1982):  32-8|"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Marqibo (vinCRIStine liposome)." Talon Therapeutics Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31280, 12310, 'Vincristine', 'Bone Marrow Failure Disorders', 'Vincristine induces dose-related myelosuppression.  Leukopenia, thrombocytopenia, and anemia have been reported, however vincristine does not appear to have a consistent or significant effect on platelets or red blood cells.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Therapy with vincristine should be administered cautiously in patients with compromised bone marrow reserve.  Monitor complete blood counts prior to each dose.  If Grade 3 or 4 neutropenia, thrombocytopenia, or anemia develops, consider a dose modification or reduction as well as supportive care measures.', '2', 'Young JA, Howell SB, Green MR "Pharmacokinetics and toxicity of 5-day continuous infusion of vinblastine." Cancer Chemother Pharmacol 12 (1984):  43-5|Chong CD  Logothetis CJ  Savaraj N  Fritsche HA  Gietner AM  Samuels ML "The correlation of vinblastine pharmacokinetics to toxicity in  testicular cancer patients." J Clin Pharmacol 28 (1988):  714-8|Neville AJ  Rand CA  Barr RD "Vinblastine-induced erythrocytotoxicity." Scand J Haematol 28 (1982):  32-8|"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Marqibo (vinCRIStine liposome)." Talon Therapeutics Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31281, 12311, 'Vincristine', 'Bone Marrow Failure Disorders', 'Vincristine induces dose-related myelosuppression.  Leukopenia, thrombocytopenia, and anemia have been reported, however vincristine does not appear to have a consistent or significant effect on platelets or red blood cells.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Therapy with vincristine should be administered cautiously in patients with compromised bone marrow reserve.  Monitor complete blood counts prior to each dose.  If Grade 3 or 4 neutropenia, thrombocytopenia, or anemia develops, consider a dose modification or reduction as well as supportive care measures.', '2', 'Young JA, Howell SB, Green MR "Pharmacokinetics and toxicity of 5-day continuous infusion of vinblastine." Cancer Chemother Pharmacol 12 (1984):  43-5|Chong CD  Logothetis CJ  Savaraj N  Fritsche HA  Gietner AM  Samuels ML "The correlation of vinblastine pharmacokinetics to toxicity in  testicular cancer patients." J Clin Pharmacol 28 (1988):  714-8|Neville AJ  Rand CA  Barr RD "Vinblastine-induced erythrocytotoxicity." Scand J Haematol 28 (1982):  32-8|"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Marqibo (vinCRIStine liposome)." Talon Therapeutics Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31282, 12318, 'Vincristine', 'Bone Marrow Failure Disorders', 'Vincristine induces dose-related myelosuppression.  Leukopenia, thrombocytopenia, and anemia have been reported, however vincristine does not appear to have a consistent or significant effect on platelets or red blood cells.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Therapy with vincristine should be administered cautiously in patients with compromised bone marrow reserve.  Monitor complete blood counts prior to each dose.  If Grade 3 or 4 neutropenia, thrombocytopenia, or anemia develops, consider a dose modification or reduction as well as supportive care measures.', '2', 'Young JA, Howell SB, Green MR "Pharmacokinetics and toxicity of 5-day continuous infusion of vinblastine." Cancer Chemother Pharmacol 12 (1984):  43-5|Chong CD  Logothetis CJ  Savaraj N  Fritsche HA  Gietner AM  Samuels ML "The correlation of vinblastine pharmacokinetics to toxicity in  testicular cancer patients." J Clin Pharmacol 28 (1988):  714-8|Neville AJ  Rand CA  Barr RD "Vinblastine-induced erythrocytotoxicity." Scand J Haematol 28 (1982):  32-8|"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Marqibo (vinCRIStine liposome)." Talon Therapeutics Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31283, 12319, 'Vincristine', 'Bone Marrow Failure Disorders', 'Vincristine induces dose-related myelosuppression.  Leukopenia, thrombocytopenia, and anemia have been reported, however vincristine does not appear to have a consistent or significant effect on platelets or red blood cells.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Therapy with vincristine should be administered cautiously in patients with compromised bone marrow reserve.  Monitor complete blood counts prior to each dose.  If Grade 3 or 4 neutropenia, thrombocytopenia, or anemia develops, consider a dose modification or reduction as well as supportive care measures.', '2', 'Young JA, Howell SB, Green MR "Pharmacokinetics and toxicity of 5-day continuous infusion of vinblastine." Cancer Chemother Pharmacol 12 (1984):  43-5|Chong CD  Logothetis CJ  Savaraj N  Fritsche HA  Gietner AM  Samuels ML "The correlation of vinblastine pharmacokinetics to toxicity in  testicular cancer patients." J Clin Pharmacol 28 (1988):  714-8|Neville AJ  Rand CA  Barr RD "Vinblastine-induced erythrocytotoxicity." Scand J Haematol 28 (1982):  32-8|"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Marqibo (vinCRIStine liposome)." Talon Therapeutics Inc', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31284, 12309, 'Vincristine', 'Kidney Diseases', 'The influence of renal impairment on the safety, efficacy, and pharmacokinetics of vincristine has not been evaluated.  Caution and monitoring of renal function is advised in patients with renal impairment.', '2', '"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31285, 12310, 'Vincristine', 'Kidney Diseases', 'The influence of renal impairment on the safety, efficacy, and pharmacokinetics of vincristine has not been evaluated.  Caution and monitoring of renal function is advised in patients with renal impairment.', '2', '"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31286, 12311, 'Vincristine', 'Kidney Diseases', 'The influence of renal impairment on the safety, efficacy, and pharmacokinetics of vincristine has not been evaluated.  Caution and monitoring of renal function is advised in patients with renal impairment.', '2', '"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31287, 12318, 'Vincristine', 'Kidney Diseases', 'The influence of renal impairment on the safety, efficacy, and pharmacokinetics of vincristine has not been evaluated.  Caution and monitoring of renal function is advised in patients with renal impairment.', '2', '"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31288, 12319, 'Vincristine', 'Kidney Diseases', 'The influence of renal impairment on the safety, efficacy, and pharmacokinetics of vincristine has not been evaluated.  Caution and monitoring of renal function is advised in patients with renal impairment.', '2', '"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31289, 12309, 'Vincristine', 'Inappropriate ADH Syndrome', 'A syndrome of sudden inappropriate antidiuretic hormone (SIADH) secretion has been reported rarely in association with the use of vincristine.  Therapy with vincristine should be administered cautiously in patients with or predisposed to abnormal antidiuretic hormone release and/or suppression.', '2', 'Otto C, Richter WO "Syndrome of inappropriate antidiuretic hormone secretion induced by different drugs." Ann Pharmacother 28 (1994):  1199-200|Cutting HO "Inappropriate secretion of antidiuretic hormone secondary to vincristine therapy." Am J Med 51 (1971):  269-71|Oldham RK, Pomeroy TC "Vincristine-induced syndrome of inappropriate secretion of antidiuretic hormone." South Med J 65 (1972):  1010-2|"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31290, 12310, 'Vincristine', 'Inappropriate ADH Syndrome', 'A syndrome of sudden inappropriate antidiuretic hormone (SIADH) secretion has been reported rarely in association with the use of vincristine.  Therapy with vincristine should be administered cautiously in patients with or predisposed to abnormal antidiuretic hormone release and/or suppression.', '2', 'Otto C, Richter WO "Syndrome of inappropriate antidiuretic hormone secretion induced by different drugs." Ann Pharmacother 28 (1994):  1199-200|Cutting HO "Inappropriate secretion of antidiuretic hormone secondary to vincristine therapy." Am J Med 51 (1971):  269-71|Oldham RK, Pomeroy TC "Vincristine-induced syndrome of inappropriate secretion of antidiuretic hormone." South Med J 65 (1972):  1010-2|"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31291, 12311, 'Vincristine', 'Inappropriate ADH Syndrome', 'A syndrome of sudden inappropriate antidiuretic hormone (SIADH) secretion has been reported rarely in association with the use of vincristine.  Therapy with vincristine should be administered cautiously in patients with or predisposed to abnormal antidiuretic hormone release and/or suppression.', '2', 'Otto C, Richter WO "Syndrome of inappropriate antidiuretic hormone secretion induced by different drugs." Ann Pharmacother 28 (1994):  1199-200|Cutting HO "Inappropriate secretion of antidiuretic hormone secondary to vincristine therapy." Am J Med 51 (1971):  269-71|Oldham RK, Pomeroy TC "Vincristine-induced syndrome of inappropriate secretion of antidiuretic hormone." South Med J 65 (1972):  1010-2|"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31292, 12318, 'Vincristine', 'Inappropriate ADH Syndrome', 'A syndrome of sudden inappropriate antidiuretic hormone (SIADH) secretion has been reported rarely in association with the use of vincristine.  Therapy with vincristine should be administered cautiously in patients with or predisposed to abnormal antidiuretic hormone release and/or suppression.', '2', 'Otto C, Richter WO "Syndrome of inappropriate antidiuretic hormone secretion induced by different drugs." Ann Pharmacother 28 (1994):  1199-200|Cutting HO "Inappropriate secretion of antidiuretic hormone secondary to vincristine therapy." Am J Med 51 (1971):  269-71|Oldham RK, Pomeroy TC "Vincristine-induced syndrome of inappropriate secretion of antidiuretic hormone." South Med J 65 (1972):  1010-2|"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31293, 12319, 'Vincristine', 'Inappropriate ADH Syndrome', 'A syndrome of sudden inappropriate antidiuretic hormone (SIADH) secretion has been reported rarely in association with the use of vincristine.  Therapy with vincristine should be administered cautiously in patients with or predisposed to abnormal antidiuretic hormone release and/or suppression.', '2', 'Otto C, Richter WO "Syndrome of inappropriate antidiuretic hormone secretion induced by different drugs." Ann Pharmacother 28 (1994):  1199-200|Cutting HO "Inappropriate secretion of antidiuretic hormone secondary to vincristine therapy." Am J Med 51 (1971):  269-71|Oldham RK, Pomeroy TC "Vincristine-induced syndrome of inappropriate secretion of antidiuretic hormone." South Med J 65 (1972):  1010-2|"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31294, 17032, 'Vinblastine', 'Infections', 'The use of vinblastine is contraindicated in patients with known infectious diseases.  Vinblastine can induce myelosuppression.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during therapy with vinblastine.  Close clinical monitoring of hematopoietic function is recommended.  Vinblastine should not be used in patients with neutrophil counts below 1000/mm3.', '3', '"Product Information. Velban (vinblastine)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31295, 29073, 'Vinblastine', 'Infections', 'The use of vinblastine is contraindicated in patients with known infectious diseases.  Vinblastine can induce myelosuppression.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during therapy with vinblastine.  Close clinical monitoring of hematopoietic function is recommended.  Vinblastine should not be used in patients with neutrophil counts below 1000/mm3.', '3', '"Product Information. Velban (vinblastine)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31296, 17032, 'Vinblastine', 'Bone Marrow Failure Disorders', 'The use of vinblastine is contraindicated in patients with significant granulocytopenia.  Vinblastine induces dose-dependent leukopenia.  Thrombocytopenia and anemia have been reported infrequently during vinblastine therapy.  Therapy with vinblastine should be administered cautiously in patients whose bone marrow reserve may be severely depressed by prior chemotherapy or irradiation or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitoring of hematopoietic function is recommended.', '3', '"Product Information. Velban (vinblastine)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31297, 29073, 'Vinblastine', 'Bone Marrow Failure Disorders', 'The use of vinblastine is contraindicated in patients with significant granulocytopenia.  Vinblastine induces dose-dependent leukopenia.  Thrombocytopenia and anemia have been reported infrequently during vinblastine therapy.  Therapy with vinblastine should be administered cautiously in patients whose bone marrow reserve may be severely depressed by prior chemotherapy or irradiation or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitoring of hematopoietic function is recommended.', '3', '"Product Information. Velban (vinblastine)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31298, 17032, 'Vinblastine', 'Respiratory Insufficiency', 'Acute shortness of breath and bronchospasm, some severe and life-threatening, have been reported with the use of vinca alkaloids.  These reactions were observed most often during combination therapy with mitomycin C, occurring within minutes to several hours after administration of the vinca alkaloid or up to 2 weeks following the mitomycin dose.  Therapy with vinca alkaloids should be administered cautiously in patients with preexisting pulmonary dysfunction.  Aggressive treatment may be necessary, including use of supplemental oxygen, bronchodilators, and/or corticosteroids.  In patients who develop progressive dyspnea requiring chronic therapy, vinca alkaloid should not be readministered.', '3', '"Product Information. Velban (vinblastine)." Lilly, Eli and Company  (2001):|"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31299, 29073, 'Vinblastine', 'Respiratory Insufficiency', 'Acute shortness of breath and bronchospasm, some severe and life-threatening, have been reported with the use of vinca alkaloids.  These reactions were observed most often during combination therapy with mitomycin C, occurring within minutes to several hours after administration of the vinca alkaloid or up to 2 weeks following the mitomycin dose.  Therapy with vinca alkaloids should be administered cautiously in patients with preexisting pulmonary dysfunction.  Aggressive treatment may be necessary, including use of supplemental oxygen, bronchodilators, and/or corticosteroids.  In patients who develop progressive dyspnea requiring chronic therapy, vinca alkaloid should not be readministered.', '3', '"Product Information. Velban (vinblastine)." Lilly, Eli and Company  (2001):|"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31300, 17032, 'Vinblastine', 'Liver Diseases', 'Vinblastine is metabolized by the liver and eliminated primarily via biliary excretion.  Patients with hepatic impairment may be at increased risk for toxicity associated with vinblastine therapy.  Therapy with vinblastine should be administered cautiously in patients with compromised hepatic function.', '2', '"Product Information. Velban (vinblastine)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31301, 29073, 'Vinblastine', 'Liver Diseases', 'Vinblastine is metabolized by the liver and eliminated primarily via biliary excretion.  Patients with hepatic impairment may be at increased risk for toxicity associated with vinblastine therapy.  Therapy with vinblastine should be administered cautiously in patients with compromised hepatic function.', '2', '"Product Information. Velban (vinblastine)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31302, 10135, 'Vigabatrin', 'Blindness', 'Vigabatrin causes permanent bilateral concentric visual field constriction.  The onset of vision loss from vigabatrin is unpredictable, and can occur within weeks of starting treatment or sooner, or at any time after starting treatment, even after months or years.  The risk of vision loss increases with increasing dose and cumulative exposure, but there is no dose or exposure known to be free of risk of vision loss.  Because of the risk of vision loss, and because, when it is effective, vigabatrin provides an observable symptomatic benefit, patient response and continued need for treatment should be periodically assessed.  If the need clearly outweighs the risk, caution should be exercised when using vigabatrin therapy in patients with, or at high risk of, other types of irreversible vision loss.  Vigabatrin should not be used in patients that are being treated for retinopathy or glaucoma.', '3', '"Product Information. Sabril (vigabatrin)." Lundbeck Inc  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31303, 10135, 'Vigabatrin', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Klonopin (clonazepam)." Roche Laboratories  (2001):|"Product Information. Dilantin (phenytoin)." Parke-Davis  (2001):|"Product Information. Cerebyx (fosphenytoin)." Parke-Davis  (2001):|"Product Information. Mysoline (primidone)." Elan Pharmaceuticals  (2001):|"Product Information. Lyrica (pregabalin)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Sabril (vigabatrin)." Lundbeck Inc  (2009):|"Product Information. Potiga (ezogabine)." GlaxoSmithKline  (2011):|"Product Information. Qsymia (phentermine-topiramate)." Vivus Inc  (2012):|"Product Information. Fycompa (perampanel)." Eisai Inc  (2012):|"Product Information. Briviact (brivaracetam)." UCB Pharma Inc  (2016):|"Product Information. Diacomit (stiripentol)." Biocodex USA  (2018):|"Product Information. Epidiolex (cannabidiol)." Greenwich Biosciences LLC  (2018):|"Product Information. Xcopri (cenobamate)." SK Life Science, Inc.  (2020):|"Product Information. Fintepla (fenfluramine)." Zogenix, Inc  (2020):|"Product Information. Ztalmy (ganaxolone)." Marinus Pharmaceuticals, Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31304, 10135, 'Vigabatrin', 'Neurotoxicity Syndromes', 'Vigabatrin has produced pathological changes in the brains of rats and long-term neurobehavioral abnormalities (convulsions, neuromotor impairment, learning deficits) were also observed.  In humans, abnormal MRI signal changes characterized by increased T2 signal and restricted diffusion in a symmetric pattern involving the thalamus, basal ganglia, brain stem, and cerebellum have been observed in some infants treated for infantile spasms (IS) with vigabatrin.  Studies of the effects of vigabatrin on MRI and changes in visual and somatosensory evoked potentials (EP) in adult epilepsy patients have not been clearly defined.', '2', '"Product Information. Sabril (vigabatrin)." Lundbeck Inc  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31305, 10135, 'Vigabatrin', 'Peripheral Nervous System Diseases', 'Vigabatrin causes symptoms of peripheral neuropathy in adults.  There is insufficient evidence to determine if development of these signs and symptoms were related to duration of vigabatrin treatment, cumulative dose, or if the findings of peripheral neuropathy were completely reversible upon discontinuation of vigabatrin.  Therapy with vigabatrin should be administered cautiously in patients with peripheral neuropathy.', '2', '"Product Information. Sabril (vigabatrin)." Lundbeck Inc  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31306, 29310, 'Vilazodone', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31307, 29311, 'Vilazodone', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31308, 29312, 'Vilazodone', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31309, 29314, 'Vilazodone', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31310, 29315, 'Vilazodone', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31311, 29316, 'Vilazodone', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31312, 29317, 'Vilazodone', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31313, 29310, 'Vilazodone', 'Glaucoma, Angle-Closure', 'Some antidepressants exert mydriatic activity that can induce increased intraocular pressure and result in angle-closure (narrow-angle) glaucoma in a patient with anatomically narrow angles who does not have a patent iridectomy.  Prior to initiating therapy with these agents, patients should be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible.  The use of these drugs in patients with untreated anatomically narrow angles should be avoided.', '2', '"Product Information. Serzone (nefazodone)." Bristol-Myers Squibb  (2001):|"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31314, 29311, 'Vilazodone', 'Glaucoma, Angle-Closure', 'Some antidepressants exert mydriatic activity that can induce increased intraocular pressure and result in angle-closure (narrow-angle) glaucoma in a patient with anatomically narrow angles who does not have a patent iridectomy.  Prior to initiating therapy with these agents, patients should be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible.  The use of these drugs in patients with untreated anatomically narrow angles should be avoided.', '2', '"Product Information. Serzone (nefazodone)." Bristol-Myers Squibb  (2001):|"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31315, 29312, 'Vilazodone', 'Glaucoma, Angle-Closure', 'Some antidepressants exert mydriatic activity that can induce increased intraocular pressure and result in angle-closure (narrow-angle) glaucoma in a patient with anatomically narrow angles who does not have a patent iridectomy.  Prior to initiating therapy with these agents, patients should be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible.  The use of these drugs in patients with untreated anatomically narrow angles should be avoided.', '2', '"Product Information. Serzone (nefazodone)." Bristol-Myers Squibb  (2001):|"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31316, 29314, 'Vilazodone', 'Glaucoma, Angle-Closure', 'Some antidepressants exert mydriatic activity that can induce increased intraocular pressure and result in angle-closure (narrow-angle) glaucoma in a patient with anatomically narrow angles who does not have a patent iridectomy.  Prior to initiating therapy with these agents, patients should be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible.  The use of these drugs in patients with untreated anatomically narrow angles should be avoided.', '2', '"Product Information. Serzone (nefazodone)." Bristol-Myers Squibb  (2001):|"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31317, 29315, 'Vilazodone', 'Glaucoma, Angle-Closure', 'Some antidepressants exert mydriatic activity that can induce increased intraocular pressure and result in angle-closure (narrow-angle) glaucoma in a patient with anatomically narrow angles who does not have a patent iridectomy.  Prior to initiating therapy with these agents, patients should be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible.  The use of these drugs in patients with untreated anatomically narrow angles should be avoided.', '2', '"Product Information. Serzone (nefazodone)." Bristol-Myers Squibb  (2001):|"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31318, 29316, 'Vilazodone', 'Glaucoma, Angle-Closure', 'Some antidepressants exert mydriatic activity that can induce increased intraocular pressure and result in angle-closure (narrow-angle) glaucoma in a patient with anatomically narrow angles who does not have a patent iridectomy.  Prior to initiating therapy with these agents, patients should be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible.  The use of these drugs in patients with untreated anatomically narrow angles should be avoided.', '2', '"Product Information. Serzone (nefazodone)." Bristol-Myers Squibb  (2001):|"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31319, 29317, 'Vilazodone', 'Glaucoma, Angle-Closure', 'Some antidepressants exert mydriatic activity that can induce increased intraocular pressure and result in angle-closure (narrow-angle) glaucoma in a patient with anatomically narrow angles who does not have a patent iridectomy.  Prior to initiating therapy with these agents, patients should be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible.  The use of these drugs in patients with untreated anatomically narrow angles should be avoided.', '2', '"Product Information. Serzone (nefazodone)." Bristol-Myers Squibb  (2001):|"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31320, 29310, 'Vilazodone', 'Hemorrhage', 'Some antidepressants should be administered with caution in patients with an increased risk for hemorrhage.  Patients should be advised to immediately report any signs and symptoms suggestive of bleeding complications, including ecchymosis, hematoma, epistaxis, and petechia.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31321, 29311, 'Vilazodone', 'Hemorrhage', 'Some antidepressants should be administered with caution in patients with an increased risk for hemorrhage.  Patients should be advised to immediately report any signs and symptoms suggestive of bleeding complications, including ecchymosis, hematoma, epistaxis, and petechia.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31322, 29312, 'Vilazodone', 'Hemorrhage', 'Some antidepressants should be administered with caution in patients with an increased risk for hemorrhage.  Patients should be advised to immediately report any signs and symptoms suggestive of bleeding complications, including ecchymosis, hematoma, epistaxis, and petechia.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31323, 29314, 'Vilazodone', 'Hemorrhage', 'Some antidepressants should be administered with caution in patients with an increased risk for hemorrhage.  Patients should be advised to immediately report any signs and symptoms suggestive of bleeding complications, including ecchymosis, hematoma, epistaxis, and petechia.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31324, 29315, 'Vilazodone', 'Hemorrhage', 'Some antidepressants should be administered with caution in patients with an increased risk for hemorrhage.  Patients should be advised to immediately report any signs and symptoms suggestive of bleeding complications, including ecchymosis, hematoma, epistaxis, and petechia.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31325, 29316, 'Vilazodone', 'Hemorrhage', 'Some antidepressants should be administered with caution in patients with an increased risk for hemorrhage.  Patients should be advised to immediately report any signs and symptoms suggestive of bleeding complications, including ecchymosis, hematoma, epistaxis, and petechia.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31326, 29317, 'Vilazodone', 'Hemorrhage', 'Some antidepressants should be administered with caution in patients with an increased risk for hemorrhage.  Patients should be advised to immediately report any signs and symptoms suggestive of bleeding complications, including ecchymosis, hematoma, epistaxis, and petechia.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31327, 29310, 'Vilazodone', 'Hyponatremia', 'Treatment with vilazodone may cause hyponatremia, in many cases secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  Caution should be used when treating patients with hyponatremia or at greater risk of developing hyponatremia such as elderly patients, patients taking diuretics or those who are volume-depleted.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31328, 29311, 'Vilazodone', 'Hyponatremia', 'Treatment with vilazodone may cause hyponatremia, in many cases secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  Caution should be used when treating patients with hyponatremia or at greater risk of developing hyponatremia such as elderly patients, patients taking diuretics or those who are volume-depleted.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31329, 29312, 'Vilazodone', 'Hyponatremia', 'Treatment with vilazodone may cause hyponatremia, in many cases secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  Caution should be used when treating patients with hyponatremia or at greater risk of developing hyponatremia such as elderly patients, patients taking diuretics or those who are volume-depleted.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31330, 29314, 'Vilazodone', 'Hyponatremia', 'Treatment with vilazodone may cause hyponatremia, in many cases secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  Caution should be used when treating patients with hyponatremia or at greater risk of developing hyponatremia such as elderly patients, patients taking diuretics or those who are volume-depleted.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31331, 29315, 'Vilazodone', 'Hyponatremia', 'Treatment with vilazodone may cause hyponatremia, in many cases secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  Caution should be used when treating patients with hyponatremia or at greater risk of developing hyponatremia such as elderly patients, patients taking diuretics or those who are volume-depleted.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31332, 29316, 'Vilazodone', 'Hyponatremia', 'Treatment with vilazodone may cause hyponatremia, in many cases secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  Caution should be used when treating patients with hyponatremia or at greater risk of developing hyponatremia such as elderly patients, patients taking diuretics or those who are volume-depleted.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31333, 29317, 'Vilazodone', 'Hyponatremia', 'Treatment with vilazodone may cause hyponatremia, in many cases secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  Caution should be used when treating patients with hyponatremia or at greater risk of developing hyponatremia such as elderly patients, patients taking diuretics or those who are volume-depleted.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31334, 29310, 'Vilazodone', 'Bipolar Disorder', 'Therapy with vilazodone may cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31335, 29311, 'Vilazodone', 'Bipolar Disorder', 'Therapy with vilazodone may cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31336, 29312, 'Vilazodone', 'Bipolar Disorder', 'Therapy with vilazodone may cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31337, 29314, 'Vilazodone', 'Bipolar Disorder', 'Therapy with vilazodone may cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31338, 29315, 'Vilazodone', 'Bipolar Disorder', 'Therapy with vilazodone may cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31339, 29316, 'Vilazodone', 'Bipolar Disorder', 'Therapy with vilazodone may cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31340, 29317, 'Vilazodone', 'Bipolar Disorder', 'Therapy with vilazodone may cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31341, 29310, 'Vilazodone', 'Epilepsy', 'Therapy with vilazodone should be administered cautiously in patients with epilepsy or a history of seizure disorder.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31342, 29311, 'Vilazodone', 'Epilepsy', 'Therapy with vilazodone should be administered cautiously in patients with epilepsy or a history of seizure disorder.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31343, 29312, 'Vilazodone', 'Epilepsy', 'Therapy with vilazodone should be administered cautiously in patients with epilepsy or a history of seizure disorder.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31344, 29314, 'Vilazodone', 'Epilepsy', 'Therapy with vilazodone should be administered cautiously in patients with epilepsy or a history of seizure disorder.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31345, 29315, 'Vilazodone', 'Epilepsy', 'Therapy with vilazodone should be administered cautiously in patients with epilepsy or a history of seizure disorder.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31346, 29316, 'Vilazodone', 'Epilepsy', 'Therapy with vilazodone should be administered cautiously in patients with epilepsy or a history of seizure disorder.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31347, 29317, 'Vilazodone', 'Epilepsy', 'Therapy with vilazodone should be administered cautiously in patients with epilepsy or a history of seizure disorder.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31348, 23315, 'Vinorelbine', 'Respiratory Insufficiency', 'Acute shortness of breath and bronchospasm, some severe and life-threatening, have been reported with the use of vinca alkaloids.  These reactions were observed most often during combination therapy with mitomycin C, occurring within minutes to several hours after administration of the vinca alkaloid or up to 2 weeks following the mitomycin dose.  Therapy with vinca alkaloids should be administered cautiously in patients with preexisting pulmonary dysfunction.  Aggressive treatment may be necessary, including use of supplemental oxygen, bronchodilators, and/or corticosteroids.  In patients who develop progressive dyspnea requiring chronic therapy, vinca alkaloid should not be readministered.', '3', '"Product Information. Velban (vinblastine)." Lilly, Eli and Company  (2001):|"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31349, 23316, 'Vinorelbine', 'Respiratory Insufficiency', 'Acute shortness of breath and bronchospasm, some severe and life-threatening, have been reported with the use of vinca alkaloids.  These reactions were observed most often during combination therapy with mitomycin C, occurring within minutes to several hours after administration of the vinca alkaloid or up to 2 weeks following the mitomycin dose.  Therapy with vinca alkaloids should be administered cautiously in patients with preexisting pulmonary dysfunction.  Aggressive treatment may be necessary, including use of supplemental oxygen, bronchodilators, and/or corticosteroids.  In patients who develop progressive dyspnea requiring chronic therapy, vinca alkaloid should not be readministered.', '3', '"Product Information. Velban (vinblastine)." Lilly, Eli and Company  (2001):|"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31350, 23317, 'Vinorelbine', 'Respiratory Insufficiency', 'Acute shortness of breath and bronchospasm, some severe and life-threatening, have been reported with the use of vinca alkaloids.  These reactions were observed most often during combination therapy with mitomycin C, occurring within minutes to several hours after administration of the vinca alkaloid or up to 2 weeks following the mitomycin dose.  Therapy with vinca alkaloids should be administered cautiously in patients with preexisting pulmonary dysfunction.  Aggressive treatment may be necessary, including use of supplemental oxygen, bronchodilators, and/or corticosteroids.  In patients who develop progressive dyspnea requiring chronic therapy, vinca alkaloid should not be readministered.', '3', '"Product Information. Velban (vinblastine)." Lilly, Eli and Company  (2001):|"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31351, 23318, 'Vinorelbine', 'Respiratory Insufficiency', 'Acute shortness of breath and bronchospasm, some severe and life-threatening, have been reported with the use of vinca alkaloids.  These reactions were observed most often during combination therapy with mitomycin C, occurring within minutes to several hours after administration of the vinca alkaloid or up to 2 weeks following the mitomycin dose.  Therapy with vinca alkaloids should be administered cautiously in patients with preexisting pulmonary dysfunction.  Aggressive treatment may be necessary, including use of supplemental oxygen, bronchodilators, and/or corticosteroids.  In patients who develop progressive dyspnea requiring chronic therapy, vinca alkaloid should not be readministered.', '3', '"Product Information. Velban (vinblastine)." Lilly, Eli and Company  (2001):|"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31352, 29366, 'Vinorelbine', 'Respiratory Insufficiency', 'Acute shortness of breath and bronchospasm, some severe and life-threatening, have been reported with the use of vinca alkaloids.  These reactions were observed most often during combination therapy with mitomycin C, occurring within minutes to several hours after administration of the vinca alkaloid or up to 2 weeks following the mitomycin dose.  Therapy with vinca alkaloids should be administered cautiously in patients with preexisting pulmonary dysfunction.  Aggressive treatment may be necessary, including use of supplemental oxygen, bronchodilators, and/or corticosteroids.  In patients who develop progressive dyspnea requiring chronic therapy, vinca alkaloid should not be readministered.', '3', '"Product Information. Velban (vinblastine)." Lilly, Eli and Company  (2001):|"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31353, 29367, 'Vinorelbine', 'Respiratory Insufficiency', 'Acute shortness of breath and bronchospasm, some severe and life-threatening, have been reported with the use of vinca alkaloids.  These reactions were observed most often during combination therapy with mitomycin C, occurring within minutes to several hours after administration of the vinca alkaloid or up to 2 weeks following the mitomycin dose.  Therapy with vinca alkaloids should be administered cautiously in patients with preexisting pulmonary dysfunction.  Aggressive treatment may be necessary, including use of supplemental oxygen, bronchodilators, and/or corticosteroids.  In patients who develop progressive dyspnea requiring chronic therapy, vinca alkaloid should not be readministered.', '3', '"Product Information. Velban (vinblastine)." Lilly, Eli and Company  (2001):|"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31354, 29368, 'Vinorelbine', 'Respiratory Insufficiency', 'Acute shortness of breath and bronchospasm, some severe and life-threatening, have been reported with the use of vinca alkaloids.  These reactions were observed most often during combination therapy with mitomycin C, occurring within minutes to several hours after administration of the vinca alkaloid or up to 2 weeks following the mitomycin dose.  Therapy with vinca alkaloids should be administered cautiously in patients with preexisting pulmonary dysfunction.  Aggressive treatment may be necessary, including use of supplemental oxygen, bronchodilators, and/or corticosteroids.  In patients who develop progressive dyspnea requiring chronic therapy, vinca alkaloid should not be readministered.', '3', '"Product Information. Velban (vinblastine)." Lilly, Eli and Company  (2001):|"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31355, 29369, 'Vinorelbine', 'Respiratory Insufficiency', 'Acute shortness of breath and bronchospasm, some severe and life-threatening, have been reported with the use of vinca alkaloids.  These reactions were observed most often during combination therapy with mitomycin C, occurring within minutes to several hours after administration of the vinca alkaloid or up to 2 weeks following the mitomycin dose.  Therapy with vinca alkaloids should be administered cautiously in patients with preexisting pulmonary dysfunction.  Aggressive treatment may be necessary, including use of supplemental oxygen, bronchodilators, and/or corticosteroids.  In patients who develop progressive dyspnea requiring chronic therapy, vinca alkaloid should not be readministered.', '3', '"Product Information. Velban (vinblastine)." Lilly, Eli and Company  (2001):|"Product Information. Oncovin (vincristine)." Lilly, Eli and Company  (2001):|"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31356, 23315, 'Vinorelbine', 'Liver Diseases', 'Vinorelbine is extensively metabolized by the liver.  The pharmacokinetic disposition of vinorelbine in patients with hepatic impairment has not been assessed.  Therapy with vinorelbine should be administered cautiously and the dosage reduced in patients with compromised hepatic function.', '3', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31357, 23316, 'Vinorelbine', 'Liver Diseases', 'Vinorelbine is extensively metabolized by the liver.  The pharmacokinetic disposition of vinorelbine in patients with hepatic impairment has not been assessed.  Therapy with vinorelbine should be administered cautiously and the dosage reduced in patients with compromised hepatic function.', '3', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31358, 23317, 'Vinorelbine', 'Liver Diseases', 'Vinorelbine is extensively metabolized by the liver.  The pharmacokinetic disposition of vinorelbine in patients with hepatic impairment has not been assessed.  Therapy with vinorelbine should be administered cautiously and the dosage reduced in patients with compromised hepatic function.', '3', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31359, 23318, 'Vinorelbine', 'Liver Diseases', 'Vinorelbine is extensively metabolized by the liver.  The pharmacokinetic disposition of vinorelbine in patients with hepatic impairment has not been assessed.  Therapy with vinorelbine should be administered cautiously and the dosage reduced in patients with compromised hepatic function.', '3', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31360, 29366, 'Vinorelbine', 'Liver Diseases', 'Vinorelbine is extensively metabolized by the liver.  The pharmacokinetic disposition of vinorelbine in patients with hepatic impairment has not been assessed.  Therapy with vinorelbine should be administered cautiously and the dosage reduced in patients with compromised hepatic function.', '3', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31361, 29367, 'Vinorelbine', 'Liver Diseases', 'Vinorelbine is extensively metabolized by the liver.  The pharmacokinetic disposition of vinorelbine in patients with hepatic impairment has not been assessed.  Therapy with vinorelbine should be administered cautiously and the dosage reduced in patients with compromised hepatic function.', '3', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31362, 29368, 'Vinorelbine', 'Liver Diseases', 'Vinorelbine is extensively metabolized by the liver.  The pharmacokinetic disposition of vinorelbine in patients with hepatic impairment has not been assessed.  Therapy with vinorelbine should be administered cautiously and the dosage reduced in patients with compromised hepatic function.', '3', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31363, 29369, 'Vinorelbine', 'Liver Diseases', 'Vinorelbine is extensively metabolized by the liver.  The pharmacokinetic disposition of vinorelbine in patients with hepatic impairment has not been assessed.  Therapy with vinorelbine should be administered cautiously and the dosage reduced in patients with compromised hepatic function.', '3', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31364, 23315, 'Vinorelbine', 'Infections', 'Vinorelbine induces myelosuppression manifested by neutropenia, anemia and thrombocytopenia.  The use of vinorelbine may be contraindicated in patients with known infectious diseases.  Patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection.  Close clinical monitoring of hematopoietic function is recommended.', '3', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31365, 23316, 'Vinorelbine', 'Infections', 'Vinorelbine induces myelosuppression manifested by neutropenia, anemia and thrombocytopenia.  The use of vinorelbine may be contraindicated in patients with known infectious diseases.  Patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection.  Close clinical monitoring of hematopoietic function is recommended.', '3', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31366, 23317, 'Vinorelbine', 'Infections', 'Vinorelbine induces myelosuppression manifested by neutropenia, anemia and thrombocytopenia.  The use of vinorelbine may be contraindicated in patients with known infectious diseases.  Patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection.  Close clinical monitoring of hematopoietic function is recommended.', '3', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31367, 23318, 'Vinorelbine', 'Infections', 'Vinorelbine induces myelosuppression manifested by neutropenia, anemia and thrombocytopenia.  The use of vinorelbine may be contraindicated in patients with known infectious diseases.  Patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection.  Close clinical monitoring of hematopoietic function is recommended.', '3', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31368, 29366, 'Vinorelbine', 'Infections', 'Vinorelbine induces myelosuppression manifested by neutropenia, anemia and thrombocytopenia.  The use of vinorelbine may be contraindicated in patients with known infectious diseases.  Patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection.  Close clinical monitoring of hematopoietic function is recommended.', '3', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31369, 29367, 'Vinorelbine', 'Infections', 'Vinorelbine induces myelosuppression manifested by neutropenia, anemia and thrombocytopenia.  The use of vinorelbine may be contraindicated in patients with known infectious diseases.  Patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection.  Close clinical monitoring of hematopoietic function is recommended.', '3', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31370, 29368, 'Vinorelbine', 'Infections', 'Vinorelbine induces myelosuppression manifested by neutropenia, anemia and thrombocytopenia.  The use of vinorelbine may be contraindicated in patients with known infectious diseases.  Patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection.  Close clinical monitoring of hematopoietic function is recommended.', '3', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31371, 29369, 'Vinorelbine', 'Infections', 'Vinorelbine induces myelosuppression manifested by neutropenia, anemia and thrombocytopenia.  The use of vinorelbine may be contraindicated in patients with known infectious diseases.  Patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection.  Close clinical monitoring of hematopoietic function is recommended.', '3', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31372, 23315, 'Vinorelbine', 'Bone Marrow Failure Disorders', 'The use of vinorelbine is contraindicated in patients with neutrophil counts < 1000/mm3.  Vinorelbine induces dose-dependent myelosuppression, primarily neutropenia.  Therapy with vinorelbine should be administered with extreme caution and dosage modification considered in patients whose bone marrow reserve may be depressed by prior chemotherapy or irradiation or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.   Close clinical monitoring of hematopoietic function is recommended.', '3', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31373, 23316, 'Vinorelbine', 'Bone Marrow Failure Disorders', 'The use of vinorelbine is contraindicated in patients with neutrophil counts < 1000/mm3.  Vinorelbine induces dose-dependent myelosuppression, primarily neutropenia.  Therapy with vinorelbine should be administered with extreme caution and dosage modification considered in patients whose bone marrow reserve may be depressed by prior chemotherapy or irradiation or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.   Close clinical monitoring of hematopoietic function is recommended.', '3', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31374, 23317, 'Vinorelbine', 'Bone Marrow Failure Disorders', 'The use of vinorelbine is contraindicated in patients with neutrophil counts < 1000/mm3.  Vinorelbine induces dose-dependent myelosuppression, primarily neutropenia.  Therapy with vinorelbine should be administered with extreme caution and dosage modification considered in patients whose bone marrow reserve may be depressed by prior chemotherapy or irradiation or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.   Close clinical monitoring of hematopoietic function is recommended.', '3', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31375, 23318, 'Vinorelbine', 'Bone Marrow Failure Disorders', 'The use of vinorelbine is contraindicated in patients with neutrophil counts < 1000/mm3.  Vinorelbine induces dose-dependent myelosuppression, primarily neutropenia.  Therapy with vinorelbine should be administered with extreme caution and dosage modification considered in patients whose bone marrow reserve may be depressed by prior chemotherapy or irradiation or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.   Close clinical monitoring of hematopoietic function is recommended.', '3', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31376, 29366, 'Vinorelbine', 'Bone Marrow Failure Disorders', 'The use of vinorelbine is contraindicated in patients with neutrophil counts < 1000/mm3.  Vinorelbine induces dose-dependent myelosuppression, primarily neutropenia.  Therapy with vinorelbine should be administered with extreme caution and dosage modification considered in patients whose bone marrow reserve may be depressed by prior chemotherapy or irradiation or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.   Close clinical monitoring of hematopoietic function is recommended.', '3', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31377, 29367, 'Vinorelbine', 'Bone Marrow Failure Disorders', 'The use of vinorelbine is contraindicated in patients with neutrophil counts < 1000/mm3.  Vinorelbine induces dose-dependent myelosuppression, primarily neutropenia.  Therapy with vinorelbine should be administered with extreme caution and dosage modification considered in patients whose bone marrow reserve may be depressed by prior chemotherapy or irradiation or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.   Close clinical monitoring of hematopoietic function is recommended.', '3', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31378, 29368, 'Vinorelbine', 'Bone Marrow Failure Disorders', 'The use of vinorelbine is contraindicated in patients with neutrophil counts < 1000/mm3.  Vinorelbine induces dose-dependent myelosuppression, primarily neutropenia.  Therapy with vinorelbine should be administered with extreme caution and dosage modification considered in patients whose bone marrow reserve may be depressed by prior chemotherapy or irradiation or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.   Close clinical monitoring of hematopoietic function is recommended.', '3', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31379, 29369, 'Vinorelbine', 'Bone Marrow Failure Disorders', 'The use of vinorelbine is contraindicated in patients with neutrophil counts < 1000/mm3.  Vinorelbine induces dose-dependent myelosuppression, primarily neutropenia.  Therapy with vinorelbine should be administered with extreme caution and dosage modification considered in patients whose bone marrow reserve may be depressed by prior chemotherapy or irradiation or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.   Close clinical monitoring of hematopoietic function is recommended.', '3', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31380, 23315, 'Vinorelbine', 'Gastrointestinal Diseases', 'Severe and fatal paralytic ileus, constipation, intestinal obstruction, necrosis, and perforation occur in patients receiving vinorelbine injection.  Institute a prophylactic bowel regimen to mitigate potential constipation, bowel obstruction and/or paralytic ileus, considering adequate dietary fiber intake, hydration and routine use of stool softeners.  Caution and monitoring is advised in patients with history of gastrointestinal issues.', '2', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31381, 23316, 'Vinorelbine', 'Gastrointestinal Diseases', 'Severe and fatal paralytic ileus, constipation, intestinal obstruction, necrosis, and perforation occur in patients receiving vinorelbine injection.  Institute a prophylactic bowel regimen to mitigate potential constipation, bowel obstruction and/or paralytic ileus, considering adequate dietary fiber intake, hydration and routine use of stool softeners.  Caution and monitoring is advised in patients with history of gastrointestinal issues.', '2', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31382, 23317, 'Vinorelbine', 'Gastrointestinal Diseases', 'Severe and fatal paralytic ileus, constipation, intestinal obstruction, necrosis, and perforation occur in patients receiving vinorelbine injection.  Institute a prophylactic bowel regimen to mitigate potential constipation, bowel obstruction and/or paralytic ileus, considering adequate dietary fiber intake, hydration and routine use of stool softeners.  Caution and monitoring is advised in patients with history of gastrointestinal issues.', '2', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31383, 23318, 'Vinorelbine', 'Gastrointestinal Diseases', 'Severe and fatal paralytic ileus, constipation, intestinal obstruction, necrosis, and perforation occur in patients receiving vinorelbine injection.  Institute a prophylactic bowel regimen to mitigate potential constipation, bowel obstruction and/or paralytic ileus, considering adequate dietary fiber intake, hydration and routine use of stool softeners.  Caution and monitoring is advised in patients with history of gastrointestinal issues.', '2', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31384, 29366, 'Vinorelbine', 'Gastrointestinal Diseases', 'Severe and fatal paralytic ileus, constipation, intestinal obstruction, necrosis, and perforation occur in patients receiving vinorelbine injection.  Institute a prophylactic bowel regimen to mitigate potential constipation, bowel obstruction and/or paralytic ileus, considering adequate dietary fiber intake, hydration and routine use of stool softeners.  Caution and monitoring is advised in patients with history of gastrointestinal issues.', '2', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31385, 29367, 'Vinorelbine', 'Gastrointestinal Diseases', 'Severe and fatal paralytic ileus, constipation, intestinal obstruction, necrosis, and perforation occur in patients receiving vinorelbine injection.  Institute a prophylactic bowel regimen to mitigate potential constipation, bowel obstruction and/or paralytic ileus, considering adequate dietary fiber intake, hydration and routine use of stool softeners.  Caution and monitoring is advised in patients with history of gastrointestinal issues.', '2', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31386, 29368, 'Vinorelbine', 'Gastrointestinal Diseases', 'Severe and fatal paralytic ileus, constipation, intestinal obstruction, necrosis, and perforation occur in patients receiving vinorelbine injection.  Institute a prophylactic bowel regimen to mitigate potential constipation, bowel obstruction and/or paralytic ileus, considering adequate dietary fiber intake, hydration and routine use of stool softeners.  Caution and monitoring is advised in patients with history of gastrointestinal issues.', '2', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31387, 29369, 'Vinorelbine', 'Gastrointestinal Diseases', 'Severe and fatal paralytic ileus, constipation, intestinal obstruction, necrosis, and perforation occur in patients receiving vinorelbine injection.  Institute a prophylactic bowel regimen to mitigate potential constipation, bowel obstruction and/or paralytic ileus, considering adequate dietary fiber intake, hydration and routine use of stool softeners.  Caution and monitoring is advised in patients with history of gastrointestinal issues.', '2', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31388, 23315, 'Vinorelbine', 'Neuromuscular Diseases', 'Sensory and motor neuropathies, including severe neuropathies, occur in patients receiving vinorelbine.  Monitor patients for new or worsening signs and symptoms of neuropathy, such as paresthesia, hyperesthesia, hyporeflexia and muscle weakness while receiving vinorelbine.  Discontinue vinorelbine for CTCAE Grade 2 or greater neuropathy.  Therapy with vinorelbine should be administered cautiously in patients with or predisposed to neuropathy.', '2', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31389, 23316, 'Vinorelbine', 'Neuromuscular Diseases', 'Sensory and motor neuropathies, including severe neuropathies, occur in patients receiving vinorelbine.  Monitor patients for new or worsening signs and symptoms of neuropathy, such as paresthesia, hyperesthesia, hyporeflexia and muscle weakness while receiving vinorelbine.  Discontinue vinorelbine for CTCAE Grade 2 or greater neuropathy.  Therapy with vinorelbine should be administered cautiously in patients with or predisposed to neuropathy.', '2', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31390, 23317, 'Vinorelbine', 'Neuromuscular Diseases', 'Sensory and motor neuropathies, including severe neuropathies, occur in patients receiving vinorelbine.  Monitor patients for new or worsening signs and symptoms of neuropathy, such as paresthesia, hyperesthesia, hyporeflexia and muscle weakness while receiving vinorelbine.  Discontinue vinorelbine for CTCAE Grade 2 or greater neuropathy.  Therapy with vinorelbine should be administered cautiously in patients with or predisposed to neuropathy.', '2', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31391, 23318, 'Vinorelbine', 'Neuromuscular Diseases', 'Sensory and motor neuropathies, including severe neuropathies, occur in patients receiving vinorelbine.  Monitor patients for new or worsening signs and symptoms of neuropathy, such as paresthesia, hyperesthesia, hyporeflexia and muscle weakness while receiving vinorelbine.  Discontinue vinorelbine for CTCAE Grade 2 or greater neuropathy.  Therapy with vinorelbine should be administered cautiously in patients with or predisposed to neuropathy.', '2', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31392, 29366, 'Vinorelbine', 'Neuromuscular Diseases', 'Sensory and motor neuropathies, including severe neuropathies, occur in patients receiving vinorelbine.  Monitor patients for new or worsening signs and symptoms of neuropathy, such as paresthesia, hyperesthesia, hyporeflexia and muscle weakness while receiving vinorelbine.  Discontinue vinorelbine for CTCAE Grade 2 or greater neuropathy.  Therapy with vinorelbine should be administered cautiously in patients with or predisposed to neuropathy.', '2', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31393, 29367, 'Vinorelbine', 'Neuromuscular Diseases', 'Sensory and motor neuropathies, including severe neuropathies, occur in patients receiving vinorelbine.  Monitor patients for new or worsening signs and symptoms of neuropathy, such as paresthesia, hyperesthesia, hyporeflexia and muscle weakness while receiving vinorelbine.  Discontinue vinorelbine for CTCAE Grade 2 or greater neuropathy.  Therapy with vinorelbine should be administered cautiously in patients with or predisposed to neuropathy.', '2', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31394, 29368, 'Vinorelbine', 'Neuromuscular Diseases', 'Sensory and motor neuropathies, including severe neuropathies, occur in patients receiving vinorelbine.  Monitor patients for new or worsening signs and symptoms of neuropathy, such as paresthesia, hyperesthesia, hyporeflexia and muscle weakness while receiving vinorelbine.  Discontinue vinorelbine for CTCAE Grade 2 or greater neuropathy.  Therapy with vinorelbine should be administered cautiously in patients with or predisposed to neuropathy.', '2', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31395, 29369, 'Vinorelbine', 'Neuromuscular Diseases', 'Sensory and motor neuropathies, including severe neuropathies, occur in patients receiving vinorelbine.  Monitor patients for new or worsening signs and symptoms of neuropathy, such as paresthesia, hyperesthesia, hyporeflexia and muscle weakness while receiving vinorelbine.  Discontinue vinorelbine for CTCAE Grade 2 or greater neuropathy.  Therapy with vinorelbine should be administered cautiously in patients with or predisposed to neuropathy.', '2', '"Product Information. Navelbine (vinorelbine)." Glaxo Wellcome  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31396, 1421, 'Beta carotene', 'Liver Diseases', 'Vitamin A (including beta-carotene) is fat soluble and requires bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin A.  Vitamin A is metabolized by the liver and primarily excreted in bile and feces. Beta-carotene is primarily metabolized in the GI mucosa to vitamin A. Hepatic and/or biliary impairment can alter the metabolic and therapeutic activity of Vitamin A.', '3', '"Product Information. Aquasol A (vitamin A)." Hospira Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31397, 1421, 'Beta carotene', 'Malabsorption Syndromes', 'Absorption of vitamin A  depends on the presence of bile and absorbable fat in the GI tract.  Prolonged fat malabsorption (cystic fibrosis, hepatic cirrhosis, sprue) or malabsorption syndromes (celiac disease, GI resection) can decrease the absorption of Vitamin A.  Water- miscible vitamin A formulations may be an appropriate alternative in malabsorption conditions for certain conditions requiring vitamin A therapy.', '2', '"Product Information. Aquasol A (vitamin A)." Hospira Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31398, 0, 'Vismodegib', 'Musculoskeletal Diseases', 'Musculoskeletal adverse reactions, which may be accompanied by serum creatine kinase elevations have been reported with the use of drugs that inhibit the hedgehog pathway.  It is recommended to obtain serum creatine kinase levels and renal function tests prior to initiating therapy, periodically during treatment, and as clinically indicated.  Care should be taken when prescribing these agents to patients presenting musculoskeletal pain or myalgia.  Temporary dose interruption or discontinuation of therapy may be required based on the severity of musculoskeletal adverse reactions.', '2', '"Product Information. Odomzo (sonidegib)." Novartis Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31399, 1172, 'Vitamin A', 'Liver Diseases', 'Vitamin A (including beta-carotene) is fat soluble and requires bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin A.  Vitamin A is metabolized by the liver and primarily excreted in bile and feces. Beta-carotene is primarily metabolized in the GI mucosa to vitamin A. Hepatic and/or biliary impairment can alter the metabolic and therapeutic activity of Vitamin A.', '3', '"Product Information. Aquasol A (vitamin A)." Hospira Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31400, 29488, 'Vitamin A', 'Liver Diseases', 'Vitamin A (including beta-carotene) is fat soluble and requires bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin A.  Vitamin A is metabolized by the liver and primarily excreted in bile and feces. Beta-carotene is primarily metabolized in the GI mucosa to vitamin A. Hepatic and/or biliary impairment can alter the metabolic and therapeutic activity of Vitamin A.', '3', '"Product Information. Aquasol A (vitamin A)." Hospira Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31401, 1172, 'Vitamin A', 'Malabsorption Syndromes', 'Absorption of vitamin A  depends on the presence of bile and absorbable fat in the GI tract.  Prolonged fat malabsorption (cystic fibrosis, hepatic cirrhosis, sprue) or malabsorption syndromes (celiac disease, GI resection) can decrease the absorption of Vitamin A.  Water- miscible vitamin A formulations may be an appropriate alternative in malabsorption conditions for certain conditions requiring vitamin A therapy.', '2', '"Product Information. Aquasol A (vitamin A)." Hospira Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31402, 29488, 'Vitamin A', 'Malabsorption Syndromes', 'Absorption of vitamin A  depends on the presence of bile and absorbable fat in the GI tract.  Prolonged fat malabsorption (cystic fibrosis, hepatic cirrhosis, sprue) or malabsorption syndromes (celiac disease, GI resection) can decrease the absorption of Vitamin A.  Water- miscible vitamin A formulations may be an appropriate alternative in malabsorption conditions for certain conditions requiring vitamin A therapy.', '2', '"Product Information. Aquasol A (vitamin A)." Hospira Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31403, 237, 'Vortioxetine', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31404, 738, 'Vortioxetine', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31405, 750, 'Vortioxetine', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31406, 7003, 'Vortioxetine', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31407, 9563, 'Vortioxetine', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31408, 11867, 'Vortioxetine', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31409, 15493, 'Vortioxetine', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31410, 15494, 'Vortioxetine', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31411, 29596, 'Vortioxetine', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31412, 29597, 'Vortioxetine', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31413, 29598, 'Vortioxetine', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31414, 29599, 'Vortioxetine', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31415, 237, 'Vortioxetine', 'Glaucoma, Angle-Closure', 'Some antidepressants exert mydriatic activity that can induce increased intraocular pressure and result in angle-closure (narrow-angle) glaucoma in a patient with anatomically narrow angles who does not have a patent iridectomy.  Prior to initiating therapy with these agents, patients should be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible.  The use of these drugs in patients with untreated anatomically narrow angles should be avoided.', '2', '"Product Information. Serzone (nefazodone)." Bristol-Myers Squibb  (2001):|"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31416, 738, 'Vortioxetine', 'Glaucoma, Angle-Closure', 'Some antidepressants exert mydriatic activity that can induce increased intraocular pressure and result in angle-closure (narrow-angle) glaucoma in a patient with anatomically narrow angles who does not have a patent iridectomy.  Prior to initiating therapy with these agents, patients should be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible.  The use of these drugs in patients with untreated anatomically narrow angles should be avoided.', '2', '"Product Information. Serzone (nefazodone)." Bristol-Myers Squibb  (2001):|"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31417, 750, 'Vortioxetine', 'Glaucoma, Angle-Closure', 'Some antidepressants exert mydriatic activity that can induce increased intraocular pressure and result in angle-closure (narrow-angle) glaucoma in a patient with anatomically narrow angles who does not have a patent iridectomy.  Prior to initiating therapy with these agents, patients should be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible.  The use of these drugs in patients with untreated anatomically narrow angles should be avoided.', '2', '"Product Information. Serzone (nefazodone)." Bristol-Myers Squibb  (2001):|"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31418, 7003, 'Vortioxetine', 'Glaucoma, Angle-Closure', 'Some antidepressants exert mydriatic activity that can induce increased intraocular pressure and result in angle-closure (narrow-angle) glaucoma in a patient with anatomically narrow angles who does not have a patent iridectomy.  Prior to initiating therapy with these agents, patients should be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible.  The use of these drugs in patients with untreated anatomically narrow angles should be avoided.', '2', '"Product Information. Serzone (nefazodone)." Bristol-Myers Squibb  (2001):|"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31419, 9563, 'Vortioxetine', 'Glaucoma, Angle-Closure', 'Some antidepressants exert mydriatic activity that can induce increased intraocular pressure and result in angle-closure (narrow-angle) glaucoma in a patient with anatomically narrow angles who does not have a patent iridectomy.  Prior to initiating therapy with these agents, patients should be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible.  The use of these drugs in patients with untreated anatomically narrow angles should be avoided.', '2', '"Product Information. Serzone (nefazodone)." Bristol-Myers Squibb  (2001):|"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31420, 11867, 'Vortioxetine', 'Glaucoma, Angle-Closure', 'Some antidepressants exert mydriatic activity that can induce increased intraocular pressure and result in angle-closure (narrow-angle) glaucoma in a patient with anatomically narrow angles who does not have a patent iridectomy.  Prior to initiating therapy with these agents, patients should be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible.  The use of these drugs in patients with untreated anatomically narrow angles should be avoided.', '2', '"Product Information. Serzone (nefazodone)." Bristol-Myers Squibb  (2001):|"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31421, 15493, 'Vortioxetine', 'Glaucoma, Angle-Closure', 'Some antidepressants exert mydriatic activity that can induce increased intraocular pressure and result in angle-closure (narrow-angle) glaucoma in a patient with anatomically narrow angles who does not have a patent iridectomy.  Prior to initiating therapy with these agents, patients should be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible.  The use of these drugs in patients with untreated anatomically narrow angles should be avoided.', '2', '"Product Information. Serzone (nefazodone)." Bristol-Myers Squibb  (2001):|"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31422, 15494, 'Vortioxetine', 'Glaucoma, Angle-Closure', 'Some antidepressants exert mydriatic activity that can induce increased intraocular pressure and result in angle-closure (narrow-angle) glaucoma in a patient with anatomically narrow angles who does not have a patent iridectomy.  Prior to initiating therapy with these agents, patients should be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible.  The use of these drugs in patients with untreated anatomically narrow angles should be avoided.', '2', '"Product Information. Serzone (nefazodone)." Bristol-Myers Squibb  (2001):|"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31423, 29596, 'Vortioxetine', 'Glaucoma, Angle-Closure', 'Some antidepressants exert mydriatic activity that can induce increased intraocular pressure and result in angle-closure (narrow-angle) glaucoma in a patient with anatomically narrow angles who does not have a patent iridectomy.  Prior to initiating therapy with these agents, patients should be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible.  The use of these drugs in patients with untreated anatomically narrow angles should be avoided.', '2', '"Product Information. Serzone (nefazodone)." Bristol-Myers Squibb  (2001):|"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31424, 29597, 'Vortioxetine', 'Glaucoma, Angle-Closure', 'Some antidepressants exert mydriatic activity that can induce increased intraocular pressure and result in angle-closure (narrow-angle) glaucoma in a patient with anatomically narrow angles who does not have a patent iridectomy.  Prior to initiating therapy with these agents, patients should be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible.  The use of these drugs in patients with untreated anatomically narrow angles should be avoided.', '2', '"Product Information. Serzone (nefazodone)." Bristol-Myers Squibb  (2001):|"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31425, 29598, 'Vortioxetine', 'Glaucoma, Angle-Closure', 'Some antidepressants exert mydriatic activity that can induce increased intraocular pressure and result in angle-closure (narrow-angle) glaucoma in a patient with anatomically narrow angles who does not have a patent iridectomy.  Prior to initiating therapy with these agents, patients should be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible.  The use of these drugs in patients with untreated anatomically narrow angles should be avoided.', '2', '"Product Information. Serzone (nefazodone)." Bristol-Myers Squibb  (2001):|"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31426, 29599, 'Vortioxetine', 'Glaucoma, Angle-Closure', 'Some antidepressants exert mydriatic activity that can induce increased intraocular pressure and result in angle-closure (narrow-angle) glaucoma in a patient with anatomically narrow angles who does not have a patent iridectomy.  Prior to initiating therapy with these agents, patients should be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible.  The use of these drugs in patients with untreated anatomically narrow angles should be avoided.', '2', '"Product Information. Serzone (nefazodone)." Bristol-Myers Squibb  (2001):|"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31427, 237, 'Vortioxetine', 'Hemorrhage', 'Some antidepressants should be administered with caution in patients with an increased risk for hemorrhage.  Patients should be advised to immediately report any signs and symptoms suggestive of bleeding complications, including ecchymosis, hematoma, epistaxis, and petechia.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31428, 738, 'Vortioxetine', 'Hemorrhage', 'Some antidepressants should be administered with caution in patients with an increased risk for hemorrhage.  Patients should be advised to immediately report any signs and symptoms suggestive of bleeding complications, including ecchymosis, hematoma, epistaxis, and petechia.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31429, 750, 'Vortioxetine', 'Hemorrhage', 'Some antidepressants should be administered with caution in patients with an increased risk for hemorrhage.  Patients should be advised to immediately report any signs and symptoms suggestive of bleeding complications, including ecchymosis, hematoma, epistaxis, and petechia.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31430, 7003, 'Vortioxetine', 'Hemorrhage', 'Some antidepressants should be administered with caution in patients with an increased risk for hemorrhage.  Patients should be advised to immediately report any signs and symptoms suggestive of bleeding complications, including ecchymosis, hematoma, epistaxis, and petechia.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31431, 9563, 'Vortioxetine', 'Hemorrhage', 'Some antidepressants should be administered with caution in patients with an increased risk for hemorrhage.  Patients should be advised to immediately report any signs and symptoms suggestive of bleeding complications, including ecchymosis, hematoma, epistaxis, and petechia.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31432, 11867, 'Vortioxetine', 'Hemorrhage', 'Some antidepressants should be administered with caution in patients with an increased risk for hemorrhage.  Patients should be advised to immediately report any signs and symptoms suggestive of bleeding complications, including ecchymosis, hematoma, epistaxis, and petechia.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31433, 15493, 'Vortioxetine', 'Hemorrhage', 'Some antidepressants should be administered with caution in patients with an increased risk for hemorrhage.  Patients should be advised to immediately report any signs and symptoms suggestive of bleeding complications, including ecchymosis, hematoma, epistaxis, and petechia.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31434, 15494, 'Vortioxetine', 'Hemorrhage', 'Some antidepressants should be administered with caution in patients with an increased risk for hemorrhage.  Patients should be advised to immediately report any signs and symptoms suggestive of bleeding complications, including ecchymosis, hematoma, epistaxis, and petechia.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31435, 29596, 'Vortioxetine', 'Hemorrhage', 'Some antidepressants should be administered with caution in patients with an increased risk for hemorrhage.  Patients should be advised to immediately report any signs and symptoms suggestive of bleeding complications, including ecchymosis, hematoma, epistaxis, and petechia.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31436, 29597, 'Vortioxetine', 'Hemorrhage', 'Some antidepressants should be administered with caution in patients with an increased risk for hemorrhage.  Patients should be advised to immediately report any signs and symptoms suggestive of bleeding complications, including ecchymosis, hematoma, epistaxis, and petechia.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31437, 29598, 'Vortioxetine', 'Hemorrhage', 'Some antidepressants should be administered with caution in patients with an increased risk for hemorrhage.  Patients should be advised to immediately report any signs and symptoms suggestive of bleeding complications, including ecchymosis, hematoma, epistaxis, and petechia.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31438, 29599, 'Vortioxetine', 'Hemorrhage', 'Some antidepressants should be administered with caution in patients with an increased risk for hemorrhage.  Patients should be advised to immediately report any signs and symptoms suggestive of bleeding complications, including ecchymosis, hematoma, epistaxis, and petechia.', '2', '"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):|"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31439, 237, 'Vortioxetine', 'Hyponatremia', 'Treatment with vortioxetine may cause hyponatremia, in many cases secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  Caution should be used when treating patients with hyponatremia or at greater risk of developing hyponatremia such as elderly patients, patients taking diuretics or those who are volume-depleted.', '2', '"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31440, 738, 'Vortioxetine', 'Hyponatremia', 'Treatment with vortioxetine may cause hyponatremia, in many cases secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  Caution should be used when treating patients with hyponatremia or at greater risk of developing hyponatremia such as elderly patients, patients taking diuretics or those who are volume-depleted.', '2', '"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31441, 750, 'Vortioxetine', 'Hyponatremia', 'Treatment with vortioxetine may cause hyponatremia, in many cases secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  Caution should be used when treating patients with hyponatremia or at greater risk of developing hyponatremia such as elderly patients, patients taking diuretics or those who are volume-depleted.', '2', '"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31442, 7003, 'Vortioxetine', 'Hyponatremia', 'Treatment with vortioxetine may cause hyponatremia, in many cases secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  Caution should be used when treating patients with hyponatremia or at greater risk of developing hyponatremia such as elderly patients, patients taking diuretics or those who are volume-depleted.', '2', '"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31443, 9563, 'Vortioxetine', 'Hyponatremia', 'Treatment with vortioxetine may cause hyponatremia, in many cases secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  Caution should be used when treating patients with hyponatremia or at greater risk of developing hyponatremia such as elderly patients, patients taking diuretics or those who are volume-depleted.', '2', '"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31444, 11867, 'Vortioxetine', 'Hyponatremia', 'Treatment with vortioxetine may cause hyponatremia, in many cases secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  Caution should be used when treating patients with hyponatremia or at greater risk of developing hyponatremia such as elderly patients, patients taking diuretics or those who are volume-depleted.', '2', '"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31445, 15493, 'Vortioxetine', 'Hyponatremia', 'Treatment with vortioxetine may cause hyponatremia, in many cases secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  Caution should be used when treating patients with hyponatremia or at greater risk of developing hyponatremia such as elderly patients, patients taking diuretics or those who are volume-depleted.', '2', '"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31446, 15494, 'Vortioxetine', 'Hyponatremia', 'Treatment with vortioxetine may cause hyponatremia, in many cases secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  Caution should be used when treating patients with hyponatremia or at greater risk of developing hyponatremia such as elderly patients, patients taking diuretics or those who are volume-depleted.', '2', '"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31447, 29596, 'Vortioxetine', 'Hyponatremia', 'Treatment with vortioxetine may cause hyponatremia, in many cases secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  Caution should be used when treating patients with hyponatremia or at greater risk of developing hyponatremia such as elderly patients, patients taking diuretics or those who are volume-depleted.', '2', '"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31448, 29597, 'Vortioxetine', 'Hyponatremia', 'Treatment with vortioxetine may cause hyponatremia, in many cases secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  Caution should be used when treating patients with hyponatremia or at greater risk of developing hyponatremia such as elderly patients, patients taking diuretics or those who are volume-depleted.', '2', '"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31449, 29598, 'Vortioxetine', 'Hyponatremia', 'Treatment with vortioxetine may cause hyponatremia, in many cases secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  Caution should be used when treating patients with hyponatremia or at greater risk of developing hyponatremia such as elderly patients, patients taking diuretics or those who are volume-depleted.', '2', '"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31450, 29599, 'Vortioxetine', 'Hyponatremia', 'Treatment with vortioxetine may cause hyponatremia, in many cases secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  Caution should be used when treating patients with hyponatremia or at greater risk of developing hyponatremia such as elderly patients, patients taking diuretics or those who are volume-depleted.', '2', '"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31451, 237, 'Vortioxetine', 'Bipolar Disorder', 'Therapy with vortioxetine may cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31452, 738, 'Vortioxetine', 'Bipolar Disorder', 'Therapy with vortioxetine may cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31453, 750, 'Vortioxetine', 'Bipolar Disorder', 'Therapy with vortioxetine may cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31454, 7003, 'Vortioxetine', 'Bipolar Disorder', 'Therapy with vortioxetine may cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31455, 9563, 'Vortioxetine', 'Bipolar Disorder', 'Therapy with vortioxetine may cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31456, 11867, 'Vortioxetine', 'Bipolar Disorder', 'Therapy with vortioxetine may cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31457, 15493, 'Vortioxetine', 'Bipolar Disorder', 'Therapy with vortioxetine may cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31458, 15494, 'Vortioxetine', 'Bipolar Disorder', 'Therapy with vortioxetine may cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31459, 29596, 'Vortioxetine', 'Bipolar Disorder', 'Therapy with vortioxetine may cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31460, 29597, 'Vortioxetine', 'Bipolar Disorder', 'Therapy with vortioxetine may cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31461, 29598, 'Vortioxetine', 'Bipolar Disorder', 'Therapy with vortioxetine may cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31462, 29599, 'Vortioxetine', 'Bipolar Disorder', 'Therapy with vortioxetine may cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31463, 1699, 'Von Willebrand Factor Human', 'Thromboembolism', 'Thromboembolic reactions including disseminated intravascular coagulation (DIC), venous thrombosis, pulmonary embolism, myocardial infarction, and stroke can occur after therapy with von Willebrand factor, particularly in patients with risk factors for thrombosis.  Monitor for early signs and symptoms of thrombosis such as pain, swelling, discoloration, dyspnea, cough, hemoptysis, and syncope and have prophylaxis measures against thromboembolism instituted according to current recommendations.', '2', '"Product Information. Humate-P (antihemophilic factor-von Willebrand factor)." CSL Behring LLC  (2022):|"Product Information. Wilate (antihemophilic factor-von Willebrand factor)." Octapharma USA  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31464, 15463, 'Von Willebrand Factor Human', 'Thromboembolism', 'Thromboembolic reactions including disseminated intravascular coagulation (DIC), venous thrombosis, pulmonary embolism, myocardial infarction, and stroke can occur after therapy with von Willebrand factor, particularly in patients with risk factors for thrombosis.  Monitor for early signs and symptoms of thrombosis such as pain, swelling, discoloration, dyspnea, cough, hemoptysis, and syncope and have prophylaxis measures against thromboembolism instituted according to current recommendations.', '2', '"Product Information. Humate-P (antihemophilic factor-von Willebrand factor)." CSL Behring LLC  (2022):|"Product Information. Wilate (antihemophilic factor-von Willebrand factor)." Octapharma USA  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31465, 7018, 'Vitamin E', 'Liver Diseases', 'Vitamin E is fat soluble and many oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin E.  Water- miscible vitamin E formulations may be better absorbed from the GI tract under these conditions.  Vitamin E is metabolized by the liver and primarily excreted in bile and feces.  Hepatic and/or biliary impairment can alter the metabolic and therapeutic activity of vitamin E.', '3', '"Product Information. Aquasol E (vitamin E)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31466, 12493, 'Vitamin E', 'Liver Diseases', 'Vitamin E is fat soluble and many oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin E.  Water- miscible vitamin E formulations may be better absorbed from the GI tract under these conditions.  Vitamin E is metabolized by the liver and primarily excreted in bile and feces.  Hepatic and/or biliary impairment can alter the metabolic and therapeutic activity of vitamin E.', '3', '"Product Information. Aquasol E (vitamin E)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31467, 18674, 'Vitamin E', 'Liver Diseases', 'Vitamin E is fat soluble and many oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin E.  Water- miscible vitamin E formulations may be better absorbed from the GI tract under these conditions.  Vitamin E is metabolized by the liver and primarily excreted in bile and feces.  Hepatic and/or biliary impairment can alter the metabolic and therapeutic activity of vitamin E.', '3', '"Product Information. Aquasol E (vitamin E)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31468, 28247, 'Vitamin E', 'Liver Diseases', 'Vitamin E is fat soluble and many oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin E.  Water- miscible vitamin E formulations may be better absorbed from the GI tract under these conditions.  Vitamin E is metabolized by the liver and primarily excreted in bile and feces.  Hepatic and/or biliary impairment can alter the metabolic and therapeutic activity of vitamin E.', '3', '"Product Information. Aquasol E (vitamin E)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31469, 28248, 'Vitamin E', 'Liver Diseases', 'Vitamin E is fat soluble and many oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin E.  Water- miscible vitamin E formulations may be better absorbed from the GI tract under these conditions.  Vitamin E is metabolized by the liver and primarily excreted in bile and feces.  Hepatic and/or biliary impairment can alter the metabolic and therapeutic activity of vitamin E.', '3', '"Product Information. Aquasol E (vitamin E)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31470, 29463, 'Vitamin E', 'Liver Diseases', 'Vitamin E is fat soluble and many oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin E.  Water- miscible vitamin E formulations may be better absorbed from the GI tract under these conditions.  Vitamin E is metabolized by the liver and primarily excreted in bile and feces.  Hepatic and/or biliary impairment can alter the metabolic and therapeutic activity of vitamin E.', '3', '"Product Information. Aquasol E (vitamin E)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31471, 29506, 'Vitamin E', 'Liver Diseases', 'Vitamin E is fat soluble and many oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin E.  Water- miscible vitamin E formulations may be better absorbed from the GI tract under these conditions.  Vitamin E is metabolized by the liver and primarily excreted in bile and feces.  Hepatic and/or biliary impairment can alter the metabolic and therapeutic activity of vitamin E.', '3', '"Product Information. Aquasol E (vitamin E)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31472, 29508, 'Vitamin E', 'Liver Diseases', 'Vitamin E is fat soluble and many oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin E.  Water- miscible vitamin E formulations may be better absorbed from the GI tract under these conditions.  Vitamin E is metabolized by the liver and primarily excreted in bile and feces.  Hepatic and/or biliary impairment can alter the metabolic and therapeutic activity of vitamin E.', '3', '"Product Information. Aquasol E (vitamin E)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31473, 29511, 'Vitamin E', 'Liver Diseases', 'Vitamin E is fat soluble and many oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin E.  Water- miscible vitamin E formulations may be better absorbed from the GI tract under these conditions.  Vitamin E is metabolized by the liver and primarily excreted in bile and feces.  Hepatic and/or biliary impairment can alter the metabolic and therapeutic activity of vitamin E.', '3', '"Product Information. Aquasol E (vitamin E)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31474, 7018, 'Vitamin E', 'Malabsorption Syndromes', 'Vitamin E is readily absorbed from the intestinal tract in the presence of bile.  Prolonged fat malabsorption (cystic fibrosis, hepatic cirrhosis, sprue) or malabsorption syndromes (celiac disease, GI resection) can decrease the absorption of many oral formulations of vitamin E.  A water- miscible formulation of vitamin E may be better absorbed in these conditions.', '1', '"Product Information. Aquasol E (vitamin E)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31475, 12493, 'Vitamin E', 'Malabsorption Syndromes', 'Vitamin E is readily absorbed from the intestinal tract in the presence of bile.  Prolonged fat malabsorption (cystic fibrosis, hepatic cirrhosis, sprue) or malabsorption syndromes (celiac disease, GI resection) can decrease the absorption of many oral formulations of vitamin E.  A water- miscible formulation of vitamin E may be better absorbed in these conditions.', '1', '"Product Information. Aquasol E (vitamin E)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31476, 18674, 'Vitamin E', 'Malabsorption Syndromes', 'Vitamin E is readily absorbed from the intestinal tract in the presence of bile.  Prolonged fat malabsorption (cystic fibrosis, hepatic cirrhosis, sprue) or malabsorption syndromes (celiac disease, GI resection) can decrease the absorption of many oral formulations of vitamin E.  A water- miscible formulation of vitamin E may be better absorbed in these conditions.', '1', '"Product Information. Aquasol E (vitamin E)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31477, 28247, 'Vitamin E', 'Malabsorption Syndromes', 'Vitamin E is readily absorbed from the intestinal tract in the presence of bile.  Prolonged fat malabsorption (cystic fibrosis, hepatic cirrhosis, sprue) or malabsorption syndromes (celiac disease, GI resection) can decrease the absorption of many oral formulations of vitamin E.  A water- miscible formulation of vitamin E may be better absorbed in these conditions.', '1', '"Product Information. Aquasol E (vitamin E)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31478, 28248, 'Vitamin E', 'Malabsorption Syndromes', 'Vitamin E is readily absorbed from the intestinal tract in the presence of bile.  Prolonged fat malabsorption (cystic fibrosis, hepatic cirrhosis, sprue) or malabsorption syndromes (celiac disease, GI resection) can decrease the absorption of many oral formulations of vitamin E.  A water- miscible formulation of vitamin E may be better absorbed in these conditions.', '1', '"Product Information. Aquasol E (vitamin E)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31479, 29463, 'Vitamin E', 'Malabsorption Syndromes', 'Vitamin E is readily absorbed from the intestinal tract in the presence of bile.  Prolonged fat malabsorption (cystic fibrosis, hepatic cirrhosis, sprue) or malabsorption syndromes (celiac disease, GI resection) can decrease the absorption of many oral formulations of vitamin E.  A water- miscible formulation of vitamin E may be better absorbed in these conditions.', '1', '"Product Information. Aquasol E (vitamin E)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31480, 29506, 'Vitamin E', 'Malabsorption Syndromes', 'Vitamin E is readily absorbed from the intestinal tract in the presence of bile.  Prolonged fat malabsorption (cystic fibrosis, hepatic cirrhosis, sprue) or malabsorption syndromes (celiac disease, GI resection) can decrease the absorption of many oral formulations of vitamin E.  A water- miscible formulation of vitamin E may be better absorbed in these conditions.', '1', '"Product Information. Aquasol E (vitamin E)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31481, 29508, 'Vitamin E', 'Malabsorption Syndromes', 'Vitamin E is readily absorbed from the intestinal tract in the presence of bile.  Prolonged fat malabsorption (cystic fibrosis, hepatic cirrhosis, sprue) or malabsorption syndromes (celiac disease, GI resection) can decrease the absorption of many oral formulations of vitamin E.  A water- miscible formulation of vitamin E may be better absorbed in these conditions.', '1', '"Product Information. Aquasol E (vitamin E)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31482, 29511, 'Vitamin E', 'Malabsorption Syndromes', 'Vitamin E is readily absorbed from the intestinal tract in the presence of bile.  Prolonged fat malabsorption (cystic fibrosis, hepatic cirrhosis, sprue) or malabsorption syndromes (celiac disease, GI resection) can decrease the absorption of many oral formulations of vitamin E.  A water- miscible formulation of vitamin E may be better absorbed in these conditions.', '1', '"Product Information. Aquasol E (vitamin E)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31483, 0, 'Vorapaxar', 'Hemorrhage', 'Vorapaxar increases the risk of bleeding and it is contraindicated in patients with active pathological bleeding such as intracranial hemorrhage or peptic ulcer.  In other patients, consider the underlying risk of bleeding before initiating therapy.  General risk factors include older age, low body weight, reduced renal or hepatic function, history of bleeding disorders, and use of certain concomitant medications.  The use of warfarin and other anticoagulants should be avoided.  Bleeding should be suspected in any patient who is hypotensive and has recently undergone coronary angiography, percutaneous coronary intervention (PCI), coronary artery bypass graft surgery (CABG), or any other surgical procedure.', '3', '"Product Information. Zontivity (vorapaxar)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31484, 0, 'Vorapaxar', 'Ischemic Stroke', 'Vorapaxar is contraindicated in patients with a history of stroke, transient ischemic attack (TIA), or intracranial bleeding.  The risk of intracranial bleeding is higher in these patients.', '3', '"Product Information. Zontivity (vorapaxar)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31485, 0, 'Vorapaxar', 'Liver Diseases', 'No dose adjustment is required in patients with renal dysfunction or mild to moderate hepatic impairment.  Vorapaxar is not recommended in patients with severe hepatic impairment due to bleeding risk.', '3', '"Product Information. Zontivity (vorapaxar)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31486, 0, 'Vorinostat', 'Thromboembolism', 'The use of vorinostat may cause pulmonary embolism and deep vein thrombosis.  It is recommended to monitor for signs and symptoms of these events, particularly in patients with a prior history of thromboembolic events.', '3', '"Product Information. Zolinza (vorinostat)." Merck & Co., Inc  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31487, 0, 'Vorinostat', 'Diabetes Mellitus', 'The use of vorinostat may cause hyperglycemia.  It is recommended to monitor serum glucose every 2 weeks during the first 2 months of therapy and monthly thereafter.  Care should be exercised when using this agent in diabetic patients.', '2', '"Product Information. Zolinza (vorinostat)." Merck & Co., Inc  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31488, 0, 'Vorinostat', 'Gastrointestinal Diseases', 'The use of vorinostat may cause gastrointestinal disturbances.  It is recommended to adequately control any preexisting nausea, vomiting, and diarrhea prior to beginning treatment with vorinostat.  Fluid and electrolytes should be replaced to prevent dehydration and the use of antiemetic and antidiarrheal medications may be appropriate.  Correct hypokalemia and hypomagnesemia prior to administration of vorinostat.  Monitor potassium and magnesium more frequently in symptomatic patients.', '2', '"Product Information. Zolinza (vorinostat)." Merck & Co., Inc  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31489, 0, 'Vorinostat', 'Liver Failure', 'Compared to patients with normal liver function, AUC increases of 50 to 66% were observed in patients with hepatic impairment.  It is recommended to reduce the starting dose of vorinostat to 300 mg orally once daily with food in patients with mild to moderate hepatic impairment (bilirubin 1 to 3  ULN or AST greater than ULN).  There is insufficient evidence to recommend a starting dose for patients with severe hepatic impairment (bilirubin greater than 3  ULN).  Precautions should be instituted when using this agent in patients with liver dysfunction.', '2', '"Product Information. Zolinza (vorinostat)." Merck & Co., Inc  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31490, 0, 'Vorinostat', 'Bone Marrow Failure Disorders', 'The use of vorinostat can cause dose-related thrombocytopenia and anemia.  It is recommended to monitor blood counts every 2 weeks during the first 2 months of therapy and monthly thereafter.  Adjust dosage or discontinue treatment as clinically appropriate.  Care should be exercised when using this agent in patients with bone marrow suppression.', '2', '"Product Information. Zolinza (vorinostat)." Merck & Co., Inc  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31491, 12260, 'Voriconazole', 'Liver Diseases', 'Serious hepatic reactions (including clinical hepatitis, cholestasis, fulminant hepatic failure [including fatalities]) have been reported infrequently during voriconazole therapy.  Hepatic reactions have primarily occurred in patients with serious underlying medical conditions (mainly hematological malignancy); however, some reactions (including hepatitis, jaundice) occurred in patients with no other identifiable risk factors.  Hepatic function should be monitored in all patients; a higher frequency of liver enzyme elevations was observed in pediatrics.  Serum transaminase levels and bilirubin should be measured at the start of therapy and monitored at least weekly for the first month of therapy; monitoring frequency can be reduced to monthly during continued use if no clinically significant changes are observed.  If liver function tests increase significantly from baseline, voriconazole should be discontinued unless, after assessing the benefit/risk to the patient, continued use is justified.Voriconazole is primarily metabolized by the liver and has been shown to accumulate significantly in patients with impaired hepatic function.  The manufacturer recommends that the maintenance dose be halved in patients with mild to moderate hepatic impairment/cirrhosis.  No dosing recommendations are available for patients with severe hepatic impairment/cirrhosis or for patients with chronic hepatitis B or C.  Voriconazole should only be used in patients with severe hepatic impairment if benefit outweighs the potential risk.  Patients with hepatic impairment must be carefully monitored for drug toxicity.', '3', '"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31492, 14824, 'Voriconazole', 'Liver Diseases', 'Serious hepatic reactions (including clinical hepatitis, cholestasis, fulminant hepatic failure [including fatalities]) have been reported infrequently during voriconazole therapy.  Hepatic reactions have primarily occurred in patients with serious underlying medical conditions (mainly hematological malignancy); however, some reactions (including hepatitis, jaundice) occurred in patients with no other identifiable risk factors.  Hepatic function should be monitored in all patients; a higher frequency of liver enzyme elevations was observed in pediatrics.  Serum transaminase levels and bilirubin should be measured at the start of therapy and monitored at least weekly for the first month of therapy; monitoring frequency can be reduced to monthly during continued use if no clinically significant changes are observed.  If liver function tests increase significantly from baseline, voriconazole should be discontinued unless, after assessing the benefit/risk to the patient, continued use is justified.Voriconazole is primarily metabolized by the liver and has been shown to accumulate significantly in patients with impaired hepatic function.  The manufacturer recommends that the maintenance dose be halved in patients with mild to moderate hepatic impairment/cirrhosis.  No dosing recommendations are available for patients with severe hepatic impairment/cirrhosis or for patients with chronic hepatitis B or C.  Voriconazole should only be used in patients with severe hepatic impairment if benefit outweighs the potential risk.  Patients with hepatic impairment must be carefully monitored for drug toxicity.', '3', '"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31493, 16702, 'Voriconazole', 'Liver Diseases', 'Serious hepatic reactions (including clinical hepatitis, cholestasis, fulminant hepatic failure [including fatalities]) have been reported infrequently during voriconazole therapy.  Hepatic reactions have primarily occurred in patients with serious underlying medical conditions (mainly hematological malignancy); however, some reactions (including hepatitis, jaundice) occurred in patients with no other identifiable risk factors.  Hepatic function should be monitored in all patients; a higher frequency of liver enzyme elevations was observed in pediatrics.  Serum transaminase levels and bilirubin should be measured at the start of therapy and monitored at least weekly for the first month of therapy; monitoring frequency can be reduced to monthly during continued use if no clinically significant changes are observed.  If liver function tests increase significantly from baseline, voriconazole should be discontinued unless, after assessing the benefit/risk to the patient, continued use is justified.Voriconazole is primarily metabolized by the liver and has been shown to accumulate significantly in patients with impaired hepatic function.  The manufacturer recommends that the maintenance dose be halved in patients with mild to moderate hepatic impairment/cirrhosis.  No dosing recommendations are available for patients with severe hepatic impairment/cirrhosis or for patients with chronic hepatitis B or C.  Voriconazole should only be used in patients with severe hepatic impairment if benefit outweighs the potential risk.  Patients with hepatic impairment must be carefully monitored for drug toxicity.', '3', '"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31494, 16703, 'Voriconazole', 'Liver Diseases', 'Serious hepatic reactions (including clinical hepatitis, cholestasis, fulminant hepatic failure [including fatalities]) have been reported infrequently during voriconazole therapy.  Hepatic reactions have primarily occurred in patients with serious underlying medical conditions (mainly hematological malignancy); however, some reactions (including hepatitis, jaundice) occurred in patients with no other identifiable risk factors.  Hepatic function should be monitored in all patients; a higher frequency of liver enzyme elevations was observed in pediatrics.  Serum transaminase levels and bilirubin should be measured at the start of therapy and monitored at least weekly for the first month of therapy; monitoring frequency can be reduced to monthly during continued use if no clinically significant changes are observed.  If liver function tests increase significantly from baseline, voriconazole should be discontinued unless, after assessing the benefit/risk to the patient, continued use is justified.Voriconazole is primarily metabolized by the liver and has been shown to accumulate significantly in patients with impaired hepatic function.  The manufacturer recommends that the maintenance dose be halved in patients with mild to moderate hepatic impairment/cirrhosis.  No dosing recommendations are available for patients with severe hepatic impairment/cirrhosis or for patients with chronic hepatitis B or C.  Voriconazole should only be used in patients with severe hepatic impairment if benefit outweighs the potential risk.  Patients with hepatic impairment must be carefully monitored for drug toxicity.', '3', '"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31495, 18521, 'Voriconazole', 'Liver Diseases', 'Serious hepatic reactions (including clinical hepatitis, cholestasis, fulminant hepatic failure [including fatalities]) have been reported infrequently during voriconazole therapy.  Hepatic reactions have primarily occurred in patients with serious underlying medical conditions (mainly hematological malignancy); however, some reactions (including hepatitis, jaundice) occurred in patients with no other identifiable risk factors.  Hepatic function should be monitored in all patients; a higher frequency of liver enzyme elevations was observed in pediatrics.  Serum transaminase levels and bilirubin should be measured at the start of therapy and monitored at least weekly for the first month of therapy; monitoring frequency can be reduced to monthly during continued use if no clinically significant changes are observed.  If liver function tests increase significantly from baseline, voriconazole should be discontinued unless, after assessing the benefit/risk to the patient, continued use is justified.Voriconazole is primarily metabolized by the liver and has been shown to accumulate significantly in patients with impaired hepatic function.  The manufacturer recommends that the maintenance dose be halved in patients with mild to moderate hepatic impairment/cirrhosis.  No dosing recommendations are available for patients with severe hepatic impairment/cirrhosis or for patients with chronic hepatitis B or C.  Voriconazole should only be used in patients with severe hepatic impairment if benefit outweighs the potential risk.  Patients with hepatic impairment must be carefully monitored for drug toxicity.', '3', '"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31496, 19469, 'Voriconazole', 'Liver Diseases', 'Serious hepatic reactions (including clinical hepatitis, cholestasis, fulminant hepatic failure [including fatalities]) have been reported infrequently during voriconazole therapy.  Hepatic reactions have primarily occurred in patients with serious underlying medical conditions (mainly hematological malignancy); however, some reactions (including hepatitis, jaundice) occurred in patients with no other identifiable risk factors.  Hepatic function should be monitored in all patients; a higher frequency of liver enzyme elevations was observed in pediatrics.  Serum transaminase levels and bilirubin should be measured at the start of therapy and monitored at least weekly for the first month of therapy; monitoring frequency can be reduced to monthly during continued use if no clinically significant changes are observed.  If liver function tests increase significantly from baseline, voriconazole should be discontinued unless, after assessing the benefit/risk to the patient, continued use is justified.Voriconazole is primarily metabolized by the liver and has been shown to accumulate significantly in patients with impaired hepatic function.  The manufacturer recommends that the maintenance dose be halved in patients with mild to moderate hepatic impairment/cirrhosis.  No dosing recommendations are available for patients with severe hepatic impairment/cirrhosis or for patients with chronic hepatitis B or C.  Voriconazole should only be used in patients with severe hepatic impairment if benefit outweighs the potential risk.  Patients with hepatic impairment must be carefully monitored for drug toxicity.', '3', '"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31497, 29218, 'Voriconazole', 'Liver Diseases', 'Serious hepatic reactions (including clinical hepatitis, cholestasis, fulminant hepatic failure [including fatalities]) have been reported infrequently during voriconazole therapy.  Hepatic reactions have primarily occurred in patients with serious underlying medical conditions (mainly hematological malignancy); however, some reactions (including hepatitis, jaundice) occurred in patients with no other identifiable risk factors.  Hepatic function should be monitored in all patients; a higher frequency of liver enzyme elevations was observed in pediatrics.  Serum transaminase levels and bilirubin should be measured at the start of therapy and monitored at least weekly for the first month of therapy; monitoring frequency can be reduced to monthly during continued use if no clinically significant changes are observed.  If liver function tests increase significantly from baseline, voriconazole should be discontinued unless, after assessing the benefit/risk to the patient, continued use is justified.Voriconazole is primarily metabolized by the liver and has been shown to accumulate significantly in patients with impaired hepatic function.  The manufacturer recommends that the maintenance dose be halved in patients with mild to moderate hepatic impairment/cirrhosis.  No dosing recommendations are available for patients with severe hepatic impairment/cirrhosis or for patients with chronic hepatitis B or C.  Voriconazole should only be used in patients with severe hepatic impairment if benefit outweighs the potential risk.  Patients with hepatic impairment must be carefully monitored for drug toxicity.', '3', '"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31498, 29591, 'Voriconazole', 'Liver Diseases', 'Serious hepatic reactions (including clinical hepatitis, cholestasis, fulminant hepatic failure [including fatalities]) have been reported infrequently during voriconazole therapy.  Hepatic reactions have primarily occurred in patients with serious underlying medical conditions (mainly hematological malignancy); however, some reactions (including hepatitis, jaundice) occurred in patients with no other identifiable risk factors.  Hepatic function should be monitored in all patients; a higher frequency of liver enzyme elevations was observed in pediatrics.  Serum transaminase levels and bilirubin should be measured at the start of therapy and monitored at least weekly for the first month of therapy; monitoring frequency can be reduced to monthly during continued use if no clinically significant changes are observed.  If liver function tests increase significantly from baseline, voriconazole should be discontinued unless, after assessing the benefit/risk to the patient, continued use is justified.Voriconazole is primarily metabolized by the liver and has been shown to accumulate significantly in patients with impaired hepatic function.  The manufacturer recommends that the maintenance dose be halved in patients with mild to moderate hepatic impairment/cirrhosis.  No dosing recommendations are available for patients with severe hepatic impairment/cirrhosis or for patients with chronic hepatitis B or C.  Voriconazole should only be used in patients with severe hepatic impairment if benefit outweighs the potential risk.  Patients with hepatic impairment must be carefully monitored for drug toxicity.', '3', '"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31499, 29592, 'Voriconazole', 'Liver Diseases', 'Serious hepatic reactions (including clinical hepatitis, cholestasis, fulminant hepatic failure [including fatalities]) have been reported infrequently during voriconazole therapy.  Hepatic reactions have primarily occurred in patients with serious underlying medical conditions (mainly hematological malignancy); however, some reactions (including hepatitis, jaundice) occurred in patients with no other identifiable risk factors.  Hepatic function should be monitored in all patients; a higher frequency of liver enzyme elevations was observed in pediatrics.  Serum transaminase levels and bilirubin should be measured at the start of therapy and monitored at least weekly for the first month of therapy; monitoring frequency can be reduced to monthly during continued use if no clinically significant changes are observed.  If liver function tests increase significantly from baseline, voriconazole should be discontinued unless, after assessing the benefit/risk to the patient, continued use is justified.Voriconazole is primarily metabolized by the liver and has been shown to accumulate significantly in patients with impaired hepatic function.  The manufacturer recommends that the maintenance dose be halved in patients with mild to moderate hepatic impairment/cirrhosis.  No dosing recommendations are available for patients with severe hepatic impairment/cirrhosis or for patients with chronic hepatitis B or C.  Voriconazole should only be used in patients with severe hepatic impairment if benefit outweighs the potential risk.  Patients with hepatic impairment must be carefully monitored for drug toxicity.', '3', '"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (31500, 29593, 'Voriconazole', 'Liver Diseases', 'Serious hepatic reactions (including clinical hepatitis, cholestasis, fulminant hepatic failure [including fatalities]) have been reported infrequently during voriconazole therapy.  Hepatic reactions have primarily occurred in patients with serious underlying medical conditions (mainly hematological malignancy); however, some reactions (including hepatitis, jaundice) occurred in patients with no other identifiable risk factors.  Hepatic function should be monitored in all patients; a higher frequency of liver enzyme elevations was observed in pediatrics.  Serum transaminase levels and bilirubin should be measured at the start of therapy and monitored at least weekly for the first month of therapy; monitoring frequency can be reduced to monthly during continued use if no clinically significant changes are observed.  If liver function tests increase significantly from baseline, voriconazole should be discontinued unless, after assessing the benefit/risk to the patient, continued use is justified.Voriconazole is primarily metabolized by the liver and has been shown to accumulate significantly in patients with impaired hepatic function.  The manufacturer recommends that the maintenance dose be halved in patients with mild to moderate hepatic impairment/cirrhosis.  No dosing recommendations are available for patients with severe hepatic impairment/cirrhosis or for patients with chronic hepatitis B or C.  Voriconazole should only be used in patients with severe hepatic impairment if benefit outweighs the potential risk.  Patients with hepatic impairment must be carefully monitored for drug toxicity.', '3', '"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):', 'DDInter', 0);
